Nucleic acid-induced nuclease

Engineered nucleic acid-guided nucleases with optimized sequences and guides address sequence specificity and delivery issues, enhancing the precision and efficiency of genome editing in diverse cellular contexts.

JP7577713B2Active Publication Date: 2024-11-05INSCRIPTA INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022138875
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-06-23
Filing Date
2022-09-01
Publication Date
2024-11-05
Estimated Expiration
2038-05-25

AI Technical Summary

Technical Problem

Nucleic acid-guided nucleases face limitations in sequence specificity, expression, and delivery issues, which hinder their effectiveness in genome editing applications.

Method used

Development of engineered nucleic acid-guided nucleases with optimized amino acid sequences and engineered guides that can complex with nucleic acids, allowing for precise genome editing by altering target regions with complementary editing sequences, including mutations at protospacer adjacent motifs (PAM) sites.

Benefits of technology

Enhances the specificity, efficiency, and versatility of genome editing by overcoming natural limitations, enabling precise modification of target sequences in various cellular environments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577713000019
    Figure 0007577713000019
  • Figure 0007577713000020
    Figure 0007577713000020
  • Figure 0007577713000021
    Figure 0007577713000021
Patent Text Reader

Abstract

A system is provided that can be used to edit gene targets. [Solution] The nucleic acid-guided nuclease system of the present disclosure includes: (a) (i) a nucleic acid-guided nuclease comprising an amino acid sequence having at least 90% identity to a specific amino acid sequence, or (ii) a nucleic acid molecule encoding the nucleic acid-guided nuclease; and (b) (i) an engineered guide nucleic acid comprising a region for complexing with the nucleic acid-guided nuclease and a region for hybridizing with a target sequence, or (ii) a nucleic acid molecule encoding the engineered guide nucleic acid.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to nucleic acid-guided nucleases. [Background technology]

[0002] Nucleic acid-guided nucleases have become important tools for research and genome editing. The applicability of these tools can be limited by sequence specificity requirements, expression or delivery issues. Summary of the Invention

[0003] Disclosed herein are methods of modifying a target region in the genome of a cell, the methods comprising contacting a cell with (a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO:7, SEQ ID NO:2 or SEQ ID NO:4, (b) an engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease, and (c) an editing sequence encoding a nucleic acid complementary to the target region, the nucleic acid having a sequence change relative to the target region, and allowing the nuclease, guide nucleic acid and editing sequence to create a genome edit in the target region of the genome of the cell. In some aspects, the engineered guide nucleic acid and the editing sequence are provided as a single nucleic acid. In some aspects, the single nucleic acid further comprises a mutation at a protospacer adjacent motif (PAM) site. In some aspects, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO:47 or 203-222. In some aspects, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO:133 or 183-202. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 153 or 243-262. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 223-242. In some embodiments, the engineered guide nucleic acid comprises any one of SEQ ID NO: 172-182. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 42 or 283-302. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 128 or 263-282. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 148 or 323-342. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NOs: 303-322. In some embodiments, the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172-182.In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 44 or 722-741. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 130 or 742-761. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 150 or 762-781. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 782-801. In some embodiments, the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172-182. In some embodiments, the engineered guide nucleic acid comprises a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU.

[0004] Disclosed herein is a nucleic acid-guided nuclease system comprising: (a) a nucleic acid-guided nuclease comprising an amino acid sequence of SEQ ID NO:7, SEQ ID NO:2 or SEQ ID NO:4; (b) an engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease; and (c) an editing sequence having a sequence change relative to the sequence of a target region in the genome of a cell, the system resulting in genome editing at a target region in the genome of a cell facilitated by the nuclease, the engineered guide nucleic acid and the editing sequence. In some aspects, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO:47 or 203-222. In some aspects, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO:133 or 183-202. In some aspects, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO:153 or 243-262. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 223-242. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 42 or 283-302. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 128 or 263-282. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 148 or 323-342. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 303-322. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 44 or 722-741. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 130 or 742-761. In some embodiments, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 150 or 762-781.In some aspects, the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NOs: 782-801. In some aspects, the nucleic acid-guided nuclease is codon-optimized for the cell to be edited. In some aspects, the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172-182. In some aspects, the engineered guide nucleic acid comprises a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU. In some aspects, the engineered guide nucleic acid and the editing sequence are provided as a single nucleic acid. In some aspects, the single nucleic acid further comprises a mutation at a protospacer adjacent motif (PAM) site.

[0005] Disclosed herein is a composition comprising (a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO:7, SEQ ID NO:2, or SEQ ID NO:4, and (b) an engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease, wherein the engineered guide nucleic acid comprises a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU. In some aspects, the engineered guide nucleic acid is a heterologous engineered guide nucleic acid. In some aspects, the engineered guide nucleic acid comprises any one of SEQ ID NOs:172-182. In some aspects, the nuclease is encoded by a nucleic acid sequence that is codon-optimized for use in a cell derived from a particular organism. In some aspects, the nucleic acid sequence is codon-optimized for Escherichia coli (E. coli). In some aspects, the nucleic acid sequence is codon-optimized for S. cerevisiae. In some aspects, the nucleic acid sequence is codon-optimized for a mammalian cell. In some aspects, the nucleic acid sequence is codon-optimized for a human cell. In some aspects, the nucleic acid sequence is codon optimized for plant cells.

[0006] Disclosed herein is a nucleic acid-guided nuclease system comprising (a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO:7, SEQ ID NO:2, or SEQ ID NO:4, and (b) a heterologous engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease. In some aspects, the targeting system further comprises (c) an editing sequence having a sequence change relative to the sequence of the target region. In some aspects, the targeting system results in editing of the target region facilitated by the nuclease, the heterologous engineered guide nucleic acid, and the editing sequence. In some aspects, the engineered guide nucleic acid comprises a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU. In some aspects, the engineered guide nucleic acid comprises any one of SEQ ID NOs:172-182. In some aspects, the nuclease is encoded by a nucleic acid sequence that is codon-optimized for use in cells derived from a particular organism. In some aspects, the nucleic acid sequence is codon-optimized for E. coli. In some aspects, the nucleic acid sequence is codon optimized for S. cerevisiae. In some aspects, the nucleic acid sequence is codon optimized for mammalian cells. In some aspects, the nucleic acid sequence is codon optimized for human cells. In some aspects, the nucleic acid sequence is codon optimized for plant cells. Incorporation by Reference All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

[0007] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [Brief description of the drawings]

[0008] [Figure 1]FIG. 1A shows partial sequence alignments MAD1-8 (SEQ ID NOs: 1-8) and MAD10-12 (SEQ ID NOs: 10-12). FIG. 1A discloses SEQ ID NO: 721, residues 703-707 of SEQ ID NO: 1, residues 625-629 of SEQ ID NO: 2, residues 587-591 of SEQ ID NO: 3, residues 654-658 of SEQ ID NO: 4, residues 581-585 of SEQ ID NO: 5, residues 637-641 of SEQ ID NO: 6, residues 590-594 of SEQ ID NO: 7, residues 645-649 of SEQ ID NO: 8, SEQ ID NO: 395, residues 619-623 of SEQ ID NO: 10, and residues 603-607 of SEQ ID NO: 12, all in order of appearance, respectively. FIG. 1B shows a phylogenetic tree of nucleases including MAD1-8. [Diagram 2] An example of a protein expression construct is shown in Figure 2, which discloses "6X-His" as SEQ ID NO:376. [Diagram 3] Shown in order of appearance are the target codons that express exemplary editing cassettes and editing sequences, SEQ ID NOs: 396 to 398, respectively. [Figure 4] 1 shows an example of a screening or selection experimental workflow. [Diagram 5] FIG. 5A shows an example of a protein expression construct, FIG. 5B shows an example of an editing cassette, and FIG. 5C shows an example of a screening or selection experimental workflow. [Figure 6] FIG. 6A shows an example of a protein expression construct, FIG. 6B shows an example of an editing cassette, and FIG. 6C shows an example of a screening or selection experimental workflow. [Figure 7] 1 shows examples of data from screening or selection experiments for functional nuclease complexes. [Figure 8] 1 shows example data from editing experiments based on targetable nuclease complexes. [Figure 9] 1 shows example data from editing experiments based on targetable nuclease complexes. [Figure 10] Figures 10A and 10B show example data from editing experiments based on targetable nuclease complexes. [Figure 11]Figure 11 shows an example of a sequence alignment of selected sequences from an editing experiment. Figure 11 discloses SEQ ID NOs: 399-401, 400, 400, 400, 400, 400, 402, 399-400 and 400, respectively, in order of appearance. [Figure 12] 1 shows example data from editing experiments based on targetable nuclease complexes. [Figure 13] An example of an alignment of scaffold sequences is shown in Figure 13, which discloses SEQ ID NOs: 403 to 415, respectively, in order of appearance. [Figure 14] 14A and 14B show example data from a primer validation experiment. [Figure 15] 1 shows example data from editing experiments based on targetable nuclease complexes. [Figure 16] An example of validation data comparing the results of two different assays is shown. [Figure 17] Figures 17A-17C show an example of a traceable genetic engineering workflow including plasmids containing editing and recording cassettes and downstream sequencing of barcodes to identify edits or mutations incorporated. Figure 17B discloses SEQ ID NOs: 416-417, respectively, in order of appearance. [Figure 18] An example of a trackable genetic engineering workflow is shown, which includes repeated rounds of engineering with a different editing cassette and a recorder cassette with a unique barcode (BC) in each round, followed by selection and tracking to ensure that the engineering steps in each round are successful. [Figure 19] 1 illustrates an example of an iterative operation workflow. [Figure 20] 20A shows an example of a target expression cassette, and FIG. 20B shows an example of a target sequence in a target gene. [Figure 21] 21A and 21B show examples of measured cell and colony growth data. [Figure 22] Figures 22A and 22B show example data comparing library quantification at the input and 15 hour time points. [Figure 23-1]23A and 23B show depletion score data from example experiments. [Figure 23-2] Figure 23C shows the target sequences and editing efficiencies of the experimental examples. Figure 23C discloses SEQ ID NOs: 419 to 423, respectively, in order of appearance. [Figure 24] Figures 24A, 25B, and 24C show depletion score data from example experiments. [Diagram 25] FIG. 1 shows a schematic of the subject assays used to determine PAM specificity and off-target effects of the subject nuclease system. [Figure 26A] 1 shows depletion score data from example experiments. [Figure 26B] 1 shows depletion score data from example experiments. [Figure 26C] 1 shows depletion score data from example experiments. [Figure 27A] 1 shows depletion score data from example experiments. [Figure 27B] 1 shows depletion score data from example experiments. [Figure 28A] 1 shows depletion score data from example experiments. [Figure 28B] 1 shows depletion score data from example experiments. [Figure 29A] 1 shows depletion score data from example experiments. [Figure 29B] 1 shows depletion score data from example experiments. [Figure 30A] 1 shows depletion score data from example experiments. [Figure 30B] 1 shows depletion score data from example experiments. [Diagram 31] Figures 31A, 32B, and 31C show depletion score data from example experiments. [Figure 32-1] Figures 32A, 32B, 32C, and 32D show the depletion score data (negative enrichment scores) from example experiments. [Figure 32-2] Figures 32E, 32F, 32G, and 32H show the depletion score data (negative enrichment scores) from example experiments. [Figure 32-3] FIG. 32I shows the depletion score data from the example experiment. [Figure 32-4] FIG. 32J shows the depletion score data from the example experiment. [Figure 32-5] FIG. 32K shows the depletion score data from the example experiments. [Figure 32-6] FIG. 32L shows the depletion score data from the example experiment. [Figure 32-7] FIG. 32M shows the depletion score data from the example experiment. [Figure 32-8] FIG. 32N shows the depletion score data from the example experiments. [Figure 32-9] FIG. 32O shows the depletion score data from the example experiments. [Figure 32-10] FIG. 32P shows the depletion score data from the example experiments. [Diagram 33] Examples of constructs and experimental designs for determining PAM specificity, characterizing guide scaffold sequences, and optimizing a subject nuclease system are provided. [Figure 34A] Figures 34A and 34B, for example, show guide nucleic acid scaffold sequence alignments of MAD crRNA sequences. Figure 34A discloses SEQ ID NOs: 639-666, respectively, in order of appearance. [Figure 34B] Figures 34A and 34B, for example, show guide nucleic acid scaffold sequence alignments of MAD crRNA sequences. Figure 34B discloses SEQ ID NOs: 667-675, respectively, in order of appearance. [Figure 35A] 1 shows examples of data characterizing preferred crRNA loop sequences. [Figure 35B] 1 shows examples of data characterizing preferred crRNA loop sequences. [Figure 35C] 1 shows examples of data characterizing preferred crRNA loop sequences. [Figure 36A] Examples of depletion score data characterizing preferred crRNA loop sequences for MAD7, MAD2 and MAD4, respectively, are shown. [Figure 36B] Examples of depletion score data characterizing preferred crRNA loop sequences for MAD7, MAD2 and MAD4, respectively, are shown. [Figure 36C]Examples of depletion score data characterizing preferred crRNA loop sequences for MAD7, MAD2 and MAD4, respectively, are shown. [Figure 36D] Examples of depletion score data characterizing preferred crRNA loop sequences for MAD7, MAD2 and MAD4, respectively, are shown. [Figure 36E] Examples of depletion score data characterizing preferred crRNA loop sequences for MAD7, MAD2 and MAD4, respectively, are shown. [Figure 36F] Examples of depletion score data characterizing preferred crRNA loop sequences for MAD7, MAD2 and MAD4, respectively, are shown. [Figure 37] 1 shows depletion score data from example experiments characterizing crRNA stem-loop sequence preferences. [Figure 38A] Examples of expression constructs for use in mammalian cells are provided. [Figure 38B] Examples of guide nucleic acid sequences are shown in Figure 38B, which discloses SEQ ID NOs: 677-678, respectively, in order of appearance. [Figure 39] Figures 39A-39B show examples of target sites targeted by the indicated gRNA sequences in the indicated target genes, and Figures 39C-39D summarize the PAM and target sequences of the indicated guide nucleic acids. Figure 38C discloses SEQ ID NOs: 679-688, respectively, in order of appearance. Figure 39D discloses SEQ ID NOs: 689-698, respectively, in order of appearance. [Diagram 40] Cleavage (cutting) efficiency by in vitro cleavage assay is shown. [Diagram 41] FIG. 1 shows MAD7-dependent (two constructs) indel formation in mammalian HEK293T cells of two genes targeted by three different guide nucleic acids with two different lengths of scaffolds (42- or 56-mer). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] The present disclosure provides nucleic acid-guided nucleases and methods of use. In many cases, the subject nucleic acid-guided nucleases are part of a targetable nuclease system that includes a nucleic acid-guided nuclease and a guide nucleic acid. The subject targetable nuclease system can be used to cleave, modify and / or edit a target polynucleotide sequence, often referred to as a target sequence. The subject targetable nuclease system collectively refers to the transcripts and other elements that are involved in the expression or direct the activity of a gene that may include a sequence that codes for the subject nucleic acid-guided nuclease protein and guide nucleic acid disclosed herein.

[0010] The methods, systems, vectors, polynucleotides and compositions described herein may be used in a variety of applications including altering or modifying the synthesis of a gene product such as a protein, polynucleotide cleavage, polynucleotide editing, polynucleotide splicing, transport of a target polynucleotide, tracking of a target polynucleotide, isolating a target polynucleotide, visualizing a target polynucleotide, etc. Aspects of the invention also include methods and uses of the compositions and systems described herein in genome editing, for example, to alter or manipulate the expression of one or more genes or one or more gene products in prokaryotic, archaeal or eukaryotic cells in vitro, in vivo or ex vivo.

[0011] Nucleic acid-induced nuclease Targetable nuclease systems in bacteria and archaea have emerged as powerful tools for precise genome editing. However, naturally occurring nucleases have some limitations, including the challenges of expression and delivery due to the size of nucleic acid sequences and proteins. Targetable nucleases that require PAM recognition are also limited in the sequences that can be targeted across gene sequences. Other challenges include processivity, specificity and efficiency of target recognition, and the efficiency of nuclease acidity, which often affect the efficiency of gene editing.

[0012] Non-naturally occurring targetable nucleases and non-naturally occurring targetable nuclease systems can address many of these challenges and limitations.

[0013] Disclosed herein is a non-naturally occurring targetable nuclease system. Such targetable nuclease system is engineered to address one or more of the above problems, and can be referred to as engineered nuclease system. Engineered nuclease system can include one or more of engineered nucleases, such as engineered nucleic acid-guided nucleases, engineered guide nucleic acids, engineered polynucleotides encoding said nucleases, or engineered polynucleotides encoding said guide nucleic acids, etc. Engineered nucleases, engineered guide nucleic acids, and engineered polynucleotides encoding engineered nucleases or engineered guide nucleic acids are not naturally occurring and are not found in nature. Engineered nuclease systems that include one or more of these elements will not be naturally occurring.

[0014] Non-limiting examples of the types of engineering that can be done to obtain a non-naturally occurring nuclease system are as follows: Engineering can include codon optimization to facilitate or improve expression in a host cell, such as a heterologous host cell. Engineering can reduce the size or molecular weight of the nuclease to facilitate expression or delivery. Engineering can change the PAM selection to alter PAM specificity or to broaden the range of PAMs recognized. Engineering can change, increase or decrease the stability, processivity, specificity or efficiency of the targetable nuclease system. Engineering can change, increase or decrease protein stability. Engineering can change, increase or decrease nucleic acid scanning processivity. Engineering can change, increase or decrease target sequence specificity. Engineering can change, increase or decrease nuclease activity. Engineering can change, increase or decrease editing efficiency. Engineering can change, increase or decrease transformation efficiency. Manipulation can alter, increase or decrease expression of the nuclease or guide nucleic acid.

[0015] Examples of non-naturally occurring nucleic acid sequences disclosed herein include sequences codon-optimized for expression in bacteria such as E. coli (e.g., SEQ ID NOs: 41-60), sequences codon-optimized for expression in unicellular eukaryotes such as yeast (e.g., SEQ ID NOs: 127-146), sequences codon-optimized for expression in multicellular eukaryotes such as human cells (e.g., SEQ ID NOs: 147-166), polynucleotides used for cloning or expression of any of the sequences disclosed herein (e.g., SEQ ID NOs: 61-80), plasmids comprising nucleic acid sequences operably linked to a heterologous promoter, or nuclear localization signal, or other heterologous element (e.g., SEQ ID NOs: 21-40), proteins produced from engineered or codon-optimized nucleic acid sequences (e.g., SEQ ID NOs: 1-20), or engineered guide nucleic acids comprising any one of SEQ ID NOs: 84-107. Such non-naturally occurring nucleic acid sequences can be obtained by amplifying, cloning, assembling, synthesizing, generating from synthetic oligonucleotides or dNTPs, or otherwise using methods known to those of skill in the art.

[0016] Nucleic acid-derived nucleases are disclosed herein. The subject nucleases function in vitro or in prokaryotic, archaeal or eukaryotic cells in in vitro, in vivo or ex vivo applications. Suitable nucleic acid-derived nucleases include those derived from Thiomicrospira, Succinivibrio, Candidatus, Porphyromonas, Acidaminococcus, Acidomonococcus, Prevotella, Smithella, Moraxella, Synergistes, and the like. gistes, Francisella, Leptospira, Catenibacterium, Kandleria, Clostridium, Dorea, Coprococcus, Enterococcus, Fructobacillus, Weissella, Pediococcus ccus, Corynebacter, Sutterella, Legionella, Treponema, Roseburia, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides s), Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor,Mycoplasma, Alicyclobacillus, Brevibacilus, Bacillus, Bacteroidetes, Brevibacilus, Carnobacterium, Clostridiaridium, Clostridium, Desulfonatronum, Desulfovibrio, Helcococcus, Leptotrichia, Listeria The species may be from organisms of genera including, but not limited to, Listeria, Methanomethyophilus, Methylobacterium, Opitutaceae, Paludibacter, Rhodobacter, Sphaerochaeta, Tuberibacillus, Oleiphilus, Omnitrophica, Parcubacteria, and Campylobacter. Species of organisms of such genera may be those discussed elsewhere herein. Suitable nucleic acid-derived nucleases may be derived from organisms of any genera within the kingdom, including, but not limited to, Firmicutes, Actinobacteria, Bacteroidetes, Proteobacteria, Spirochetes, and Tenericutes, or from unclassified genus. Suitable nucleic acid-derived nucleases may be derived from organisms of any genera within the kingdom, including, but not limited to, Erysipelotrichia, Erysipelotrichi, Bacilli, Actinobacteria, Bacteroidetes,The proteobacteria may be derived from organisms of any genera within a phylum, including, but not limited to, Flavobacteria, Alphaproteobacteria, Betaproteobacteria, Gammaproteobacteria, Deltaproteobacteria, Epsilonproteobacteria, Spirochaetes, and Mollicutes, or from unclassified genus of organisms. Suitable nucleic acid-derived nucleases may be derived from organisms of genera within the order Clostridiales, Lactobacillales, Actinomycetales, Bacteroidales, Flavobacteriales, Rhizobiales, Rhodospirillales, Burkholderiales, Neisseriales, Legionellales, Nautiliales, Campylobacterales, Spirochaetales, Mycoplasmatales, and Thiotrichales, or unclassified genus. Suitable nucleic acid-derived nucleases include those from the following genus: Lachnospiraceae, Enterococcus, Leuconostocaceae, Lactobacillaceae, Streptococcus, Peptostreptococcaceae, Staphylococcus, Eubacteriaceae, Corynebacterium, Bacteroidaceae,The bacteria may be derived from organisms of any genera within a family or an unclassified genus, including, but not limited to, Flavobacterium, Cryomoorphaceae, Rhodobiaceae, Rhodospirillaceae, Acetobacteraceae, Sutterellaceae, Neisseriaceae, Legionellaceae, Nautiliaceae, Campylobacteraceae, Spirochaetaceae, Mycoplasmataceae, Pisciririckettsiaceae, and Francisellaceae. Other nucleic acid-guided nucleases are described in U.S. Patent Application Publication No. 20160208243, filed December 18, 2015, U.S. Patent Application Publication No. 20140068797, filed March 15, 2013, U.S. Patent No. 8,697,359, filed October 15, 2013, and Zetsche et al., Cell, October 22, 2015, Vol. 163, No. 3, pp. 759-71, each of which is incorporated herein by reference in its entirety.

[0017] Some nucleic acid-guided nucleases suitable for use in the methods, systems, and compositions of the present disclosure include, but are not limited to, Thiomicrospira sp. XS5, Eubacterium rectale, Candidatus Methanoplasma termitum, Candidatus Methanomethylophilus alvus, Porphyromonas cleviolicanis, and the like. crevioricanis, Flavobacterium branchiophilum, Acidaminococcus sp., Acidomonococcus sp., Lachnospiraceae COE1, Prevotella brevis ATCC19188, Smithella sp. SCADC, Moraxella bovoculi, Synergistes jonesii, Bacteroidetes oral taxon 274, Francisella tularensis, Leptospira inadai serovar Lyme strain 10, str.10), Acidomonococcus sp. crystal structure (5B43) Streptococcus mutans, Streptococcus agalactiae, Streptococcus equisimilis, Streptococcus sanguinis, Streptococcus pneumonia, Campylobacter jejuni, Campylobacter coli, Nitratifractor salsuginis, Nitratifractor tergalcus rgarcus, Staphylococcus auricularis (S. auricularis), Staphylococcus carnosus (S. carnosus), Neisseria meningitidis (N. meningitides), Neisseria gonorrhoeae (N. gonorrhoeae), Listeria monocytogenes (L. monocytogenes), Listeria ivanovii (L. ivanovii), Clostridium botulinum (C. botulinum), Clostridium difficile (C. difficile), Clostridium tetani (C. tetani), Clostridium sordellii (C.sordellii, Francisella tularensis 1, Prevotella albensis, Lachnospiraceae bacterium MC2017 1, Butyrivibrio proteoclasticus, Butyrivibrio proteoclasticus B316, Peregrinibacteria bacterium GW2011_GWA2_33_10, Parcubacteria bacterium GW2011_GWC2_44_17, Smithella sp. SCADC, Acidaminococcus sp. BV3L6, Lachnospiraceae MA2020, Candidatus Methanoplasma termitum, Eubacterium eligens, Moraxella bovoculi 237, Leptospira inadai, Lachnospiraceae ND2006, Porphyromonas crevioricanis 3, Prevotella disiens, Porphyromonas macacae, Catenibacterium sp. CAG:290, Kandleria vitulina vitulina, Clostridiales bacteria KA00274, Lachnospiraceae bacteria 3-2, Dorea longicatena, Coprococcus catus GD / 7, Enterococcus columbae DSM 7374, Fructobacillus sp.) EFB-N1, Weissella halotolerans, Pediococcus acidilactici, Lactobacillus curvatus, Streptococcus pyogenes, Lactobacillus versmoldensis, Filifactor alocis ATCC 35896, Alicyclobacillus acidoterrestris, Alicyclobacillus acidoterrestris ATCC 49025, Desulfovibrio inopinatus inopinatus, Desulfovibrio inopinatus DSM 10711, Oleiphilus sp. Oleiphilus sp. HI0009, Candidus kefeldibacteria, Parcubacteria CasY.4, Omnitrophica WOR 2 bacteria GWF2, Bacillus sp. NSP2.1 and Bacillus thermoamylovorans.

[0018] In some examples, the nucleic acid-guided nucleases disclosed herein comprise an amino acid sequence that comprises at least 50% amino acid identity to any one of SEQ ID NOs: 1-20. In some examples, the nuclease comprises an amino acid sequence that comprises at least about 10%, 20%, 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, greater than 95% or 100% amino acid identity to any one of SEQ ID NOs: 1-20. In some cases, the nucleic acid-guided nuclease comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, greater than 95% amino acid identity to any one of SEQ ID NOs: 1-20. In some cases, the nucleic acid-guided nuclease comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% amino acid identity to any one of SEQ ID NOs: 1-8 or 10-12. In some cases, the nucleic acid-guided nuclease comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% amino acid identity to any one of SEQ ID NOs: 1-8 or 10-11. In some cases, the nucleic acid-guided nuclease comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% amino acid identity to SEQ ID NO: 2. In some cases, the nucleic acid-guided nuclease comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% amino acid identity to SEQ ID NO: 7. In some cases, the nucleic acid-guided nuclease comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% amino acid identity to SEQ ID NO: 4.

[0019] In some cases, the nucleic acid-induced nuclease comprises any one of SEQ ID NOs: 1-20. In some cases, the nucleic acid-induced nuclease comprises any one of SEQ ID NOs: 1-8 or 10-12. In some cases, the nucleic acid-induced nuclease comprises any one of SEQ ID NOs: 1-8 or 10-11. In some cases, the nucleic acid-induced nuclease comprises SEQ ID NO: 2. In some cases, the nucleic acid-induced nuclease comprises SEQ ID NO: 7. In some cases, the nucleic acid-induced nuclease comprises SEQ ID NO: 4.

[0020] In some examples, the nucleic acid-guided nuclease comprises an amino acid sequence that comprises up to 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% amino acid identity to SEQ ID NO: 12 or any one of SEQ ID NOs: 108-110. In some examples, the nucleic acid-guided nuclease comprises an amino acid sequence that comprises up to 50% amino acid identity to SEQ ID NO: 12 or any one of SEQ ID NOs: 108-110. In some examples, the nucleic acid-guided nuclease comprises an amino acid sequence that comprises up to 45% amino acid identity to SEQ ID NO: 12 or any one of SEQ ID NOs: 108-110. In some examples, the nucleic acid-guided nuclease comprises an amino acid sequence that comprises up to 40% amino acid identity to SEQ ID NO: 12 or any one of SEQ ID NOs: 108-110. In some examples, the nucleic acid-guided nuclease comprises an amino acid sequence that comprises up to 35% amino acid identity to SEQ ID NO: 12 or any one of SEQ ID NOs: 108-110. In some examples, the nucleic acid-guided nuclease comprises an amino acid sequence that comprises up to 30% amino acid identity to SEQ ID NO: 12 or any one of SEQ ID NOs: 108-110.

[0021] In some examples, the nucleic acid-derived nuclease disclosed herein is encoded by a nucleic acid sequence that comprises at least 50% sequence identity to any one of SEQ ID NOs: 21-40. In some examples, the nuclease is encoded by a nucleic acid sequence that comprises at least about 10%, 20%, 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, greater than 95% or 100% sequence identity to any one of SEQ ID NOs: 21-40. In some examples, the nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, greater than 95% sequence identity to any one of SEQ ID NOs: 21-40. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 21-40. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 21-28 or 30-32. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 21-28 or 30-31. In some cases, the nucleic acid-derived nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to SEQ ID NO: 22. In some cases, the nucleic acid-derived nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to SEQ ID NO: 27. In some cases, the nucleic acid-derived nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to SEQ ID NO: 24.

[0022] In some cases, the nucleic acid-induced nuclease is encoded by a nucleic acid sequence of any one of SEQ ID NOs: 21-40. In some cases, the nucleic acid-induced nuclease is encoded by a nucleic acid sequence of any one of SEQ ID NOs: 21-28 or 30-32. In some cases, the nucleic acid-induced nuclease is encoded by a nucleic acid sequence of any one of SEQ ID NOs: 21-28 or 30-31. In some cases, the nucleic acid-induced nuclease is encoded by a nucleic acid sequence of SEQ ID NO: 22. In some cases, the nucleic acid-induced nuclease is encoded by a nucleic acid sequence of SEQ ID NO: 27. In some cases, the nucleic acid-induced nuclease is encoded by a nucleic acid sequence of SEQ ID NO: 24.

[0023] In some examples, the nucleic acid-induced nuclease disclosed herein is encoded on a nucleic acid sequence. Such nucleic acids can be codon-optimized for expression in a desired host cell. Suitable host cells can include, by way of non-limiting example, prokaryotic cells such as E. coli, P. aeruginosa, B. subtilus, and V. natriegens, as well as eukaryotic cells such as S. cerevisiae, plant cells such as Arabidopsis thaliana or tobacco cells, insect cells, nematode cells, amphibian cells, fish cells, or mammalian cells, including human cells.

[0024] The nucleic acid sequence encoding the nucleic acid-guided nuclease can be codon-optimized for expression in Gram-positive bacteria, such as Bacillus subtilis, or Gram-negative bacteria, such as E. coli. In some examples, the nucleic acid-guided nuclease disclosed herein is encoded by a nucleic acid sequence that comprises at least 50% sequence identity to any one of SEQ ID NOs: 41-60, 203-222, 283-302, or 722-741. In some examples, the nuclease is encoded by a nucleic acid sequence that comprises at least about 10%, 20%, 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, more than 95% or 100% sequence identity to any one of SEQ ID NOs: 41-60, 203-222, 283-302, or 722-741. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 41-48, 50-51, 53-60, 203-222, 283-302, or 722-741. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 41-48, 50-52, 203-222, 283-302, or 722-741. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 41-48, 50-51, 203-222, 283-302, or 722-741. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to SEQ ID NOs: 42 or 283-302.In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to SEQ ID NO: 47 or 203-222. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to SEQ ID NO: 44 or 722-741.

[0025] In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 41-60, 203-222, 283-302, or 722-741. In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 41-48, 50-52, 203-222, 283-302, or 722-741. In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 41-48, 50-51, 203-222, 283-302, or 722-741. In some cases, the nucleic acid-induced nuclease is encoded by the nucleic acid sequence of SEQ ID NOs: 42 or 283-302. In some cases, the nucleic acid-induced nuclease is encoded by the nucleic acid sequence of SEQ ID NOs: 47 or 203-222. In some cases, the nucleic acid-guided nuclease is encoded by the nucleic acid sequence of SEQ ID NO: 44 or 722-741.

[0026] The nucleic acid sequence encoding the nucleic acid-guided nuclease can be codon-optimized for expression in a species of yeast, such as S. cerevisiae. In some examples, the nucleic acid-guided nuclease disclosed herein is encoded by a nucleic acid sequence that comprises at least 50% sequence identity to any one of SEQ ID NOs: 127-146, 183-202, 263-282, or 742-761. In some examples, the nuclease is encoded by a nucleic acid sequence that comprises at least about 10%, 20%, 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, more than 95% or 100% sequence identity to any one of SEQ ID NOs: 127-146, 183-202, 263-282, or 742-761. In some examples, the nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 127-146, 183-202, 263-282, or 742-761. In some cases, the nucleic acid-derived nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 127-146, 183-202, 263-282, or 742-761. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 127-134, 136-138, 183-202, 263-282, or 742-761. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 127-134, 136-137, 183-202, 263-282, or 742-761.In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 95% or more sequence identity to SEQ ID NO: 128 or 263-282. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 95% or more sequence identity to SEQ ID NO: 133 or 183-202. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 95% or more sequence identity to SEQ ID NO: 130 or 742-761.

[0027] In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 127-146, 183-202, 263-282, or 742-761. In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 127-134, 136-138, 183-202, 263-282, or 742-761. In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 127-134, 136-137, 183-202, 263-282, or 742-761. In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 128 or 263-282. In some cases, the nucleic acid-induced nuclease is encoded by the nucleic acid sequence of SEQ ID NOs: 133 or 183-202. In some cases, the nucleic acid-guided nuclease is encoded by the nucleic acid sequence of SEQ ID NO: 130 or 742-761.

[0028] The nucleic acid sequence encoding the nucleic acid-guided nuclease can be codon-optimized for expression in mammalian cells. In some examples, the nucleic acid-guided nuclease disclosed herein is encoded by a nucleic acid sequence that comprises at least 50% sequence identity to any one of SEQ ID NOs: 147-166, 243-262, 323-342, or 762-781. In some examples, the nuclease is encoded by a nucleic acid sequence that comprises at least about 10%, 20%, 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, more than 95% or 100% sequence identity to any one of SEQ ID NOs: 147-166, 243-262, 323-342, or 762-781. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 147-166, 243-262, 323-342, or 762-781. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 147-154, 156-158, 243-262, 323-342, or 762-781. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 147-154, 156-157, 243-262, 323-342, or 762-781. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to SEQ ID NOs: 148 or 323-342. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to SEQ ID NO: 153 or 243-262.In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to SEQ ID NO: 150 or 762-781.

[0029] In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 147-166, 243-262, 323-342, or 762-781. In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 147-154, 156-158, 243-262, 323-342, or 762-781. In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 147-154, 156-157, 243-262, 323-342, or 762-781. In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 148 or 323-342. In some cases, the nucleic acid-induced nuclease is encoded by the nucleic acid sequence of SEQ ID NOs: 153 or 243-262. In some cases, the nucleic acid-guided nuclease is encoded by the nucleic acid sequence of SEQ ID NO: 150 or 762-781.

[0030] The nucleic acid sequence encoding the nucleic acid-guided nuclease can be codon-optimized for expression in plant cells. In some examples, the nucleic acid-guided nuclease disclosed herein is encoded by a nucleic acid sequence that comprises at least 50% sequence identity to any one of SEQ ID NOs: 343-359, 223-242, 303-322, or 782-801. In some examples, the nuclease is encoded by a nucleic acid sequence that comprises at least about 10%, 20%, 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, more than 95% or 100% sequence identity to any one of SEQ ID NOs: 343-359, 223-242, 303-322, or 782-801. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 343-359, 223-242, 303-322, or 782-801. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 343-347, 349-351, 223-242, 303-322, or 782-801. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to any one of SEQ ID NOs: 343-347, 349-350, 223-242, 303-322, or 782-801. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to SEQ ID NOs: 303-322. In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to SEQ ID NOs: 223-242.In some cases, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence that comprises at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95% sequence identity to SEQ ID NOs: 782-801.

[0031] In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 343-359, 223-242, 303-322, or 782-801. In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 343-347, 349-351, 223-242, 303-322, or 782-801. In some cases, the nucleic acid-induced nuclease is encoded by any one of the nucleic acid sequences of SEQ ID NOs: 343-347, 349-350, 223-242, 303-322, or 782-801. In some cases, the nucleic acid-induced nuclease is encoded by the nucleic acid sequence of SEQ ID NOs: 303-322. In some cases, the nucleic acid-induced nuclease is encoded by the nucleic acid sequence of SEQ ID NOs: 223-242. In some instances, the nucleic acid-guided nuclease is encoded by a nucleic acid sequence of SEQ ID NOs:782-801.

[0032] The nucleic acid sequence encoding the nucleic acid-guided nuclease can be operably linked to a promoter. Such nucleic acid sequences can be linear or circular. The nucleic acid sequence can be included in a larger linear or circular nucleic acid sequence that includes other components of the targetable nuclease system, such as an origin of replication, a selectable or screenable marker, a terminator, a guide nucleic acid, or additional elements, such as an editing or recording cassette as disclosed herein. As described in more detail below, these larger nucleic acid sequences can be recombinant expression vectors.

[0033] Guide Nucleic Acid Generally, the guide nucleic acid can form a complex with a compatible nucleic acid-guided nuclease and hybridize with a target sequence, thereby guiding the nuclease to the target sequence. The subject nucleic acid-guided nuclease that can form a complex with the guide nucleic acid can be referred to as a nucleic acid-guided nuclease that is compatible with the guide nucleic acid. Similarly, the guide nucleic acid that can form a complex with the nucleic acid-guided nuclease can be referred to as a guide nucleic acid that is compatible with the nucleic acid-guided nuclease.

[0034] The guide nucleic acid can be DNA. The guide nucleic acid can be RNA. The guide nucleic acid can include both DNA and RNA. The guide nucleic acid can include modified or non-naturally occurring nucleotides. When the guide nucleic acid includes RNA, the RNA guide nucleic acid can be encoded by a DNA sequence on a polynucleotide molecule, such as a plasmid, a linear construct, or an editing cassette, as disclosed herein.

[0035] The guide nucleic acid may comprise a guide sequence. A guide sequence is a polynucleotide sequence that has sufficient complementarity to a target polynucleotide sequence to hybridize to the target sequence and direct the sequence-specific binding of the complexed nucleic acid-guided nuclease to the target sequence. The degree of complementarity between a guide sequence and its corresponding target sequence is about 50% or more, about 60% or more, about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, about 97.5% or more, about 99% or more, or more, when optimally aligned using a suitable alignment algorithm. Optimal alignment can be determined using any suitable algorithm for aligning sequences. In some embodiments, the guide sequence is about 5 nucleotides or more, about 10 nucleotides or more, about 11 nucleotides or more, about 12 nucleotides or more, about 13 nucleotides or more, about 14 nucleotides or more, about 15 nucleotides or more, about 16 nucleotides or more, about 17 nucleotides or more, about 18 nucleotides or more, about 19 nucleotides or more, about 20 nucleotides or more, about 21 nucleotides or more, about 22 nucleotides or more, about 23 nucleotides or more, about 24 nucleotides or more, about 25 nucleotides or more, about 26 nucleotides or more, about 27 nucleotides or more, about 28 nucleotides or more, about 29 nucleotides or more, about 30 nucleotides or more, about 35 nucleotides or more, about 40 nucleotides or more, about 45 nucleotides or more, about 50 nucleotides or more, about 75 nucleotides or more in length. In some embodiments, the guide sequence is less than about 75 nucleotides, less than about 50 nucleotides, less than about 45 nucleotides, less than about 40 nucleotides, less than about 35 nucleotides, less than about 30 nucleotides, less than about 25 nucleotides, less than about 20 nucleotides in length. The guide sequence is preferably 10 to 30 nucleotides in length. The guide sequence may be 15-20 nucleotides in length. The guide sequence may be 15 nucleotides in length. The guide sequence may be 16 nucleotides in length. The guide sequence may be 17 nucleotides in length. The guide sequence may be 18 nucleotides in length. The guide sequence may be 19 nucleotides in length. The guide sequence may be 20 nucleotides in length.

[0036] The guide nucleic acid may include a scaffold sequence. In general, a "scaffold sequence" includes any sequence that has a sufficient sequence to promote the formation of a targetable nuclease complex, where the targetable nuclease complex includes a nucleic acid-guided nuclease and a guide nucleic acid that includes a scaffold sequence and a guide sequence. The sequence in the scaffold sequence that is sufficient to promote the formation of a targetable nuclease complex may include a degree of complementarity along the length of two sequence regions in the scaffold sequence, such as one or two sequence regions that are involved in the formation of a secondary structure. In some cases, the one or two sequence regions are included or encoded on the same polynucleotide. In some cases, the one or two sequence regions are included or encoded on separate polynucleotides. The optimal alignment can be determined by any suitable alignment algorithm, and can further account for secondary structures, such as self-complementarity within either one or two sequence regions. In some embodiments, the degree of complementarity between one or two sequence regions along the shorter of the two lengths, when optimally aligned, is about 25% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, about 95% or more, about 97.5% or more, about 99% or more or more. In some embodiments, at least one of the two sequence regions is about 5 nucleotides or more, about 6 nucleotides or more, about 7 nucleotides or more, about 8 nucleotides or more, about 9 nucleotides or more, about 10 nucleotides or more, about 11 nucleotides or more, about 12 nucleotides or more, about 13 nucleotides or more, about 14 nucleotides or more, about 15 nucleotides or more, about 16 nucleotides or more, about 17 nucleotides or more, about 18 nucleotides or more, about 19 nucleotides or more, about 20 nucleotides or more, about 25 nucleotides or more, about 30 nucleotides or more, about 40 nucleotides or more, about 50 nucleotides or more in length.

[0037] The scaffold sequence of the subject guide nucleic acid may comprise a secondary structure. The secondary structure may comprise a pseudoknot region. In some cases, the binding kinetics of the guide nucleic acid to the nucleic acid-guided nuclease is determined in part by the secondary structure in the scaffold sequence. In some cases, the binding kinetics of the guide nucleic acid to the nucleic acid-guided nuclease is determined in part by the nucleic acid sequence in the scaffold sequence. An example of a pseudoknot region in the scaffold sequence is shown in Figure 49C.

[0038] The scaffold sequence may include a loop sequence. The loop sequence may include one or more nucleotides. In some examples, the loop sequence includes 4 nucleotides. In some examples, the loop sequence includes 5 nucleotides. The loop sequence may be a region of the scaffold sequence that does not hybridize to another sequence or does not hybridize to another sequence within the scaffold sequence. An example of a loop sequence within a scaffold sequence is shown in Figure 49C.

[0039] The scaffold sequence may comprise any one of SEQ ID NOs: 84 to 107 or 172 to 182. The scaffold sequence may comprise any one of SEQ ID NOs: 84 to 103. The scaffold sequence may comprise any one of SEQ ID NOs: 84 to 91 or 93 to 95. The scaffold sequence may comprise any one of SEQ ID NOs: 88, 93, 94 or 95. The scaffold sequence may comprise the sequence of SEQ ID NO: 88. The scaffold sequence may comprise the sequence of SEQ ID NO: 93. The scaffold sequence may comprise the sequence of SEQ ID NO: 94. The scaffold sequence may comprise the sequence of SEQ ID NO: 95. The scaffold sequence may comprise a sequence or consensus sequence shown in Figure 49A, 49B or 49C.

[0040] In some aspects, the present disclosure provides nucleases that bind to guide nucleic acids that include a conserved scaffold sequence. For example, nucleic acid-guided nucleases for use in the present disclosure can bind to a conserved pseudoknot region as shown in FIG. 13. Specifically, nucleic acid-guided nucleases for use in the present disclosure can bind to a guide nucleic acid that includes a conserved pseudoknot region as shown in FIG. 13. Certain nucleic acid-guided nucleases for use in the present disclosure can bind to a pseudoknot region that has at least 75%, 80%, 85%, 90%, 95% or 100% sequence identity to the pseudoknot region of scaffold-1 (SEQ ID NO: 172). Other nucleic acid-guided nucleases for use in the present disclosure can bind to a pseudoknot region that has at least 75%, 80%, 85%, 90%, 95% or 100% sequence identity to the pseudoknot region of scaffold-3 (SEQ ID NO: 173). Still other nucleic acid-guided nucleases for use in the present disclosure can bind to a pseudoknot region having at least 75%, 80%, 85%, 90%, 95% or 100% sequence identity to the pseudoknot region of scaffold-4 (SEQ ID NO: 174). Other nucleic acid-guided nucleases for use in the present disclosure can bind to a pseudoknot region having at least 75%, 80%, 85%, 90%, 95% or 100% sequence identity to the pseudoknot region of scaffold-5 (SEQ ID NO: 175). Other nucleic acid-guided nucleases for use in the present disclosure can bind to a pseudoknot region having at least 75%, 80%, 85%, 90%, 95% or 100% sequence identity to the pseudoknot region of scaffold-6 (SEQ ID NO: 176). Still other nucleic acid-guided nucleases for use in the present disclosure can bind to a pseudoknot region having at least 75%, 80%, 85%, 90%, 95% or 100% sequence identity to the pseudoknot region of scaffold-7 (SEQ ID NO: 177).Other nucleic acid-guided nucleases for use in the present disclosure can bind to a pseudoknot region having at least 75%, 80%, 85%, 90%, 95% or 100% sequence identity to the pseudoknot region of scaffold-8 (SEQ ID NO: 178). Other nucleic acid-guided nucleases for use in the present disclosure can bind to a pseudoknot region having at least 75%, 80%, 85%, 90%, 95% or 100% sequence identity to the pseudoknot region of scaffold-10 (SEQ ID NO: 179). Still other nucleic acid-guided nucleases for use in the present disclosure can bind to a pseudoknot region having at least 75%, 80%, 85%, 90%, 95% or 100% sequence identity to the pseudoknot region of scaffold-11 (SEQ ID NO: 180). Certain nucleic acid guided nucleases for use in the present disclosure can bind to a pseudoknot region having at least 75%, 80%, 85%, 90%, 95% or 100% sequence identity to the pseudoknot region of scaffold-12 (SEQ ID NO: 181). Certain nucleic acid guided nucleases for use in the present disclosure can bind to a pseudoknot region having at least 75%, 80%, 85%, 90%, 95% or 100% sequence identity to the pseudoknot region of scaffold-25 (SEQ ID NO: 182).

[0041] Certain nucleic acid guided nucleases for use in the present disclosure can bind to a scaffold sequence having at least 75%, 80%, 85%, 90%, 95% or 100% sequence identity to any one of SEQ ID NOs: 84-107 or 172-182. Certain nucleic acid guided nucleases for use in the present disclosure can bind to a scaffold sequence having at least 75%, 80%, 85%, 90%, 95% or 100% sequence identity to any one of the sequences shown in Figures 49A, 49B or 49C.

[0042] Certain nucleic acid-guided nucleases for use in the present disclosure can bind to a scaffold sequence having a loop sequence as shown in Figure 49A, 49B or 49C. Certain nucleic acid-guided nucleases for use in the present disclosure can bind to a scaffold sequence having a loop sequence of UAUU, UUU, UGUU, UCUU, UCUUU or UAGU.

[0043] Certain nucleic acid-guided nucleases for use in the present disclosure can bind to a scaffold sequence comprising an RNA version of SEQ ID NO: 181, in which T is replaced with U. In some cases, the scaffold sequence comprises at least one mutation compared to the RNA version of SEQ ID NO: 181. For example, the scaffold sequence can comprise an altered sequence in the loop sequence of the scaffold sequence. For example, the loop sequence can comprise UAUU, UUU, UGUU, UCUU, UCUUU, or UAGU.

[0044] The guide nucleic acid may comprise any one of the sequences of SEQ ID NOs: 84 to 107. The guide nucleic acid may comprise any one of the sequences of SEQ ID NOs: 84 to 103. The guide nucleic acid may comprise any one of the sequences of SEQ ID NOs: 84 to 91 or 93 to 95. The guide nucleic acid may comprise any one of the sequences of SEQ ID NOs: 88, 93, 94 or 95. The guide nucleic acid may comprise the sequence of SEQ ID NO: 88. The guide nucleic acid may comprise the sequence of SEQ ID NO: 93. The guide nucleic acid may comprise the sequence of SEQ ID NO: 94. The guide nucleic acid may comprise the sequence of SEQ ID NO: 95.

[0045] In aspects of the present invention, the term "guide nucleic acid" refers to one or more polynucleotides that include 1) a guide sequence that can hybridize to a target sequence, and 2) a scaffold sequence that can interact with or form a complex with a nucleic acid-guided nuclease as described herein. The guide nucleic acid may be provided as one or more nucleic acids. In certain embodiments, the guide sequence and the scaffold sequence are provided as a single polynucleotide.

[0046] A guide nucleic acid and a nucleic acid-induced nuclease can be compatible when the two elements can form a functional targetable nuclease complex that can cleave a target sequence.In many cases, a compatible scaffold sequence for a compatible guide nucleic acid can be found by scanning the sequences adjacent to the native nucleic acid-induced nuclease locus.In other words, a native nucleic acid-induced nuclease can be encoded on the genome in the vicinity of the corresponding compatible guide nucleic acid or scaffold sequence.

[0047] The nucleic acid-guided nuclease may be adapted to a guide nucleic acid not found in the nuclease's endogenous host. Such an orthogonal guide nucleic acid can be determined by empirical testing. The orthogonal guide nucleic acid may be derived from a different bacterial species and may be synthetic or otherwise engineered to be non-naturally occurring.

[0048] Orthogonal guide nucleic acids that are compatible with a common nucleic acid-guided nuclease may include one or more common features. The common features may include a sequence outside the pseudoknot region. The common features may include the pseudoknot region. The common features may include a primary sequence or a secondary structure.

[0049] A guide nucleic acid can be engineered to target a desired target sequence by altering the guide sequence such that the guide sequence is complementary to the target sequence, thereby allowing hybridization of the guide sequence with the target sequence. A guide nucleic acid having an engineered guide sequence can be referred to as an engineered guide nucleic acid. Engineered guide nucleic acids are often not naturally occurring and are not found in nature.

[0050] Guide nucleic acid or scaffold sequences compatible with a nuclease of interest can be identified or tested using screening assays disclosed herein. Generally, a library of vectors can be generated as disclosed herein, the vectors comprising a target sequence flanked by a PAM sequence. The vectors can comprise a selectable or screenable marker. The vectors can comprise a guide nucleic acid sequence to be tested. The vectors can comprise a barcode or other unique identifier that allows identification of the guide nucleic acid to be tested. The guide nucleic acid can comprise a targeting sequence capable of targeting the target sequence of the vector. The guide nucleic acid can comprise a scaffold sequence. Generally, within such a library of vectors, the scaffold sequence can vary between different vectors, allowing for screening or testing of a large number of different scaffold sequences in a single experiment or in a high-throughput manner. In some cases, the stem-loop sequence within the scaffold sequence can vary between different vectors, allowing for screening or testing of a large number of different scaffold sequences in a single experiment or in a high-throughput manner. In some cases, the vector library comprises a variety of different PAM sequences flanking a target sequence. The vector library can then be introduced into a host cell, which contains the nuclease of interest. The nuclease of interest can be expressed from the same or different vector introduced into the cell at the same time as the guide nucleic acid vector, before or after. In other cases, the nuclease of interest can be introduced into the cell as an mRNA transcript. In other cases, the nuclease of interest can be introduced into the cell as a protein. Without wishing to be bound by theory, the guide nucleic acid will be expressed in each cell. If the expressed guide nucleic acid is compatible with the nuclease of interest, the guide nucleic acid will form a complex with the nuclease of interest, targeting the nuclease to the target sequence, which can then be cleaved by the nuclease. This cleavage event will cause the host cell to lose the vector containing the target sequence, or lose the function of the selectable or screenable marker, and the host cell will die during selection or be lost during screening.On the other hand, if the guide nucleic acid is not compatible with the nuclease of interest, the target sequence will not be cleaved and thus the host cell will maintain the selectable or screenable marker. Depleted vectors can be identified by comparing the input vectors with those selected or screened for vectors from surviving or selected output host cells. Sequencing or analyzing the barcodes or unique identifiers of the input and output vectors will allow identification of depleted barcodes or unique identifiers, which will allow identification of depleted guide nucleic acids. Depleted guide nucleic acids will include those that are compatible with the nuclease of interest.

[0051] In some cases, when performing the guide nucleic acid screening or testing assays described herein, the assays can also be used to identify or screen for PAM sequences that are compatible with a nuclease of interest. In such cases, the vectors in the vector library can include a barcode or unique identifier adjacent to the PAM. By comparing the input vectors to the output vectors, depleted PAM sequences can be identified. The depleted PAM sequences will include those that are compatible with a nuclease of interest. In some cases, the assays described herein can be used to identify or test guide nucleic acid and PAM sequences that are compatible with a nuclease of interest in a single experiment or screen or in a high-throughput format.

[0052] Depletion may refer to a reduction in a subject sequence relative to the starting frequency or reference sequence frequency. Depletion is the opposite of enrichment and therefore may also be expressed as a negative enrichment value. Depletion can be calculated using any method known in the art. In some cases, a depletion score can be calculated by calculating the frequency of each sequence or construct in the experimental data and comparing the subject frequency to the control. Here, depletion is the level of change in the subject frequency relative to the control or reference frequency. In some cases, a threshold frequency is used to reduce noise. For example, there may be a cutoff of at least 50 counts before the data is used to calculate the depletion score. The mean or standard deviation is calculated for sequences that show no change relative to the control or reference frequency. This mean and standard deviation can be used to derive a z-score that can obtain a p-value of less than 0.05 to infer a significance threshold. In some cases, a cutoff is used to correct for possible overestimation of the depletion score, above which depletion scores are considered depleted. In some cases, the threshold is a log 2 -1, log 2 -2, log 2 -3, log 2 -4 or log 2 It could be -5.

[0053] In some examples, the depletion score can be calculated as a log2 depletion score using the following formula: W = log2(Fx,f / Fx,i), where Fx,f is the frequency of cassette X at the final time point, Fx,i is the initial frequency of cassette X, and W is the absolute fitness of each variant. Frequency was determined by dividing the read counts for each variant by the total experimental counts, including those lost in filtering. A count-weighted average of multiple replicates can be used to infer the average fitness score for each mutation as follows: W = (Σ N i=1 counts i *W i ) / (Σ N i=1 counts i). The calculated score may be referred to as a depletion score if the calculated value is negative, or an enrichment score if the calculated value is positive.

[0054] Targetable Nuclease Systems Disclosed herein is a targetable nuclease system. The targetable nuclease system may comprise a nucleic acid-guided nuclease and a suitable guide nucleic acid. The targetable nuclease system may comprise a nucleic acid-guided nuclease or a polynucleotide sequence encoding the nucleic acid-guided nuclease. The targetable nuclease system may comprise a guide nucleic acid or a polynucleotide sequence encoding the guide nucleic acid.

[0055] In general, the targetable nuclease systems disclosed herein are characterized by elements that promote the formation of a targetable nuclease complex at the site of a target sequence, where the targetable nuclease complex comprises a nucleic acid-guided nuclease and a guide nucleic acid.

[0056] The guide nucleic acid and the nucleic acid-guided nuclease together form a targetable nuclease complex that can bind to a target sequence within a target polynucleotide, as determined by the guide sequence of the guide nucleic acid.

[0057] Generally, to generate a double-stranded break, in most cases a targetable nucleic acid nuclease complex must bind to a target sequence determined by a guide nucleic acid, and the nuclease must recognize a protospacer adjacent motif (PAM) sequence adjacent to the target sequence.

[0058] The targetable nuclease complex may comprise a nucleic acid-guided nuclease of any one of SEQ ID NOs: 1-20 and a compatible guide nucleic acid. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of any one of SEQ ID NOs: 1-8 or 10-12 and a compatible guide nucleic acid. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of any one of SEQ ID NOs: 1-8 or 10-11 and a compatible guide nucleic acid. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 2 and a compatible guide nucleic acid. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid. In any of these cases, the guide nucleic acid may comprise a scaffold sequence compatible with the nucleic acid-guided nuclease. In any of these cases, the scaffold sequence may be a natural scaffold sequence or a heterologous scaffold sequence. In any of these cases, the guide nucleic acid may further comprise a guide sequence. The guide sequence may be engineered to target any desired target sequence. The guide sequence may be engineered to be complementary to any desired target sequence. The guide sequence may be engineered to hybridize to any desired target sequence.

[0059] The targetable nuclease complex may comprise a nucleic acid-guided nuclease of any one of SEQ ID NOs: 1-20 and a compatible guide nucleic acid comprising any one of SEQ ID NOs: 84-107. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of any one of SEQ ID NOs: 1-20 and a compatible guide nucleic acid comprising any one of SEQ ID NOs: 172-182. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of any one of SEQ ID NOs: 1-8 or 10-12 and a compatible guide nucleic acid comprising any one of SEQ ID NOs: 84-95. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of any one of SEQ ID NOs: 1-8 or 10-12 and a compatible guide nucleic acid comprising any one of SEQ ID NOs: 172-182. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of any one of SEQ ID NOs: 1-8 or 10-11 and a compatible guide nucleic acid comprising any one of SEQ ID NOs: 84-91 or 93-95. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of any one of SEQ ID NOs: 1-8 or 10-11 and a compatible guide nucleic acid comprising any one of SEQ ID NOs: 172-182. In any of these cases, the guide nucleic acid may further comprise a guide sequence. The guide sequence may be engineered to target any desired target sequence. The guide sequence may be engineered to be complementary to any desired target sequence. The guide sequence may be engineered to hybridize to any desired target sequence.

[0060] The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 2 and a compatible guide nucleic acid comprising any one of SEQ ID NOs: 84-107 or 172-182. The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 2 and a compatible guide nucleic acid comprising any one of SEQ ID NOs: 88, 93, 94 or 95. The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 2 and a compatible guide nucleic acid comprising SEQ ID NO: 88. The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 2 and a compatible guide nucleic acid comprising SEQ ID NO: 93. The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 2 and a compatible guide nucleic acid comprising SEQ ID NO: 94. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO:2 and a compatible guide nucleic acid comprising SEQ ID NO:95. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO:2 and a compatible guide nucleic acid comprising SEQ ID NO:172. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO:2 and a compatible guide nucleic acid comprising SEQ ID NO:173. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO:2 and a compatible guide nucleic acid comprising SEQ ID NO:174. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO:2 and a compatible guide nucleic acid comprising SEQ ID NO:175. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO:2 and a compatible guide nucleic acid comprising SEQ ID NO:176. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO:2 and a compatible guide nucleic acid comprising SEQ ID NO:177. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO:2 and a compatible guide nucleic acid including SEQ ID NO:178. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO:2 and a compatible guide nucleic acid including SEQ ID NO:179.The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO:2 and a compatible guide nucleic acid comprising SEQ ID NO:180. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO:2 and a compatible guide nucleic acid comprising SEQ ID NO:181. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO:2 and a compatible guide nucleic acid comprising SEQ ID NO:182. In any of these cases, the guide nucleic acid may further comprise a guide sequence. The guide sequence may be engineered to target any desired target sequence. The guide sequence may be engineered to be complementary to any desired target sequence. The guide sequence may be engineered to hybridize to any desired target sequence.

[0061] The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising any one of SEQ ID NOs: 84-107 or 172-182. The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising any one of SEQ ID NOs: 88, 93, 94 or 95. The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising SEQ ID NO: 88. The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising SEQ ID NO: 93. The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising SEQ ID NO: 94. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising SEQ ID NO: 95. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising SEQ ID NO: 172. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising SEQ ID NO: 173. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising SEQ ID NO: 174. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising SEQ ID NO: 175. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising SEQ ID NO: 176. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising SEQ ID NO: 177. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid including SEQ ID NO: 178. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid including SEQ ID NO: 179.The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising SEQ ID NO: 180. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising SEQ ID NO: 181. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 7 and a compatible guide nucleic acid comprising SEQ ID NO: 182. In any of these cases, the guide nucleic acid may further comprise a guide sequence. The guide sequence may be engineered to target any desired target sequence. The guide sequence may be engineered to be complementary to any desired target sequence. The guide sequence may be engineered to hybridize to any desired target sequence.

[0062] The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising any one of SEQ ID NOs: 84-107 or 172-182. The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising any one of SEQ ID NOs: 88, 93, 94 or 95. The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising SEQ ID NO: 88. The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising SEQ ID NO: 93. The targetable nuclease complex may comprise a nucleic acid guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising SEQ ID NO: 94. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising SEQ ID NO: 95. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising SEQ ID NO: 172. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising SEQ ID NO: 173. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising SEQ ID NO: 174. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising SEQ ID NO: 175. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising SEQ ID NO: 176. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising SEQ ID NO: 177. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid including SEQ ID NO: 178. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid including SEQ ID NO: 179.The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising SEQ ID NO: 180. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising SEQ ID NO: 181. The targetable nuclease complex may comprise a nucleic acid-guided nuclease of SEQ ID NO: 4 and a compatible guide nucleic acid comprising SEQ ID NO: 182. In any of these cases, the guide nucleic acid may further comprise a guide sequence. The guide sequence may be engineered to target any desired target sequence. The guide sequence may be engineered to be complementary to any desired target sequence. The guide sequence may be engineered to hybridize to any desired target sequence.

[0063] The targetable nuclease complex may include a targetable nuclease of interest and a guide nucleic acid. In some cases, the guide nucleic acid is selected based on its compatibility with the nucleic acid of interest. Methods for determining and selecting a compatible guide nucleic acid are disclosed herein and described in more detail elsewhere. In some cases, the guide nucleic acid is selected based on the cleavage efficiency conferred to the targetable nuclease complex. The cleavage efficiency can be the frequency of cleaving the target nucleic acid. In some cases, the guide nucleic acid is selected based on the targeting efficiency conferred to the targetable nuclease complex. The targeting efficiency can be the frequency of targeting the target nucleic acid of interest. In some cases, the guide nucleic acid is selected based on the cleavage specificity conferred to the targetable nuclease complex. The cleavage specificity can be the frequency of cleavage of the intended target sequence compared to the cleavage of the unintended target sequence. In some cases, the guide nucleic acid is selected based on the targeting specificity conferred to the targetable nuclease complex. Targeting specificity can be the frequency of targeting an intended target sequence compared to targeting an unintended target sequence.

[0064] Characteristics such as cleavage specificity, cleavage efficiency, targeting specificity or targeting efficiency can be determined based on the characteristics of the guide nucleic acid. For example, the scaffold sequence, the pseudoknot region or the loop sequence can affect the targeting or cleavage properties of the nuclease complex of interest, either individually or in combination. In some cases, the part of the scaffold sequence that interacts with the nuclease affects the specificity or efficiency of the cleavage or targeting of the complex. In some cases, the guide sequence (sometimes referred to as the targeting sequence) of the guide nucleic acid affects the specificity or efficiency of the cleavage or targeting of the complex. In some cases, the selection of the target sequence affects the specificity or efficiency of the cleavage or targeting of the complex. For example, the mismatch between the guide sequence and the target sequence can affect the specificity or efficiency of the cleavage or targeting of the complex. In some cases, the position of the mismatch relative to the PAM can affect the specificity or efficiency of the cleavage or targeting of the complex. In some cases, the number of mismatches or the spacing of the mismatches relative to each other can affect the specificity or efficiency of the cleavage or targeting of the complex. In any of these cases, the recited parameters can increase or decrease the targeting specificity, targeting efficiency, cleavage specificity or cleavage efficiency of the subject targetable nuclease complex.

[0065] The target sequence of the targetable nuclease complex can be any polynucleotide that is endogenous or exogenous to a prokaryotic or eukaryotic cell or in vitro. For example, the target sequence can be a polynucleotide present in the nucleus of a eukaryotic cell. The target sequence can be a sequence that encodes a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or junk DNA). Without wishing to be bound by theory, it is believed that the target sequence should be associated with a PAM, a short sequence that is recognized by the targetable nuclease complex. The exact sequence and length requirements of the PAM will vary depending on the nucleic acid-guided nuclease used, but the PAM is typically a 2-5 base pair sequence adjacent to the target sequence. Examples of PAM sequences are provided in the Examples section below, and one of skill in the art will be able to identify additional PAM sequences for use with a given nucleic acid-guided nuclease. Furthermore, engineering of PAM interacting (PI) domains may allow programming of PAM specificity, improving the fidelity of target site recognition and increasing the versatility of the nucleic acid guided nuclease genome editing platform. Nucleic acid guided nucleases may be engineered to alter PAM specificity, for example, as described in Kleinstiver BP et al., "Engineered CRISPR-Cas9 nucleases with altered PAM specificities," Nature, July 23, 2015, Vol. 523 (No. 7561), p. 481-5, doi:10.1038 / nature14592.

[0066] A PAM site is a nucleotide sequence that is adjacent to a target sequence. In most cases, a nucleic acid-guided nuclease can only cleave a target sequence if the appropriate PAM is present. The PAM is nucleic acid-guided nuclease specific and can vary between two different nucleic acid-guided nucleases. The PAM can be 5' or 3' of the target sequence. The PAM can be upstream or downstream of the target sequence. The PAM can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleotides in length. In most cases, the PAM is 2-6 nucleotides in length.

[0067] PAM sites that are compatible with a nuclease or targetable nuclease complex of interest can be identified using the methods disclosed herein. In general, a library of vectors can be generated as disclosed herein, the vectors comprising a target sequence adjacent to a PAM sequence. Within such a library of vectors, the PAM sequence can vary between different vectors, allowing for screening or testing of a large number of different PAM sequences in a single experiment or in a high-throughput manner. The vectors can comprise a barcode or other unique identifier that allows for identification of the PAM being tested. The vectors can comprise a selectable or screenable marker. The vectors can comprise a guide nucleic acid sequence. The guide nucleic acid can comprise a targeting sequence that can target the target sequence of the vector. The guide nucleic acid can comprise a scaffold sequence. In some cases, the vector library comprises a variety of different guide nucleic acid sequences or scaffold sequences. The vector library can then be introduced into a host cell, the host cell comprising the nuclease of interest. The nuclease of interest can be expressed from the same or different vector introduced into the cell at the same time as the guide nucleic acid vector, before or after. In other cases, the nuclease of interest can be introduced into the cell as an mRNA transcript. In other cases, the nuclease of interest can be introduced into the cell as a protein. Without wishing to be bound by theory, the guide nucleic acid will be expressed in each cell and will form a complex with the nuclease of interest. The guide nucleic acid can then target the nuclease to the target sequence. In some cases, if the PAM adjacent to the target sequence is compatible with the nuclease of interest, the nuclease of interest can cleave the target sequence. This cleavage event will cause the host cell to lose the vector containing the target sequence or lose the function of the selectable or screenable marker, so the host cell will die during selection or be lost during screening. On the other hand, if the PAM is not compatible with the nuclease of interest, the target sequence will not be cleaved and thus the host cell will maintain the selectable or screenable marker.Depleted vectors can be identified by comparing the input vectors to those selected or screened for vectors from viable or selected output host cells. By sequencing or analyzing the barcodes or unique identifiers of the input and output vectors, depleted barcodes or unique identifiers can be identified, which will allow for the identification of depleted PAM sequences. Depleted PAM sequences will include those that are compatible with a nuclease of interest.

[0068] In some cases, when performing the PAM screening or testing assays described herein, the assays can also be used to identify or screen for guide nucleic acid sequences that are compatible with the nuclease of interest. In such cases, the vectors in the vector library can include a barcode or unique identifier adjacent to the guide nucleic acid. By comparing the input vectors to the output vectors, depleted guide nucleic acid sequences can be identified. The depleted guide nucleic acid sequences will include those that are compatible with the nuclease of interest. In some cases, the assays described herein can be used to identify or test guide nucleic acid and PAM sequences that are compatible with the nuclease of interest in a single experiment or screen or in a high-throughput format. The methods for calculating and evaluating depletion described above can also be applied to calculate and evaluate depletion in these cases.

[0069] In some cases, the PAM may be provided on a separate oligonucleotide. In such cases, providing the PAM on the oligonucleotide allows for cleavage of a target sequence that would otherwise be unable to be cleaved due to the absence of an adjacent PAM on the same polynucleotide as the target sequence.

[0070] The polynucleotide sequence encoding the components of the targetable nuclease system may comprise one or more vectors. In general, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it is linked. Vectors include, but are not limited to, single-stranded, double-stranded or partially double-stranded nucleic acid molecules; nucleic acid molecules with one or more free ends or without free ends (e.g., circular); nucleic acid molecules containing DNA, RNA or both; and other types of polynucleotides known in the art. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, in which DNA or RNA sequences from a virus are present in the vector for packaging into a virus (e.g., retroviruses, replication-defective retroviruses, adenoviruses, replication-defective adenoviruses and adeno-associated viruses). Viral vectors also include polynucleotides carried by viruses for transfection into host cells. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operably linked. Such vectors are referred to herein as "expression vectors." Common expression vectors useful in recombinant DNA techniques are often in the form of plasmids. Further discussion of vectors is provided herein.

[0071] A recombinant expression vector may contain the nucleic acid of the present invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vector contains one or more regulatory elements, which may be selected based on the host cell used for expression, operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to a regulatory element in a manner that allows expression of the nucleotide sequence (e.g., in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell). Methods of recombination and cloning are referred to in U.S. Patent Application Publication No. 10 / 815,730, published as U.S. Patent Application Publication No. 2004-0171156 A1 on September 2, 2004, the contents of which are incorporated herein by reference in their entirety.

[0072] In some embodiments, a regulatory element is operably linked to one or more elements of the targetable nuclease system so as to drive expression of one or more components of the targetable nuclease system.

[0073] In some embodiments, the vector comprises a regulatory element operably linked to a polynucleotide sequence encoding a nucleic acid-induced nuclease. The polynucleotide sequence encoding the nucleic acid-induced nuclease can be codon-optimized for expression in a particular cell, such as a prokaryotic cell or a eukaryotic cell. The eukaryotic cell can be a yeast, fungus, algae, plant, animal or human cell. The eukaryotic cell can be of or derived from a particular organism, such as a mammal, including but not limited to a human, mouse, rat, rabbit, dog or non-human mammal, including a non-human primate.

[0074] Generally, codon optimization refers to the process of modifying a nucleic acid sequence to enhance expression in a host cell of interest by replacing at least one codon (e.g., about one or more, two or more, three or more, four or more, five or more, ten or more, fifteen or more, twenty or more, twenty-five or more, fifty or more or more codons) of the native sequence with a codon that is more or most frequently used in genes of that host cell while maintaining the native amino acid sequence. Different species show a certain bias for certain codons of certain amino acids. Codon bias (differences in codon usage between organisms) is often thought to correlate with the efficiency of translation of messenger RNA (mRNA), which depends, among other things, on the properties of the codon being translated and the availability of certain transfer RNA (tRNA) molecules. The dominance of selected tRNAs in a cell generally reflects the codons most frequently used in peptide synthesis. Thus, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example at the "Codon Usage Database" at www.kazusa.orjp / codon / (accessed July 9, 2002), and these tables can be adapted in a number of ways. See Nakamura, Y. et al., "Codon Usage Compiled from International DNA Sequence Databases: Status in the Year 2000," Nucl. Acids Res. 28:292 (2000). Computer algorithms are also available that codon-optimize specific sequences for expression in specific host cells, such as Gene Forge (Aptagen, Jacobus, PA). In some embodiments, one or more codons (e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more, or all codons) in the sequence encoding the engineered nuclease correspond to the most frequently used codon for a particular amino acid.

[0075] In some embodiments, the vector encodes a nucleic acid-guided nuclease that includes one or more nuclear localization sequences (NLSs), such as about one or more, about two or more, about three or more, about four or more, about five or more, about six or more, about seven or more, about eight or more, about nine or more, about ten or more or more NLSs. In some embodiments, the engineered nuclease comprises about one or more, about two or more, about three or more, about four or more, about five or more, about six or more, about seven or more, about eight or more, about nine or more, about ten or more or more NLSs at or near the amino terminus and about one or more, about two or more, about three or more, about four or more, about five or more, about six or more, about seven or more, about eight or more, about nine or more, about ten or more or more NLSs at or near the carboxy terminus, or combinations thereof (e.g., one or more NLSs at the amino terminus and one or more NLSs at the carboxy terminus). When more than one NLS is present, each can be selected independently of the other NLSs, and thus a single NLS can be present in more than one copy and / or in combination with one or more other NLSs present in one or more copies. In a preferred embodiment of the invention, the engineered nuclease comprises up to six NLSs. In some embodiments, an NLS is considered to be near the N- or C-terminus if the nearest amino acid to the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more amino acids along the polypeptide chain from the N- or C-terminus.Non-limiting examples of NLSs include an NLS sequence derived from the NLS of the SV40 virus large T-antigen having the amino acid sequence PKKKRKV (SEQ ID NO: 111); an NLS sequence derived from an NLS from nucleoplasmin (e.g., the nucleoplasmin bipartite NLS having the sequence KRPAATKKAGQAKKKK (SEQ ID NO: 112)); an NLS sequence derived from a c-myc NLS having the amino acid sequence PAAKRVKLD (SEQ ID NO: 113) or RQRRNELKRSP (SEQ ID NO: 114); an NLS sequence derived from a hRNPA1 M9 NLS having the sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO: 115); an NLS sequence derived from the IBB domain from importin-alpha having the sequence RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO: 1 116); the NLS sequence derived from the sequences VSRKRPRP (SEQ ID NO: 117) and PPKKARED (SEQ ID NO: 118) of the sarcoma T protein; the NLS sequence derived from the sequence PQPKKKPL (SEQ ID NO: 119) of human p53; the NLS sequence derived from the sequence SALIKKKKKMAP (SEQ ID NO: 120) of mouse c-abl IV; the NLS sequence derived from the sequences DRLRR (SEQ ID NO: 121) and PKQKKRK (SEQ ID NO: 122) of influenza virus NS1; the NLS sequence derived from the sequence RKLKKKIKKL (SEQ ID NO: 123) of the hepatitis virus delta antigen; the NLS sequence derived from the sequence REKKKFLKRR (SEQ ID NO: 124) of the mouse Mx1 protein; the NLS sequence derived from the sequence KRKGDEVDGVDEVAKKKSKK (SEQ ID NO: 125) of human poly(ADP-ribose) polymerase; and the NLS sequence derived from the sequence RKCLQAGMNLEARKTKK (SEQ ID NO: 126) of the steroid hormone receptor (human) glucocorticoid.

[0076] In general, the one or more NLSs are of sufficient strength to drive the accumulation of the nucleic acid-guided nuclease in a detectable amount in the nucleus of a eukaryotic cell. In general, the strength of the nuclear localization activity can be derived from the number of NLSs, the specific NLS used, or a combination of these factors. The detection of the accumulation in the nucleus can be performed by any suitable technique. For example, a detectable marker can be fused to the nucleic acid-guided nuclease, and thus the intracellular location can be visualized, for example, in combination with a means for detecting the location of the nucleus (e.g., a nuclear-specific stain such as DAPI). The cell nucleus can also be isolated from the cell, and its contents can then be analyzed by any suitable process for detecting proteins, such as immunohistochemistry, Western blot, or enzyme activity assay. Accumulation in the nucleus can also be determined indirectly, for example, by assaying for the effect of nucleic acid-guided nuclease complex formation (e.g., assaying for DNA cleavage or mutations in the target sequence or assaying for changes in gene expression activity affected by targetable nuclease complex formation and / or nucleic acid-guided nuclease activity) compared to a control not exposed to a nucleic acid-guided nuclease or targetable nuclease complex, or exposed to a nucleic acid-guided nuclease lacking one or more NLSs.

[0077] The nucleic acid-guided nuclease and one or more guide nucleic acids can be delivered as DNA or RNA. Delivery of both the nucleic acid-guided nuclease and the guide nucleic acid as RNA (unmodified or with base or backbone modifications) molecules can be used to reduce the time that the nucleic acid-guided nuclease remains in the cell. This can reduce the level of off-target cleavage activity in the target cell. Because delivery of the nucleic acid-guided nuclease as mRNA takes time to be translated into protein, it may be advantageous to deliver the guide nucleic acid several hours after delivery of the nucleic acid-guided nuclease mRNA to maximize the level of guide nucleic acid available for interaction with the nucleic acid-guided nuclease protein. In other cases, the nucleic acid-guided nuclease mRNA and the guide nucleic acid are delivered simultaneously. In other examples, the guide nucleic acid is delivered sequentially 0.5, 1, 2, 3, 4 hours or more after the nucleic acid-guided nuclease mRNA.

[0078] In situations where the amount of guide nucleic acid is limiting, it may be desirable to introduce the guide nucleic acid in the form of a DNA expression cassette with a promoter driving expression of the nucleic acid-guided nuclease and guide nucleic acid as mRNA, thereby amplifying the amount of available guide nucleic acid by transcription.

[0079] Guide nucleic acids in the form of RNA or encoded on a DNA expression cassette can be introduced into a host cell that contains a nucleic acid-guided nuclease encoded on a vector or chromosome. The guide nucleic acid can be provided in the cassette as one or more polynucleotides that can be contiguous or non-contiguous within the cassette. In certain embodiments, the guide nucleic acid is provided in the cassette as a single contiguous polynucleotide.

[0080] A variety of delivery systems can be used to introduce the nucleic acid-guided nuclease (DNA or RNA) and guide nucleic acid (DNA or RNA) into the host cell. These include the use of yeast systems, lipofection systems, microinjection systems, gene gun systems, virosomes, liposomes, immunoliposomes, polycations, lipid:nucleic acid conjugates, virions, artificial virions, viral vectors, electroporation, cell-penetrating peptides, nanoparticles, nanowires (Shalek et al., Nano Letters, 2012), and exosomes. Trojan horse molecule liposomes (Pardridge et al., Cold Spring Harb Protoc, 2010, doi:10.1101 / pdb.prot5407) can be used to deliver engineered nucleases and guide them across the blood-brain barrier.

[0081] In some embodiments, an editing template is also provided. The editing template is a component of the vector described herein and may be included in a separate vector or provided as a separate polynucleotide, such as an oligonucleotide, a linear polynucleotide, or a synthetic polynucleotide. In some cases, the editing template is on the same polynucleotide as the guide nucleic acid. In some embodiments, the editing template is designed to function as a template for homologous recombination, such as within or near the target sequence that is nicked or cleaved by the nucleic acid-guided nuclease as part of the complex disclosed herein. The editing template polynucleotide may be of any suitable length, such as about 10 nucleotides or more, about 15 nucleotides or more, about 20 nucleotides or more, about 25 nucleotides or more, about 50 nucleotides or more, about 75 nucleotides or more, about 100 nucleotides or more, about 150 nucleotides or more, about 200 nucleotides or more, about 500 nucleotides or more, about 1000 nucleotides or more, or more in length. In some embodiments, the editing template polynucleotide is complementary to a portion of a polynucleotide that includes a target sequence. When optimally aligned, the editing template polynucleotide may overlap one or more nucleotides of the target sequence (e.g., about 1 nucleotide or more, about 5 nucleotides or more, about 10 nucleotides or more, about 15 nucleotides or more, about 20 nucleotides or more, about 25 nucleotides or more, about 30 nucleotides or more, about 35 nucleotides or more, about 40 nucleotides or more or more). In some embodiments, when a polynucleotide comprising an editing template sequence and a target sequence is optimally aligned, the nearest nucleotide of the template polynucleotide is within about 1 nucleotide, about 5 nucleotides, about 10 nucleotides, about 15 nucleotides, about 20 nucleotides, about 25 nucleotides, about 50 nucleotides, about 75 nucleotides, about 100 nucleotides, about 200 nucleotides, about 300 nucleotides, about 400 nucleotides, about 500 nucleotides, about 1000 nucleotides, about 5000 nucleotides, about 10000 nucleotides or more of the target sequence.

[0082] In many examples, the editing template comprises at least one mutation compared to the target sequence. The editing template may comprise an insertion, a deletion, a modification, or any combination thereof, compared to the target sequence. Some examples of editing templates are described in more detail in the following sections.

[0083] In some aspects, the disclosure provides methods comprising delivering to a host cell one or more polynucleotides, such as one or more vectors or linear polynucleotides described herein, one or more transcripts thereof and / or one or more proteins transcribed therefrom to the host cell. In some aspects, the invention further provides cells produced by such methods and organisms comprising or produced from such cells. In some embodiments, an engineered nuclease in combination (and optionally complexed) with a guide nucleic acid is delivered to the cell.

[0084] Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids into cells, such as prokaryotic cells, eukaryotic cells, mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding components of engineered nucleic acid-guided nuclease systems to cells in culture or in a host organism. Non-viral vector delivery systems include DNA plasmids, RNA (e.g., transcripts of vectors described herein), naked nucleic acids and nucleic acids complexed with delivery vehicles such as liposomes. Viral vector delivery systems include DNA and RNA viruses that have either episomal or integrated genomes after delivery to cells.For reviews of gene therapy procedures, see Anderson, Science 256:808-813 (1992); Nabel and Feigner, TIBTECH 11:211-217 (1993); Mitani and Caskey, TIBTECH 11:162-166 (1993); Dillon, TIBTECH 11:167-175 (1993); Miller, Nature 357:455-460 (1992); Van Brunt, Brunt, Biotechnology, vol. 6, no. 10, pp. 1149-1154 (1988); Vigne, Restorative Neurology and Neuroscience, vol. 8, pp. 35-36 (1995); Kremer and Perricaudet, British Medical Bulletin, vol. 51, no. 1, pp. 31-44 (1995); Haddada et al., Current Topics in Microbiology and Immunology, eds. Doerfler and Bohm (1995); and Yu et al., Gene Therapy, vol. 1, pp. 1171-1175 (1995). Therapy), Vol. 1, pp. 13-26 (1994).

[0085] Methods of non-viral delivery of nucleic acids include lipofection, microinjection, gene guns, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and drug-enhanced uptake of DNA. Lipofection is described, for example, in U.S. Pat. Nos. 5,049,386, 4,946,787, and 4,897,355, and lipofection reagents are commercially available (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids suitable for efficient receptor-recognition lipofection of polynucleotides include those of Felgner, WO 91 / 17424, WO 91 / 16024. Delivery can be to cells (e.g., in vitro or ex vivo administration) or to target tissues (e.g., in vivo administration).

[0086] The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to those of skill in the art (e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et al., Bioconjugate Chem. 5:382-389 (1994); Remy et al., Bioconjugate Chem. 5:647-654 (1994); Gao et al., Gene Ther. 5:111-112 (1994)). Therapy, 2:710-722 (1995); Ahmad et al., Cancer Res., 52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787.

[0087] The use of RNA or DNA virus-based systems for delivery of nucleic acids exploits highly evolved processes for targeting viruses to specific cells in culture or within a host and transporting the viral load into the nucleus or host cell genome. Viral vectors can be administered directly to cells in culture, to a patient (in vivo), or used to treat cells in vitro, and the modified cells can optionally be administered to a patient (ex vivo). Traditional virus-based systems can include retroviral, lentiviral, adenoviral, adeno-associated, and herpes simplex virus vectors for gene transfer. Retroviral, lentiviral, and adeno-associated viral gene transfer methods allow integration in the host genome, often resulting in long-term expression of the inserted transgene. Furthermore, high transduction efficiencies have been observed in many different cell types and target tissues.

[0088] The tropism of retroviruses can be altered by incorporating foreign envelope proteins, expanding the potential target population of target cells. Lentiviral vectors are retroviral vectors that can transduce or infect non-dividing cells and typically result in high viral titers. Thus, the choice of retroviral gene transfer system will depend on the target tissue. Retroviral vectors consist of cis-acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The minimal cis-acting LTRs are sufficient for vector replication and packaging, which are then used to integrate therapeutic genes into target cells to provide sustained transgene expression. Widely used retroviral vectors include those based on murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al., J. Virol. 66:2731-2739 (1992); Johann et al., J. Virol. 66:1635 (1993)). 176:58-59 (1990); Wilson et al., J. Virol. 63:2374-2378 (1989); Miller et al., J. Virol. 65:2220-2224 (1991); see PCT / U.S. Patent Application Publication No. 94 / 05700).

[0089] For applications where transient expression is preferred, adenovirus-based systems can be used. Adenovirus-based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. Higher titers and expression levels have been obtained with such vectors. This vector can be produced in large quantities with a relatively simple system.

[0090] Adeno-associated virus ("AAV") vectors can also be used, for example, in in vitro production of nucleic acids and peptides, and to transduce cells with target nucleic acids for in vivo and ex vivo gene therapy procedures (see, e.g., West et al., Virology 160:38-47 (1987); U.S. Pat. No. 4,797,368; WO 93 / 24641; Kotin, Human Gene Therapy 5:793-801 (1994); Muzyczka, J. Clin. Invest. 94:1351 (1994)). Construction of recombinant AAV vectors has been described in detail in U.S. Pat. No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin et al., Mol. Cell. Biol. 4:202-204 (1986); 72-2081 (1984); Hermonat and Muzyczka, Proceedings of the National Academy of Sciences of the United States of America, vol. 81, pp. 6466-6470 (1984); and Samulski et al., J. Virol. 63, pp. 03822-3828 (1989).

[0091] In some embodiments, the host cells are transiently or non-transiently transfected with one or more vectors, linear polynucleotides, polypeptides, nucleic acid-protein complexes, or any combination thereof described herein. In some embodiments, the cells are transfected in vitro, in culture, or ex vivo. In some embodiments, the cells are transfected as they naturally occur in the subject. In some embodiments, the transfected cells are taken from the subject. In some embodiments, the cells are derived from cells taken from the subject, such as a cell line.

[0092] In some embodiments, cells transfected with one or more vectors, linear polynucleotides, polypeptides, nucleic acid-protein complexes, or any combination thereof described herein, are used to establish new cell lines that contain one or more transfection-derived sequences. In some embodiments, cells that have been transiently transfected with components of the engineered nucleic acid-guided nuclease systems described herein (such as by transient transfection of one or more vectors or transfection with RNA) and modified by the activity of the engineered nuclease complexes are used to establish new cell lines that include cells that contain the modifications but lack other exogenous sequences.

[0093] In some embodiments, one or more vectors described herein are used to produce non-human transgenic cells, organisms, animals or plants. In some embodiments, the transgenic animal is a mammal, such as a mouse, rat or rabbit. Methods for producing transgenic cells, organisms, plants and animals are known in the art and generally begin with a method of cell transformation or transfection, such as those described herein.

[0094] The methods disclosed herein can be used to analyze off-target cleavage events. Off-target cleavage events can be cleavage events that occur at a nucleic acid sequence location other than the intended target sequence, thereby making them unintended target sequences. In general, a library of vectors can be generated as disclosed herein, the vectors comprising a target sequence or an unintended target sequence adjacent to a PAM sequence. Within such a library of vectors, the target sequence or the unintended target sequence can vary between different vectors, so that a large number of different target sequences or unintended target sequences can be screened or tested in a single experiment or in a high-throughput manner. The vectors can comprise a barcode or other unique identifier that allows identification of the target sequence or the unintended target sequence being tested. The vectors can comprise a selectable or screenable marker. The vectors can comprise a guide nucleic acid sequence. The guide nucleic acid can comprise a target sequence that can target a compatible target sequence within the vector. The guide nucleic acid can comprise a scaffold sequence. The vector library can then be introduced into a host cell, the host cell comprising the nuclease of interest. The nuclease of interest can be expressed from the same or different vector introduced into the cell at the same time as the guide nucleic acid vector, before or after. In other cases, the nuclease of interest can be introduced into the cell as an mRNA transcript. In other cases, the nuclease of interest can be introduced into the cell as a protein. Without wishing to be bound by theory, the guide nucleic acid will be expressed in each cell and will form a complex with the nuclease of interest. The guide nucleic acid can then target the nuclease to a compatible target sequence. In some cases, if the guide nucleic acid can hybridize with the target sequence or an unintended target sequence, the nuclease of interest can cleave the target sequence or an unintended target sequence. This cleavage event will cause the host cell to lose the vector containing the target sequence or lose the function of the selectable or screenable marker, so the host cell will die during selection or be lost during screening.On the other hand, if the guide nucleic acid cannot hybridize to the unintended target sequence, the unintended target sequence will not be cleaved and the host cell will maintain the selectable or screenable marker. Depleted vectors can be identified by comparing the input vectors to those selected or screened for vectors from viable or selected output host cells. Sequencing or analyzing the barcodes or unique identifiers of the input and output vectors will allow identification of depleted or unintended target sequences. Depleted or unintended target sequences will include those that can hybridize with the guide nucleic acid and thus be cleaved by the nuclease of interest. Depleted unintended target sequences will therefore include off-target cleavage events or off-target sequences that can be cleaved by the nuclease system of interest.

[0095] The unintended target sequence to be tested or screened in the off-target assay disclosed herein can be a variant of a known target sequence that can be targeted by the guide nucleic acid of interest.For example, using a known target sequence of interest, the unintended target sequence can be designed to include insertions, deletions, rearrangements or other sequence changes compared to the known target sequence.Such sequence changes can include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleotides.The changed nucleotides can be contiguous or non-contiguous.

[0096] The methods of depletion calculation and evaluation described above are also applicable to depletion calculation and evaluation in these cases. Other off-target evaluation assays have involved sequencing the genome of the host organism to identify off-target cleavage events, which are often identifiable due to sequence mutations, such as insertions, deletions, and mutations of one or more nucleotides. Thus, these other methods are limited by the genomic sequence of the host cell when evaluating the off-target effects of the subject nuclease system. The subject assay disclosed herein allows for a much more robust and high-throughput method of identifying the off-target effects of virtually any sequence, which is not limited by the genomic sequence of the host cell.

[0097] How to use In the context of the formation of an engineered nuclease complex, a "target sequence" refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between the target sequence and the guide sequence promotes the formation of an engineered nuclease complex. A target sequence may comprise any polynucleotide, such as DNA, RNA, or a DNA-RNA hybrid. A target sequence may be located in the nucleus or cytoplasm of a cell. A target sequence may be located in vitro or in a cell-free environment.

[0098] Typically, formation of an engineered nuclease complex comprising a guide nucleic acid hybridized to a target sequence and complexed with one or more engineered nucleases disclosed herein results in cleavage of one or both strands in or near (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs therefrom) the target sequence. Cleavage can occur within the target sequence, 5' of the target sequence, upstream of the target sequence, 3' of the target sequence or downstream of the target sequence.

[0099] In some aspects, one or more vectors driving the expression of one or more components of the targetable nuclease system are introduced into a host cell or in vitro to form a targetable nuclease complex at one or more target sites. For example, the nucleic acid-guided nuclease and the guide nucleic acid can each be operably linked to separate regulatory elements on separate vectors. Alternatively, two or more elements expressed from the same or different regulatory elements can be combined into a single vector, with one or more additional vectors providing any components of the targetable nuclease system not included in the first vector. The elements of the targetable nuclease system combined into a single vector can be positioned in any suitable orientation, such as one element located 5' with respect to ("upstream") the second element or 3' with respect to ("downstream") the second element. The coding sequence of one element can be located on the same or opposite strand of the coding sequence of the second element and oriented in the same or opposite direction. In some embodiments, a single promoter drives expression of transcripts encoding the nucleic acid-induced nuclease and one or more guide nucleic acids. In some embodiments, the nucleic acid-induced nuclease and one or more guide nucleic acids are operably linked to and expressed from the same promoter. In other embodiments, the one or more guide nucleic acids or polynucleotides encoding the one or more guide nucleic acids are introduced into a cell or in vitro environment that already contains the nucleic acid-induced nuclease or a polynucleotide sequence encoding the nucleic acid-induced nuclease.

[0100] When multiple different guide sequences are used, a single expression construct can be used to direct nuclease activity to multiple different corresponding target sequences in cells or in vitro. For example, a single vector can contain about 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 15 or more, 20 or more or more guide sequences. In some embodiments, about 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more or more such guide sequence-containing vectors can be provided and optionally delivered into cells or in vitro.

[0101] The methods and compositions disclosed herein may include multiple guide nucleic acids, where each guide nucleic acid has a different guide sequence, thereby targeting a different target sequence. In such cases, multiple guide nucleic acids can be used for multiplexing, targeting multiple targets simultaneously. Additionally or alternatively, multiple guide nucleic acids are introduced into a population of cells, such that each cell in the population receives a different or random guide nucleic acid, thereby targeting multiple different target sequences across the population of cells. In such cases, the collection of altered cells may then be referred to as a library.

[0102] The methods and compositions disclosed herein include multiple different nucleic acid-guided nucleases, each with one or more different corresponding guide nucleic acids, thereby allowing targeting of different target sequences by the different nucleic acid-guided nucleases. In some such cases, each nucleic acid-guided nuclease can correspond to a separate multiplexing nucleic acid, thereby allowing two or more non-overlapping, partially overlapping, or fully overlapping multiplexing events.

[0103] In some embodiments, the nucleic acid-guided nuclease has DNA cleavage activity or RNA cleavage activity. In some embodiments, the nucleic acid-guided nuclease induces cleavage of one or both strands at the location of the target sequence, such as within the target sequence and / or within the complement of the target sequence. In some embodiments, the nucleic acid-guided nuclease induces cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500 or more base pairs from the first or last nucleotide of the target sequence.

[0104] In some embodiments, the nucleic acid-induced nuclease may form a component of an inducible system. The inducibility of the system may allow for spatiotemporal control of gene editing or gene expression using a form of energy. The form of energy may include, but is not limited to, electromagnetic radiation, sound energy, chemical energy, light energy, temperature, and thermal energy. Examples of inducible systems include tetracycline-inducible promoters (Tet-On or Tet-Off), small molecule two-hybrid transcriptional activation systems (FKBP, ABA, etc.) or light-inducible systems (phytochrome, LOV domain, or cryptochrome). In one embodiment, the nucleic acid-induced nuclease may be part of a Light Inducible Transcriptional Effector (LITE) to induce changes in transcriptional activity in a sequence-specific manner. Components of light-inducible systems can include nucleic acid-induced nucleases, light-responsive cytochrome heterodimers (e.g., from Arabidopsis thaliana), and transcription activation / repression domains. Further examples of inducible DNA-binding proteins and methods for their use are provided in U.S. Patent Nos. 61 / 736,465 and 61 / 721,283, which are incorporated by reference in their entireties. Inducible systems can be temperature-inducible such that increasing or decreasing the temperature turns the system on or off. In some temperature-inducible systems, increasing the temperature turns the system on. In some temperature-inducible systems, increasing the temperature turns the system off.

[0105] In some aspects, the disclosure provides a method of modifying a target sequence in vitro or in a prokaryotic or eukaryotic cell, which may be in vivo, ex vivo or in vitro. In some embodiments, the method includes sampling a cell or a cell population, such as a prokaryotic cell, or one from a human or non-human animal or plant (including microalgae), and modifying the cell. The culturing may be performed at any stage, in vitro or ex vivo. One or more cells may even be reintroduced into a host, such as a non-human animal or plant (including microalgae). In the case of reintroduced cells, it is particularly preferred that the cell is a stem cell.

[0106] In some embodiments, the method comprises binding a targetable nuclease complex to a target sequence to effect cleavage of said target sequence, thereby modifying the target sequence, wherein the targetable nuclease complex comprises a nucleic acid-guided nuclease complexed with a guide nucleic acid, the guide sequence of the guide nucleic acid hybridized to the target sequence within the target polynucleotide.

[0107] In some aspects, the present disclosure provides a method for modifying the expression of a target polynucleotide in vitro or in a prokaryotic or eukaryotic cell. In some embodiments, the method comprises binding a targetable nuclease complex to a target sequence together with a target polynucleotide, such that said binding results in an increase or decrease in expression of said target polynucleotide, wherein the targetable nuclease complex comprises a nucleic acid-guided nuclease complexed with a guide nucleic acid, and the guide sequence of the guide nucleic acid is hybridized to a target sequence within said target polynucleotide. Similar considerations apply as above for methods of modifying a target polynucleotide. Indeed, these sampling, culturing and reintroduction options apply throughout the aspects of the present invention.

[0108] In some aspects, the present disclosure provides kits that contain any one or more of the elements disclosed in the methods and compositions above. The elements can be provided individually or in combination and can be provided in any suitable container, such as a vial, bottle, or tube. In some embodiments, the kit includes instructions in one or more languages, for example in multiple languages.

[0109] In some embodiments, the kit includes one or more reagents for use in a process utilizing one or more of the elements described herein. The reagents may be provided in any suitable container. For example, the kit may provide one or more reaction or storage buffers. The reagents may be provided in a form that is usable in a particular assay or that requires the addition of one or more other components prior to use (e.g., concentrated or lyophilized form). The buffer may be any buffer, including, but not limited to, sodium carbonate buffer, sodium bicarbonate buffer, borate buffer, Tris buffer, MOPS buffer, HEPES buffer, and combinations thereof. In some embodiments, the buffer is alkaline. In some embodiments, the buffer has a pH of about 7 to about 10. In some embodiments, the kit includes one or more oligonucleotides corresponding to the guide sequence for insertion into a vector to operably link the guide sequence and the regulatory element. In some embodiments, the kit includes an editing template.

[0110] In some aspects, the present disclosure provides a method of using one or more elements of the engineered targetable nuclease system. The targetable nuclease complex of the present disclosure provides an effective means for modifying a target sequence in a target polynucleotide. The targetable nuclease complex of the present disclosure has diverse utilities, including modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target sequence in multiple cell types. Thus, the targetable nuclease complex of the present invention has a wide range of applications, for example, in biochemical pathway optimization, genome-wide studies, genome editing, gene therapy, drug screening, disease diagnosis and prognosis. An exemplary targetable nuclease complex includes a nucleic acid-guided nuclease disclosed herein complexed with a guide nucleic acid, where the guide sequence of the guide nucleic acid can hybridize to a target sequence in a target polynucleotide. The guide nucleic acid may include a guide sequence linked to a scaffold sequence. The scaffold sequence may include one or more sequence regions that have a degree of complementarity such that together they form a secondary structure. In some cases, one or more sequence regions are contained on or encoded by the same polynucleotide. In some cases, one or more sequence regions are contained on or encoded by separate polynucleotides.

[0111] A method for cleaving a target polynucleotide is provided herein. The method includes cleaving a target polynucleotide using a targetable nuclease complex, which binds to a target sequence in the target polynucleotide and causes the cleavage of the target polynucleotide. Typically, the targetable nuclease complex of the present invention causes cleavage (e.g., single-strand or double-strand cleavage) in the target sequence when introduced into a cell. For example, this method can be used to cleave a target gene in a cell or replace a wild-type sequence with a modified sequence.

[0112] The breaks made by the targetable nuclease complex can be repaired by repair or recombination processes such as the error-prone non-homologous end joining (NHEJ) pathway, high-fidelity homology-directed repair (HDR), etc. During these repair processes, an editing template can be introduced into the genomic sequence. Some methods use HDR or recombination processes to modify the target sequence. For example, an editing template is introduced into a cell that includes a sequence to be integrated, flanked by upstream and downstream sequences. The upstream and downstream sequences share sequence similarity with either side of the integration site of the chromosome, target vector, or target polynucleotide.

[0113] The editing template can be DNA or RNA, such as a DNA plasmid, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), a viral vector, a linear piece of DNA, a PCR fragment, an oligonucleotide, a synthetic polynucleotide, a naked nucleic acid, or a nucleic acid complexed with a delivery vehicle such as a liposome or poloxamer.

[0114] The editing template polynucleotide may include a sequence to be integrated (e.g., a mutant gene). The sequence for integration may be an endogenous or exogenous sequence to the cell. Examples of sequences to be integrated include polynucleotides that code for proteins or non-coding RNA (e.g., microRNA). Thus, the sequence for integration may be operably linked to an appropriate control sequence. Alternatively, the sequence to be integrated may provide a regulatory function. The sequence to be integrated may be a mutant or variant of an endogenous wild-type sequence. Alternatively, the sequence to be integrated may be a wild-type version of an endogenous mutant sequence. Additionally or alternatively, the sequence to be integrated may be a variant or mutant form of an endogenous mutant or variant sequence.

[0115] The upstream and downstream sequences of the editing template polynucleotide can be selected to promote recombination between the target polynucleotide of interest and the editing template polynucleotide. The upstream sequence can be a nucleic acid sequence that has sequence similarity with the sequence upstream of the target site for integration. Similarly, the downstream sequence can be a nucleic acid sequence that has similarity with the sequence downstream of the target site for integration. The upstream and downstream sequences of the editing template can have 75%, 80%, 85%, 90%, 95% or 100% sequence identity with the target polynucleotide. Preferably, the upstream and downstream sequences of the editing template polynucleotide have about 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the target polynucleotide. In some methods, the upstream and downstream sequences of the editing template polynucleotide have about 99% or 100% sequence identity with the target polynucleotide.

[0116] The upstream or downstream sequence may comprise from about 20 bp to about 2500 bp, e.g., about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 bp. In some methods, exemplary upstream or downstream sequences have from about 15 bp to about 50 bp, from about 30 bp to about 100 bp, from about 200 bp to about 2000 bp, from about 600 bp to about 1000 bp, or more particularly from about 700 bp to about 1000 bp.

[0117] In some methods, the editing template polynucleotide may further comprise a marker. Such a marker facilitates screening of targeted integration. Examples of suitable markers include restriction sites, fluorescent proteins, or selectable markers. The exogenous polynucleotide template of the present invention can be constructed using recombinant techniques (see, for example, Green and Sambrook et al., 2014 and Ausubel et al., 2017).

[0118] In an exemplary method for modifying a target polynucleotide by incorporating an editing template polynucleotide, a double-stranded break is introduced into a genomic sequence by an engineered nuclease complex, and the break can be repaired via homologous recombination using the editing template such that the template is incorporated into the target polynucleotide. The presence of the double-stranded break can increase the efficiency of the incorporation of the editing template.

[0119] Disclosed herein are methods for modifying expression of a polynucleotide in a cell. Some methods include increasing or decreasing expression of a target polynucleotide by using a targetable nuclease complex that binds to the target polynucleotide.

[0120] In some methods, target polynucleotides can be inactivated to cause altered expression in cells.For example, when a targetable nuclease complex binds to a target sequence in a cell, the target polynucleotide is inactivated so that the sequence is not transcribed, the encoded protein is not produced, or the sequence does not function like a wild-type sequence.For example, protein or microRNA coding sequences can be inactivated so that protein is not produced.

[0121] In some methods, a control sequence can be inactivated so that it no longer functions as a control sequence. As used herein, a "regulatory sequence" can refer to any nucleic acid sequence that affects the transcription, translation, or accessibility of a nucleic acid sequence. Examples of regulatory sequences include promoters, transcription terminators, and enhancers.

[0122] An inactivated target sequence may comprise a deletion mutation (i.e., a deletion of one or more nucleotides), an insertion mutation (i.e., an insertion of one or more nucleotides), or a nonsense mutation (i.e., the substitution of a single nucleotide for another such that a stop codon is introduced). In some methods, inactivation of a target sequence results in a "knockout" of the target sequence.

[0123] The change in expression of one or more target polynucleotides associated with a signal transduction biochemical pathway can be determined by assaying the difference in mRNA levels of the corresponding genes between the test model cells and the control cells upon contact with a candidate agent. Alternatively, the differential expression of sequences associated with a signal transduction biochemical pathway is determined by detecting the difference in the levels of the encoded polypeptide or gene product.

[0124] To assay drug-induced changes in the level of mRNA transcripts or corresponding polynucleotides, the nucleic acids contained in the sample are first extracted according to standard methods in the art. For example, mRNA can be isolated using various lytic enzymes or chemical solutions according to the procedures described in Green and Sambrook (2014), or extracted by nucleic acid-binding resin according to the accompanying instructions provided by the manufacturer. The mRNA contained in the extracted nucleic acid sample is then detected by amplification procedures or conventional hybridization assays (e.g., Northern blot analysis) according to methods widely known in the art or based on the methods exemplified herein.

[0125] For the purposes of the present invention, amplification refers to any method using primers and polymerases that can replicate target sequences with reasonable fidelity. Amplification can be performed by natural or recombinant DNA polymerases such as TaqGold™, T7 DNA polymerase, Klenow fragment of E. coli DNA polymerase, and reverse transcriptase. A preferred amplification method is PCR. In particular, isolated RNA can be subjected to reverse transcription assays combined with quantitative polymerase chain reaction (RT-PCR) to quantify the expression levels of sequences related to signal transduction biochemical pathways.

[0126] Detection of gene expression levels can be performed in real time in an amplification assay. In one embodiment, the amplification product can be directly visualized with fluorescent DNA binding agents, including but not limited to DNA intercalators and DNA group binders. Since the amount of intercalator incorporated into a double-stranded DNA molecule is typically proportional to the amount of amplified DNA product, the amount of amplified product can be conveniently determined by quantifying the fluorescence of the intercalated dye using conventional optical systems in the art. DNA binding dyes suitable for this application include SYBR Green, SYBR Blue, DAPI, propidium iodide, Hoeste, SYBR Gold, ethidium bromide, acridine, proflavine, acridine orange, acriflavine, fluorcoumanin, ellipticine, daunomycin, chloroquine, distamycin D, chromomycin, homidium, mithramycin, ruthenium polypyridyl, anthramycin, and the like.

[0127] In another embodiment, other fluorescent labels, such as sequence-specific probes, can be used in the amplification reaction to facilitate detection and quantification of the amplification products. Probe-based quantitative amplification relies on sequence-specific detection of the desired amplification product. It utilizes fluorescent target-specific probes (e.g., TaqMan™ probes) to improve specificity and sensitivity. Methods for performing probe-based quantitative amplification are well established in the art and are taught in U.S. Pat. No. 5,210,015.

[0128] In yet another embodiment, conventional hybridization assays can be carried out using hybridization probes that share sequence homology with sequences associated with signal transduction biochemical pathways.Typically, the probes can form stable complexes with sequences associated with signal transduction biochemical pathways contained in biological samples from test subjects in hybridization reactions.It will be understood by those skilled in the art that when antisense is used as probe nucleic acid, the target polynucleotide provided in the sample is selected to be complementary to the sequence of antisense nucleic acid.On the contrary, when the nucleotide probe is a sense nucleic acid, the target polynucleotide is selected to be complementary to the sequence of sense nucleic acid.

[0129] Hybridization can be performed under various stringency conditions, for example, as described herein. Hybridization conditions suitable for carrying out the present invention are such that the recognition interaction between the probe and the sequence associated with the signal transduction biochemical pathway is both sufficiently specific and sufficiently stable. Conditions that increase the stringency of a hybridization reaction are widely known and published in the art. See, for example, (Green and Sambrook et al., 2014, Nonradioactive in Situ Hybridization Application Manual, Boehringer Mannheim, 2nd Edition). Hybridization assays can be formed using probes immobilized on any solid support, including, but not limited to, nitrocellulose, glass, silicon, and various gene arrays. A preferred hybridization assay is performed on a high-density gene chip, as described in U.S. Pat. No. 5,445,934.

[0130] For convenient detection of the probe-target complex formed during the hybridization assay, the nucleotide probe is bound to a detectable label. Detectable labels suitable for use in the present invention include any composition detectable by photochemical, biochemical, spectroscopic, immunochemical, electrical, optical or chemical means. A variety of suitable detectable labels are known in the art, including fluorescent or chemiluminescent labels, radioisotope labels, enzymes or other ligands. In a preferred embodiment, it may be desirable to use fluorescent labels or enzyme tags, such as digoxigenin, β-galactosidase, urease, alkaline phosphatase or peroxidase, avidin / biotin complexes, etc.

[0131] The detection method used to detect or quantify hybridization intensity typically depends on the label selected above. For example, radiolabels can be detected using photographic film or a phosphorimager. Fluorescent markers can be detected and quantified using a photodetector to detect emitted light. Enzyme labels are typically detected by providing the enzyme with a substrate and measuring the reaction product generated by the action of the enzyme on the substrate, and finally, colorimetric labels are detected by simply visualizing the colored label.

[0132] Drug-induced changes in the expression of sequences associated with a signal transduction biochemical pathway can also be determined by examining the corresponding gene products. Determining protein levels typically involves a) contacting proteins contained in a biological sample with an agent that specifically binds to a protein associated with a signal transduction biochemical pathway, and (b) identifying the drug:protein complex formed. In one aspect of this embodiment, the agent that specifically binds to a protein associated with a signal transduction biochemical pathway is an antibody, preferably a monoclonal antibody.

[0133] The reaction can be carried out by contacting the agent with a sample of a protein associated with a signal transduction biochemical pathway from a test sample under conditions in which a complex is formed between the agent and the protein associated with the signal transduction biochemical pathway. The formation of the complex can be detected directly or indirectly according to standard procedures in the art. In direct detection methods, the agent is provided with a detectable label, unreacted agent can be removed from the complex, and the amount of label remaining indicates the amount of complex formed. For such methods, it is preferable to select a label that remains attached to the agent even under stringent washing conditions. It is preferable that the label does not interfere with the binding reaction. Alternatively, in indirect detection procedures, agents containing a chemically or enzymatically introduced label can be used. Desirable labels generally do not interfere with the binding or stability of the resulting agent:polypeptide complex. However, the label is typically designed to be accessible to the antibody for effective binding, so that a detectable signal is generated.

[0134] A wide variety of labels suitable for detecting protein levels are known in the art, non-limiting examples include radioisotopes, enzymes, colloidal metals, fluorescent compounds, bioluminescent compounds and chemiluminescent compounds.

[0135] The amount of drug:polypeptide complex formed during the binding reaction can be quantified by standard quantitative assays. As described above, the formation of drug:polypeptide complex can be measured directly by the amount of label left at the binding site. In another method, proteins related to signal transduction biochemical pathways are tested for their ability to compete with a labeled analogue for the binding site of a particular drug. In this competitive assay, the amount of captured label is inversely proportional to the amount of protein sequence related to signal transduction biochemical pathways present in the test sample.

[0136] Many techniques for protein analysis based on the general principles outlined above are available in the art, including, but not limited to, radioimmunoassays, ELISA (enzyme-linked immunoradiometric assays), "sandwich" immunoassays, immunoradiometric assays, in situ immunoassays (using, for example, colloidal gold, enzyme or radioisotope labels), Western blot analysis, immunoprecipitation assays, immunofluorescence assays and SDS-PAGE.

[0137] Antibodies that specifically recognize or bind proteins associated with signal transduction biochemical pathways are preferred for performing the aforementioned protein analysis. If necessary, antibodies that recognize a particular type of post-translational modification (e.g., signal transduction biochemical pathway-inducible modification) can be used. Post-translational modifications include, but are not limited to, glycosylation, lipidation, acetylation, and phosphorylation. These antibodies can be purchased from commercial vendors. For example, anti-phosphotyrosine antibodies that specifically recognize tyrosine phosphorylated proteins are available from a number of vendors, such as Invitrogen and Perkin Elmer. Anti-phosphotyrosine antibodies are particularly useful for detecting proteins whose tyrosine residues are specifically phosphorylated in response to ER stress. Such proteins include, but are not limited to, eukaryotic translation initiation factor 2 alpha (eIF-2.alpha). Alternatively, these antibodies can be generated using conventional polyclonal or monoclonal antibody techniques by immunizing a host animal or antibody-producing cells with a target protein that exhibits the desired post-translational modification.

[0138] In carrying out the subject methods, it may be desirable to identify expression patterns of proteins associated with signaling biochemical pathways in different body tissues, different cell types and / or different subcellular structures. These studies can be carried out using tissue-, cell- or subcellular structure-specific antibodies capable of binding to protein markers that are preferentially expressed in particular tissues, cell types or subcellular structures.

[0139] Changes in expression of genes associated with signal transduction biochemical pathways can also be determined by examining changes in the activity of the gene product compared to control cells. Assays for drug-induced changes in the activity of proteins associated with signal transduction biochemical pathways depend on the biological activity and / or signal transduction pathway under investigation. For example, if the protein is a kinase, changes in its ability to phosphorylate downstream substrates can be determined by a variety of assays known in the art. Exemplary assays include, but are not limited to, immunoblotting and immunoprecipitation using antibodies such as anti-phosphotyrosine antibodies that recognize phosphorylated proteins. In addition, kinase activity can be detected by high-throughput chemiluminescence assays such as AlphaScreen™ (available from Perkin Elmer) and eTag™ assays (Chan-Hui et al., 2003, Clinical Immunology, vol. 111, pp. 162-174).

[0140] If the protein associated with the signal transduction biochemical pathway is part of a signal transduction cascade that leads to fluctuations in intracellular pH conditions, pH-sensitive molecules such as fluorescent pH dyes can be used as reporter molecules. In another example, where the protein associated with the signal transduction biochemical pathway is an ion channel, fluctuations in membrane potential and / or intracellular ion concentrations can be monitored. Many commercially available kits and high-throughput devices are particularly suited for rapid and robust screening of modulators of ion channels. Representative instruments include FLIPR™ (Molecular Devices, Inc.) and VIPR (Aurora Biosciences). These instruments can simultaneously detect reactions in microplates with over 1000 sample wells and provide real-time measurement and functional data within a second or a fraction of a second.

[0141] In carrying out any of the methods disclosed herein, a suitable vector can be introduced into a cell, tissue, organism, or embryo by one or more methods known in the art, including, but not limited to, microinjection, electroporation, sonoporation, gene gun, calcium phosphate-mediated transfection, cationic transfection, liposome transfection, dendrimer transfection, heat shock transfection, nucleofection transfection, magnetofection, lipofection, impalefection, phototransfection, proprietary agent-enhanced nucleic acid uptake, and delivery by liposomes, immunoliposomes, virosomes, or artificial virions. In some methods, the vector is introduced into an embryo by microinjection. The vector can be microinjected into the nucleus or cytoplasm of the embryo. In some methods, the vector can be introduced into a cell by nucleofection.

[0142] Target sequence The target polynucleotide of the targetable nuclease complex can be any polynucleotide that is endogenous or exogenous to the host cell. For example, the target polynucleotide can be a polynucleotide that is present in the nucleus of a eukaryotic cell, the genome of a prokaryotic cell, or an extrachromosomal vector of a host cell. The target polynucleotide can be a sequence that codes for a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or junk DNA).

[0143] Examples of target polynucleotides include sequences associated with signal transduction biochemical pathways, such as genes or polynucleotides associated with signal transduction biochemical pathways. Examples of target polynucleotides include disease-associated genes or polynucleotides. A "disease-associated" gene or polynucleotide refers to any gene or polynucleotide whose transcription or translation product occurs at an abnormal level or in an abnormal form in cells derived from disease-affected tissues compared to non-disease control tissues or cells. It may be a gene that becomes expressed at an abnormally high level, or it may be a gene that becomes expressed at an abnormally low level, and the change in expression correlates with the development and / or progression of the disease. A disease-associated gene also refers to a gene that has a mutation or genetic variation that is directly responsible for, or in linkage disequilibrium with, the causative gene for the etiology of the disease. The transcription or translation product may be known or unknown, and may be at a normal or abnormal level.

[0144] The present invention also relates to methods and compositions related to gene knockout, gene editing, gene modification, gene amplification and repair of specific mutations. Genetic modification may refer to epigenetic manipulation of a target sequence. This may be modification of the methylation state of the target sequence (i.e. methylation or methylation pattern or addition or removal of CpG islands), histone modification, chromatin state of the target sequence by increasing or decreasing the accessibility of the target sequence or promoting 3D folding, etc. When referring to a method of modifying a cell, an organism or a mammal, including a human or non-human mammal, or an organism by manipulation of a target sequence at a genomic locus of interest, it will be understood that this may apply to the whole organism (or mammal) or only a single cell or a cell population of that organism (if the organism is multicellular). For example, in the case of humans, the applicants envisage, inter alia, single cells or populations of cells, which may be modified ex vivo and then reintroduced. In this case, a biopsy or other tissue or fluid sample may be required. Stem cells are also particularly preferred in this regard. However, of course, in vivo embodiments are also envisaged. The present invention is also particularly advantageous with respect to HSCs.

[0145] The functionality of the targetable nuclease complex can be evaluated by any suitable assay. For example, sufficient components of the targetable nuclease system, including the guide nucleic acid and the nucleic acid-guided nuclease, to form a targetable nuclease complex can be provided to a host cell having a corresponding target sequence, such as by transfection with a vector encoding the engineered nuclease system components, followed by evaluation of preferential cleavage within the target sequence. Similarly, cleavage of the target sequence can be evaluated in vitro by providing the target sequence and the components of the targetable nuclease complex. Other assays are possible and will occur to those skilled in the art. The guide sequence can be selected to target any target sequence. In some embodiments, the target sequence is a sequence within the genome of the cell. Exemplary target sequences include those that are unique in the target genome.

[0146] Editing Cassette Disclosed herein are compositions and methods for editing target polynucleotide sequences. Such compositions include polynucleotides that contain one or more components of a targetable nuclease system. The polynucleotide sequences used in these methods can be referred to as editing cassettes.

[0147] The editing cassette may include one or more primer sites. The primer sites can be used to amplify the editing cassette by using an oligonucleotide primer that includes a reverse complement sequence that can hybridize to the one or more primer sites. The editing cassette may include two or more primer sites. Sometimes, the editing cassette includes a primer site at each end of the editing cassette, the primer site being adjacent to one or more of the other components of the editing cassette. The primer sites can be approximately 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 or more nucleotides in length.

[0148] The editing cassette may comprise an editing template as disclosed herein. The editing cassette may comprise an editing sequence. The editing sequence may be homologous to a target sequence. The editing sequence may comprise at least one mutation compared to the target sequence. The editing sequence often comprises a homology region (or homology arm) flanking at least one mutation to the target sequence, which flanking homology regions facilitate homologous recombination of the editing sequence into the target sequence. The editing sequence may comprise an editing template as disclosed herein. For example, the editing sequence may comprise at least one mutation to the target sequence, including one or more PAM mutations that mutate or delete a PAM site. The editing sequence may comprise one or more mutations in a codon or non-coding sequence associated with a non-edited target site.

[0149] The PAM mutation may be a silent mutation. A silent mutation may be a change in at least one nucleotide of a codon compared to the original codon that does not change the amino acid encoded by the original codon. A silent mutation may be a change in a nucleotide in a non-coding region, such as an intron, a 5' untranslated region, a 3' untranslated region, or other non-coding region.

[0150] The PAM mutation may be a non-silent mutation. A non-silent mutation may include a missense mutation. A missense mutation may be a change in at least one nucleotide of a codon compared to the original codon, which changes the amino acid encoded by the original codon. A missense mutation may occur within an exon, an open reading frame, or other coding region.

[0151] The edited sequence may comprise at least one mutation compared to the target sequence. The mutation may be a silent mutation or a non-silent mutation such as a missense mutation. The mutation may comprise an insertion of one or more nucleotides or base pairs. The mutation may comprise a deletion of one or more nucleotides or base pairs. The mutation may comprise a substitution of one or more nucleotides or base pairs with a different one or more nucleotides or base pairs. The inserted or replaced sequence may comprise an exogenous or heterologous sequence.

[0152] The editing cassette may comprise a polynucleotide encoding a guide nucleic acid sequence. In some cases, the guide nucleic acid sequence is optionally operably linked to a promoter. The guide nucleic acid sequence may comprise a scaffold sequence and a guide sequence as described herein.

[0153] The editing cassette may include a barcode. The barcode may be a unique DNA sequence corresponding to the editing sequence such that the barcode can identify one or more mutations of the corresponding editing sequence. In some examples, the barcode is 15 nucleotides. The barcode may include less than 10 nucleotides, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 88, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200 nucleotides, or more than 200 nucleotides. The barcode may be a non-naturally occurring sequence. The editing cassette including the barcode may be a non-naturally occurring sequence.

[0154] The editing cassette may comprise one or more editing sequences and a polynucleotide encoding a guide nucleic acid, optionally operably linked to a promoter, wherein the editing cassette and the guide nucleic acid sequence are flanked by primer sites. The editing cassette may further comprise a barcode.

[0155] Examples of editing cassettes are shown in Figure 3. Each editing cassette can be designed to edit a site within the target sequence. The targeted site can be a coding region, a non-coding region, a functionally neutral site, or a screenable or selectable marker gene. Regions of homology within the editing sequence can flank one or more mutations in the editing cassette and be inserted into the target sequence by recombination. Recombination can include DNA cleavage, such as by nucleic acid-guided nucleases, and repair by homologous recombination.

[0156] The editing cassette can be generated by chemical synthesis, Gibson assembly, SLIC, CPEC, PCA, ligation-free cloning, overlap oligo extension, in vitro assembly, in vitro oligo assembly, PCR, traditional ligation-based cloning, other methods known in the art, or any combination thereof.

[0157] A traceable sequence, such as a barcode or recorder sequence, can be designed in silico with degenerate mutations at the target codon according to a standard code. The degenerate mutations can include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more than 30 nucleic acid residues. In some examples, the degenerate mutations can include 15 nucleic acid residues (N15).

[0158] Homology arms can be added to the editing sequence to allow the editing sequence to be integrated into the desired location by homologous recombination or homology-driven repair. Homology arms can be added by synthesis, in vitro assembly, PCR or other methods known in the art. For example, chemical synthesis, Gibson assembly, SLIC, CPEC, PCA, ligation-free cloning, overlap oligo extension, in vitro assembly, in vitro oligo assembly, PCR, traditional ligation-based cloning, other methods known in the art, or any combination thereof. Homology arms can be added to both ends of the barcode, recorder sequence and / or editing sequence, thereby flanking the sequence with two separate homology arms, for example, a 5' homology arm and a 3' homology arm.

[0159] A homology arm may comprise a sequence homologous to a target sequence. A homology arm may comprise a sequence homologous to a sequence adjacent to a target sequence. A homology arm may comprise a sequence homologous to a sequence upstream or downstream of a target sequence. A homology arm may comprise a sequence homologous to a sequence in the same gene or open reading frame as the target sequence. A homology arm may comprise a sequence homologous to a sequence upstream or downstream of a gene or open reading frame in which the target sequence is contained. A homology arm may comprise a sequence homologous to a 5'UTR or 3'UTR of a gene or open reading frame in which the target sequence is found. A homology arm may comprise a sequence homologous to a gene, open reading frame, promoter, terminator or nucleic acid sequence different from the one in which the target sequence is contained.

[0160] The same 5' and 3' homology arms can be added to multiple separate editing sequences, thereby generating a library of unique editing sequences, each with the same targeted insertion site. The same 5' and 3' homology arms can be added to multiple separate editing templates, thereby generating a library of unique editing templates, each with the same targeted insertion site. In an alternative example, different or various 5' or 3' homology arms can be added to multiple editing sequences or editing templates.

[0161] The barcode library or recorder sequence library with flanking homology arms can be cloned into a vector backbone. In some examples, the barcode with flanking homology arms is cloned into an editing cassette. Cloning can be performed by chemical synthesis, Gibson assembly, SLIC, CPEC, PCA, ligation-free cloning, overlap oligo extension, in vitro assembly, in vitro oligo assembly, PCR, traditional ligation-based cloning, other methods known in the art, or any combination thereof.

[0162] The editing sequence library including the adjacent homology arms can be cloned into a vector backbone. In some cases, the editing sequence and the homology arms are cloned into an editing cassette. The editing cassette may further include a nucleic acid sequence encoding a desired editing sequence insertion site, such as a guide nucleic acid or gRNA engineered to target a target sequence. The editing cassette may further include a barcode or recorder sequence. Cloning can be performed by chemical synthesis, Gibson assembly, SLIC, CPEC, PCA, ligation-free cloning, overlap oligo extension, in vitro assembly, in vitro oligo assembly, PCR, traditional ligation-based cloning, other methods known in the art, or any combination thereof.

[0163] Whole gene or whole genome editing libraries can be cloned into the vector backbone. Barcode or recorder sequence libraries can be inserted or assembled into a second site to generate a competent traceable plasmid that can embed the recording barcodes into a fixed locus while simultaneously integrating the editing library into multiple user-defined sites. Cloning can be performed by chemical synthesis, Gibson assembly, SLIC, CPEC, PCA, ligation-free cloning, overlapping oligo extension, in vitro assembly, in vitro oligo assembly, PCR, traditional ligation-based cloning, other methods known in the art, or any combination thereof.

[0164] The guide nucleic acid or the sequence encoding it can be assembled or inserted into the vector backbone first, followed by the editing sequence and / or cassette. In other cases, the editing sequence and / or cassette can be inserted or assembled into the vector backbone first, followed by the guide nucleic acid or the sequence encoding it. In other cases, the guide nucleic acid or the sequence encoding it and the editing sequence and / or cassette can be inserted or assembled into the vector simultaneously. The recorder sequence or barcode can be inserted before or after any of these steps. In other words, it should be understood that there are many possible permutations of the order in which the elements of the disclosure are assembled. The vectors can be linear or circular, and can be generated by chemical synthesis, Gibson assembly, SLIC, CPEC, PCA, ligation-free cloning, overlapping oligo extension, in vitro assembly, in vitro oligo assembly, PCR, traditional ligation-based cloning, other methods known in the art, or any combination thereof.

[0165] A nucleic acid molecule can be synthesized that includes one or more elements disclosed herein. A nucleic acid molecule can be synthesized that includes an editing cassette. A nucleic acid molecule can be synthesized that includes a guide nucleic acid. A nucleic acid molecule can be synthesized that includes a recorder cassette. A nucleic acid molecule can be synthesized that includes a barcode. A nucleic acid molecule can be synthesized that includes a homology arm. A nucleic acid molecule can be synthesized that includes an editing cassette and a guide nucleic acid. A nucleic acid molecule can be synthesized that includes an editing cassette and a barcode. A nucleic acid molecule can be synthesized that includes an editing cassette, a guide nucleic acid and a recorder cassette. A nucleic acid molecule can be synthesized that includes an editing cassette, a recorder cassette and two guide nucleic acids. A nucleic acid molecule can be synthesized that includes a recorder cassette and a guide nucleic acid. In any of these cases, the guide nucleic acid can be optionally operably linked to a promoter. In any of these cases, the nucleic acid molecule can further include one or more barcodes.

[0166] Synthesis can be performed by any nucleic acid synthesis method known in the art. Synthesis can be performed by enzymatic nucleic acid synthesis. Synthesis can be performed by chemical synthesis. Synthesis can be performed by array-based synthesis. Synthesis can be performed by solid phase synthesis or phosphoramidite methods. Synthesis can be performed by column or multi-well methods. The synthesized nucleic acid molecule can be a non-naturally occurring nucleic acid molecule.

[0167] Software and automation methods can be used for multiplex synthesis and generation. For example, software and automation can be used to generate multiplexed 2 , 10 3 , 10 4 , 10 5 , 10 6 or more synthetic polynucleotides, cassettes or plasmids can be created. Automated methods can generate desired sequences and libraries in a rapid manner that is processed through a workflow with minimal steps and can generate precisely defined libraries, such as whole gene or whole genome editing libraries.

[0168] A polynucleotide or library can be generated that includes two or more nucleic acid molecules or plasmids that include any combination of recorder sequences, editing sequences, guide nucleic acids, and optional barcodes disclosed herein, including any one or more combinations of any of the aforementioned elements. For example, such libraries can include at least 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10or more of the nucleic acid molecules or plasmids of the present disclosure. It should be understood that such libraries can contain any number of nucleic acid molecules or plasmids, even if a specific number is not explicitly recited above.

[0169] A traceable plasmid library or nucleic acid molecule library can be sequenced to determine the pairing of recorder and editing sequences contained in each traceable plasmid. In other cases, known recorder sequences are paired with known editing sequences during the library generation process. Other methods of determining the association of recorder and editing sequences contained on a common nucleic acid molecule or plasmid are envisioned, such that the editing sequences can be identified by identifying or sequencing the recorder sequences.

[0170] Methods and compositions are provided herein for tracking libraries of edited episomes shuttled between E. coli and other organisms / cell lines. Libraries can be contained on plasmids, bacterial artificial chromosomes (BACs), yeast artificial chromosomes (YACs), synthetic chromosomes, or viral or phage genomes. These methods and compositions can be used to generate portable barcoded libraries in host organisms such as E. coli. Library generation in such organisms can provide the benefits of established techniques for performing homologous recombination. Barcoded plasmid libraries can be deep sequenced at one site to track the diversity due to mutations targeted to the remainder of the plasmid, allowing for a dramatic improvement in library coverage depth.

[0171] Any nucleic acid molecule disclosed herein can be an isolated nucleic acid. An isolated nucleic acid can be produced by any method known in the art, for example, using standard recombinant methods, assembly methods, synthetic techniques, or a combination thereof. In some embodiments, the nucleic acid can be cloned, amplified, assembled, or otherwise constructed.

[0172] Isolated nucleic acids can be obtained from cells, bacteria, or other sources using any number of cloning methodologies known in the art. In some embodiments, isolated nucleic acids can be isolated or identified using oligonucleotide probes that selectively hybridize under stringent conditions to other oligonucleotides or nucleic acids of the organism or cell.

[0173] The genomic DNA, RNA or cDNA of the cells can be screened for the presence of the identified genetic element of interest using a probe based on one or more sequences.Various degrees of stringency of hybridization can be used in the assay.

[0174] High stringency conditions for nucleic acid hybridization are well known in the art. For example, conditions can include low salt and / or high temperature conditions, such as those provided by about 0.02M to about 0.15M NaCl at a temperature of about 50°C to about 70°C. It is understood that the temperature and ionic strength of the desired stringency will be determined, in part, by the length of the particular nucleic acid, the length and nucleotide content of the target sequence, the charge composition of the nucleic acid, and by the presence or concentration of formamide, tetramethylammonium chloride, or other solvents in the hybridization mixture. The nucleic acid can be fully complementary to the target sequence or can exhibit one or more mismatches.

[0175] Nucleic acids of interest can also be amplified using various known amplification techniques. For example, target sequences can be directly amplified from DNA, RNA or cDNA using polymerase chain reaction (PCR) technology. PCR and other in vitro amplification methods can also be useful, for example, for cloning nucleic acid sequences, for generating nucleic acids for use as probes to detect the presence of target nucleic acids in samples, for nucleic acid sequencing, or for other purposes.

[0176] The isolated nucleic acid can be prepared by direct chemical synthesis, such as by the phosphotriester method, or by using an automatic synthesizer. Chemical synthesis generally produces a single-stranded oligonucleotide. This can be converted into double-stranded DNA by hybridization with a complementary sequence, or by polymerization using a DNA polymerase with the single strand as a template.

[0177] Recorder In some cases, two editing cassettes can be used together to track the steps of genetic engineering. For example, one editing cassette can include an editing template and an encoded guide nucleic acid, and a second editing cassette, called a recorder cassette, can include an editing template that includes a recorder sequence and an encoding nucleic acid with a separate guide sequence compared to that of the first editing cassette. In such cases, the editing sequence and the recorder sequence can be inserted into separate target sequences and determined by their corresponding guide nucleic acids. The recorder sequence can include a barcode, a trackable or traceable sequence, and / or a regulatory element that can be operated with a screenable or selectable marker.

[0178] A multiplexed cloning approach allows the recorder cassette to be covalently coupled to at least one editing cassette in a plasmid (e.g., FIG. 17A) to generate a plasmid library with unique recorder and editing cassette combinations. This library can be sequenced to generate a recorder / editing map, which can be used to track the editing library across large segments of the target DNA (e.g., FIG. 17C). The recorder and editing sequences can be included on the same cassette, where they are both incorporated into a target nucleic acid sequence, such as a genome or plasmid, by the same recombination event. In other examples, the recorder and editing sequences can be included on separate cassettes in the same plasmid, where they are incorporated into a target nucleic acid sequence simultaneously or sequentially by separate recombination events.

[0179] Provided herein are methods that combine multiplexed oligonucleotide synthesis and recombineering to create libraries of specifically designed, traceable mutations. Screening and / or selection, followed by high-throughput sequencing and / or barcode microarray methods, can allow rapid mapping of mutations that result in phenotypes of interest.

[0180] Using the methods and compositions disclosed herein, engineering events in target nucleic acid sequences can be simultaneously engineered and tracked. Such plasmids can be generated using in vitro assembly or cloning techniques, for example, the plasmids can be generated using chemical synthesis, Gibson assembly, SLIC, CPEC, PCA, ligation-free cloning, other in vitro oligo assembly techniques, traditional ligation-based cloning, or any combination thereof.

[0181] Such a plasmid may include at least one recording sequence, such as a barcode, and at least one editing sequence. In most cases, the recording sequence is used to record and track the manipulation events. The editing sequences can each be used to incorporate a desired edit into the target nucleic acid sequence. The desired edit includes an insertion, deletion, substitution, or alteration of the target nucleic acid sequence. In some cases, one or more recording sequences and editing sequences are included on a single cassette contained within the plasmid and are thus incorporated into the target nucleic acid sequence by the same manipulation event. In other cases, the recording and editing sequences are included on separate cassettes within the plasmid and are thus each incorporated into the target nucleic acid by a separate manipulation event. In some cases, the plasmid includes two or more editing sequences. For example, one editing sequence can be used to alter or silence the PAM sequence while a second editing sequence can be used to incorporate a mutation into a separate sequence.

[0182] The recoder sequence can be inserted at a site separated from the editing sequence insertion site. The inserted recoder sequence can be separated from the editing sequence by 1 bp to 1 Mbp. For example, the separation distance can be about 1 bp, 10 bp, 50 bp, 100 bp, 500 bp, 1 kp, 2 kb, 5 kb, 10 kb or more. The separation distance can be any discrete integer between 1 bp and 10 Mbp. In some cases, the maximum separation distance depends on the size of the target nucleic acid or genome.

[0183] The Recoder sequence can be inserted adjacent to or near the editing sequence. For example, the Recoder sequence can be inserted outside of the open reading frame into which the editing sequence is inserted. The Recoder sequence can be inserted in an untranslated region adjacent to the open reading frame into which the editing sequence is inserted. The Recoder sequence can be inserted in a functionally neutral or non-functional site. The Recoder sequence can be inserted in a screenable or selectable marker gene.

[0184] In some examples, the target nucleic acid sequence is contained in a genome, an artificial chromosome, a synthetic chromosome, or an episomal plasmid. In various examples, the target nucleic acid sequence can be in vitro or in vivo. When the target nucleic acid sequence is in vivo, the plasmid can be introduced into the host organism by transformation, transfection, conjugation, gene gun, nanoparticle, cell penetration technology, or other known methods for DNA delivery, or any combination thereof. In such examples, the host organism can be a eukaryote, a prokaryote, a bacterium, an archaea, a yeast, or another fungus.

[0185] The engineering events may include recombineering, non-homologous end joining, homologous recombination, or homology-driven repair. In some examples, the engineering events are performed in vitro or in vivo. The methods described herein can be carried out in any cell type in which a targetable nuclease system can function (e.g., target and cleave DNA), including prokaryotic and eukaryotic cells. In some embodiments, the cell is a bacterial cell, such as an Escherichia spp. (e.g., E. coli). In other embodiments, the cell is a fungal cell, such as a yeast cell, e.g., a Saccharomyces spp. In other embodiments, the cell is an algae cell, a plant cell, an insect cell, or a mammalian cell, including a human cell.

[0186] In some cases, the cell is a recombinant organism. For example, the cell may contain a non-native targetable nuclease system. Additionally or alternatively, the cell may contain a recombination system mechanism. Such recombination systems may include the lambda red recombination system, Cre / Lox, attB / attP or other integrase systems. Where appropriate, the plasmid may carry the complementary components or mechanisms required for the selected recombination system to function correctly and efficiently.

[0187] A method for genome editing may include: (a) introducing a vector encoding at least one editing cassette and at least one guide nucleic acid into a first population of cells, thereby generating a second population of cells comprising the vector; (b) maintaining the second population of cells under conditions in which a nucleic acid-guided nuclease is expressed or maintained, wherein the nucleic acid-guided nuclease is encoded on the vector, on a second vector, on the genome of the cells of the second population of cells, or otherwise introduced into the cells, resulting in DNA cleavage and incorporation of the editing cassette; (c) obtaining surviving cells; and (d) sequencing the target DNA molecule in at least one cell of the second population of cells to identify at least one codon mutation.

[0188] A method for genome editing may include: (a) introducing a vector encoding at least one editing cassette and at least one guide nucleic acid comprising a PAM mutation as disclosed herein into a first population of cells, thereby generating a second population of cells comprising the vector; (b) maintaining the second population of cells under conditions in which a nucleic acid-guided nuclease is expressed or maintained, wherein the nucleic acid-guided nuclease is encoded on the vector, on a second vector, on the genome of the cells of the second population of cells, or otherwise introduced into the cells, resulting in DNA cleavage, incorporation of the editing cassette, and cells of the second population of cells comprising the PAM mutation being viable, while cells of the second population of cells that do not comprise the PAM mutation are dead; (c) obtaining surviving cells; and (d) sequencing the target DNA in at least one cell of the second population of cells to identify at least one codon mutation.

[0189] A method for trackable genome editing may include: (a) introducing a vector encoding at least one editing cassette, at least one recorder cassette, and at least two guide nucleic acids into a first population of cells, thereby generating a second population of cells comprising the vectors; (b) maintaining the second population of cells under conditions in which a nucleic acid-guided nuclease is expressed or maintained, the nucleic acid-guided nuclease being encoded on the vector, on a second vector, on the genome of the cells of the second population of cells, or otherwise introduced into the cells, resulting in DNA cleavage and incorporation of the editing and recorder cassettes; (c) obtaining surviving cells; and (d) sequencing the recorder sequence of a target DNA molecule in at least one cell of the second population of cells to identify at least one codon mutation.

[0190] In some examples where the plasmid comprises a second editing sequence designed to silence the PAM, a method for trackable genome editing comprises the steps of: (a) introducing a vector encoding at least one editing cassette, a recorder cassette, and at least two guide nucleic acids into a first population of cells, thereby generating a second population of cells comprising the vector; and (b) maintaining the second population of cells under conditions in which a nucleic acid-guided nuclease is expressed or maintained, the nucleic acid-guided nuclease being present on the vector. The method may include (a) encoding the recode cassette on a second vector, encoded on the genome of cells of the second population of cells, or otherwise introducing the recode cassette into cells, such that cells of the second population of cells containing the DNA cleavage, editing, and incorporation of the recode cassette and the PAM mutation are viable, while cells of the second population of cells that do not contain the PAM mutation are dead; (c) obtaining surviving cells; and (d) sequencing the recode cassette sequence of the target DNA in at least one cell of the second population of cells to identify at least one codon mutation.

[0191] In some cases, transformation efficiency is determined by using a non-targeting control guide nucleic acid, which allows validation of the recombineering procedure and calculation of CFU / ng. In some cases, absolute efficiency is obtained by counting the total number of colonies on each transformation plate, for example, by counting both red and white colonies from the galK control. In some cases, relative efficiency is calculated by the total number of successful transformants (e.g., white colonies) among all colonies from the control (e.g., galK control).

[0192] The methods of the present disclosure can, for example, result in greater than 1000× improvements in the efficiency, scale, cost of generating combinatorial libraries and / or accuracy of generating such libraries.

[0193] The methods of the disclosure can result in, for example, greater than 10x, greater than 50x, greater than 100x, greater than 200x, greater than 300x, greater than 400x, greater than 500x, greater than 600x, greater than 700x, greater than 800x, greater than 900x, greater than 1000x, greater than 1100x, greater than 1200x, greater than 1300x, greater than 1400x, greater than 1500x, greater than 1600x, greater than 1700x, greater than 1800x, greater than 1900x, greater than 2000x or greater improvements in the efficiency of generation of genomic or combinatorial libraries.

[0194] The methods of the disclosure can result in improvements in the scale of generation of genomic or combinatorial libraries, for example, greater than 10x, greater than 50x, greater than 100x, greater than 200x, greater than 300x, greater than 400x, greater than 500x, greater than 600x, greater than 700x, greater than 800x, greater than 900x, greater than 1000x, greater than 1100x, greater than 1200x, greater than 1300x, greater than 1400x, greater than 1500x, greater than 1600x, greater than 1700x, greater than 1800x, greater than 1900x, greater than 2000x or greater.

[0195] The methods of the disclosure can result in, for example, greater than a 10-fold, greater than a 50-fold, greater than a 100-fold, greater than a 200-fold, greater than a 300-fold, greater than a 400-fold, greater than a 500-fold, greater than a 600-fold, greater than a 700-fold, greater than a 800-fold, greater than a 900-fold, greater than a 1000-fold, greater than a 1100-fold, greater than a 1200-fold, greater than a 1300-fold, greater than a 1400-fold, greater than a 1500-fold, greater than a 1600-fold, greater than a 1700-fold, greater than a 1800-fold, greater than a 1900-fold, greater than a 2000-fold or more reduction in the cost of generating a genomic or combinatorial library.

[0196] The methods of the present disclosure can result in improvements in the accuracy of genomic or combinatorial library generation, for example, greater than 10x, greater than 50x, greater than 100x, greater than 200x, greater than 300x, greater than 400x, greater than 500x, greater than 600x, greater than 700x, greater than 800x, greater than 900x, greater than 1000x, greater than 1100x, greater than 1200x, greater than 1300x, greater than 1400x, greater than 1500x, greater than 1600x, greater than 1700x, greater than 1800x, greater than 1900x, greater than 2000x or more.

[0197] Iterative Tracking of Combinatorial Operations Methods and compositions for repeated rounds of engineering are disclosed herein. Iterative engineering strategies are disclosed herein that allow CREATE recording at the single cell level to be performed in several successive cycles of engineering (e.g., Figures 18 and 19). These disclosed methods and compositions can enable search-based techniques that can effectively build and explore complex genotype space. The terms iterative and iterative can be used interchangeably.

[0198] Combinatorial engineering methods can include multiple rounds of engineering. The methods disclosed herein can include more than one round of engineering. For example, the methods can include 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30 rounds or more than 30 rounds of engineering.

[0199] In some cases, during each round of engineering, new recorder sequences, such as barcodes, are incorporated into the same locus at nearby sites (e.g., Figure 18, grey bars or Figure 19, black bars), thus after multiple cycles of engineering to build combinatorial diversity throughout the genome (e.g., Figure 18, grey bars or Figure 19, grey bars), simple PCR of the recording loci can be used to reconstruct each combinatorial genotype or to confirm that the engineered edits from each round were incorporated into the target sites.

[0200] Disclosed herein is a method for selecting successive rounds of engineering. Selection can be performed by the PAM mutation incorporated by the editing cassette. Selection can be performed by the PAM mutation incorporated by the recorder cassette. Selection can be performed using a screenable, selectable or counter-selectable marker. Selection can be performed by targeting the site for editing or recording incorporated by the previous round of engineering, thereby selecting variants that successfully incorporate editing and recorder sequences from both or all previous rounds of engineering.

[0201] Quantification of these genotypes can be used to understand the effects of combinatorial mutations on large populations and to investigate important biological phenomena such as epistasis.

[0202] Sequential editing and combinatorial tracking can be performed using the repetitive vector systems disclosed herein. These repetitive vector systems can be used to expedite the transformation procedure. In some cases, these systems consist of two or more plasmids containing an orthogonal origin of replication, an antibiotic marker, and an encoded guide nucleic acid. The encoded guide nucleic acid in each vector can be designed to target one of the other's resistance markers for destruction by nucleic acid-induced nuclease-mediated cleavage. These systems can be used in some cases to perform transformations in which antibiotic selection pressure switches to remove the previous plasmid and drive the enrichment of the next round of engineered genomes. Two or more passages can be performed through the transformation loop, or in other words, multiple rounds of engineering can be performed. The introduction of the necessary recording and editing cassettes into the repetitive vectors disclosed herein can be used for simultaneous genome editing and plasmid curing with high efficiency at each transformation step.

[0203] In some examples, the repetitive vector systems disclosed herein include 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 unique plasmids. In some examples, the repetitive vector systems allow a particular plasmid to be used more than once where separate plasmids are used in earlier and later rounds.

[0204] The iterative methods and compositions disclosed herein can be used to restore the function of selectable or screenable elements in targeted genomes or plasmids. The selectable or screenable elements can include antibiotic resistance genes, fluorescent genes, unique DNA sequences or watermarks or other known reporters, screenable or selectable genes. In some cases, each successive round of engineering can incorporate a fragment of the selectable or screenable element, so that at the end of the engineering round, the entire selectable or screenable element is incorporated into the target genome or plasmid. In such cases, only genomes or plasmids that have successfully incorporated all of the fragments, and therefore all of the desired corresponding mutations, can be selected or screened. In this way, the selected or screened cells are enriched for those that have incorporated the edits at each iterative round of engineering.

[0205] Iterative methods can be used to switch selectable or screenable markers between on and off positions or off and on positions in each successive round of manipulation. Using such methods allows for conservation of available selectable or screenable markers, for example by requiring the use of only one screenable or selectable marker. Furthermore, short regulatory sequences or start codons or non-start codons can be used to turn screenable or selectable markers on and off. Such short sequences can be easily accommodated in the synthesized cassette or polynucleotide.

[0206] The methods and compositions disclosed herein can be used to perform one or more rounds of engineering. In some examples, each round of engineering is used to incorporate a unique edit compared to the edits of the previous round. Each round of engineering can incorporate a unique recording sequence. Each round of engineering can result in the removal or curing of the plasmid used in the previous round of engineering. In some examples, successful incorporation of the recording sequence of each round of engineering results in a complete and functional screenable or selectable marker or unique sequence combination.

[0207] A unique recorder cassette containing a recording sequence, such as a barcode or a screenable or selectable marker, can be inserted with each round of manipulation, thereby generating a recorder sequence indicative of the combination of editing or manipulation steps performed. Consecutive recording sequences can be inserted adjacent to each other. Consecutive recording sequences can be inserted near each other. Consecutive sequences can be inserted some distance away from each other.

[0208] Consecutive sequences can be inserted at some distance from each other. For example, consecutive recorder sequences can be inserted and the following sequence can be entered: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more than 100 bp apart. In some examples, consecutive recorder sequences are separated by more than about 10, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500 or 1500 bp.

[0209] Consecutive recorder sequences can be separated by any desired number of base pairs, which may depend on and be limited by the number of contiguous recorder sequences to be inserted, the size of the target nucleic acid or target genome, and / or the design of the desired final recorder sequence. For example, if the collected recorder sequences are functional screenable or selectable markers, the contiguous recording sequences can be inserted adjacent to each other and in the same reading frame. If the collected recorder sequences are a unique set of barcodes identified by sequencing and do not have coding sequence elements, the contiguous recorder sequences can be inserted by any desired number of base pairs apart. In these cases, the separation distance may depend on the sequencing technology used and the read length limitations.

[0210] While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes and substitutions will immediately occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein can be used in the practice of the invention. The following claims define the scope of the invention, and it is intended to cover all methods and structures within the scope of these claims and their equivalents.

[0211] Some definitions As used herein, the term "wild-type" is a term of art understood by those skilled in the art and means a typical form of a naturally occurring organism, strain, gene or characteristic, as distinguished from mutant or variant forms.

[0212] As used herein, the term "variant" should be taken to mean a display of a quality having a pattern that deviates from that found in nature. The terms "orthologue" (also referred to herein as "ortholog") and "homologue" (also referred to herein as "homolog") are well known in the art. By further guidance, as used herein, a "homolog" of a protein is a protein of the same species that performs the same or similar function as the protein to which it is a homolog. Homologous proteins may, but need not, be structurally related, or are only partially structurally related. An "ortholog" of a protein, as used herein, is a protein of a different species that performs the same or similar function as the protein to which it is an ortholog. Orthologous proteins may, but need not, be structurally related, or are only partially structurally related. Homologs and orthologs can be identified by homology modeling (e.g., Greer, Science 228:1055 (1985) and Blundell et al., Eur J Biochem 172:513 (1988)) or "structural BLAST" (Dey F, Cliff Zhang Q, Petrey D, Honig B, Toward a "structural BLAST": using structural relationships to infer function, Protein Sci. 2013 Apr. 22(4):359-66, doi:10.1002 / pro.2225).

[0213] The terms "polynucleotide", "nucleotide", "nucleotide sequence", "nucleic acid" and "oligonucleotide" are used interchangeably. They refer to polymeric forms of nucleotides of any length, either deoxyribonucleotides or ribonucleotides or analogs thereof. Polynucleotides can have any three-dimensional structure and can perform any function, known or unknown. Coding or non-coding regions of genes or gene fragments, loci defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers are non-limiting examples of polynucleotides. The term also encompasses nucleic acid-like structures with synthetic backbones. See, for example, Eckstein, 1991; Baserga et al., 1992; Milligan, 1993; WO 97 / 03211; WO 96 / 39154; Mata, 1997; Strauss-Soukup, 1997; and Samstag, 1996. A polynucleotide may contain one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.

[0214] "Complementarity" refers to the ability of a nucleic acid to form hydrogen bonds with another nucleic acid sequence, either by conventional Watson-Crick base pairing or other non-conventional types. Percent complementarity indicates the percentage of residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 are 50%, 60%, 70%, 80%, 90%, 100% complementary). "Fully complementary" means that all contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues of a second nucleic acid sequence. As used herein, "substantially complementary" refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50 or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions.

[0215] As used herein, "stringent conditions" for hybridization refer to conditions under which a nucleic acid having complementarity to a target sequence hybridizes primarily to the target sequence and does not substantially hybridize to non-target sequences. Stringent conditions are generally sequence-dependent and vary depending on many factors. In general, the longer the sequence, the higher the temperature at which the sequence will specifically hybridize to its target sequence. Non-limiting examples of stringent conditions are described in Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, 1993. In Biochemistry And Molecular Biology-Hybridization With Nucleic Acid Probes, Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assay" (Elsevier, New York). When referring to polynucleotide sequences, complementary or partially complementary sequences are also envisaged. These are preferably capable of hybridizing to a reference sequence under highly stringent conditions. Generally, relatively low stringency hybridization conditions are selected to maximize the hybridization rate: about 20-25 degrees Celsius. Lower than the thermal melting point (Tm). Tm is the temperature at which 50% of a specific target sequence hybridizes to a completely complementary probe in a solution at a defined ionic strength and pH. Generally, highly stringent wash conditions are selected to be about 5-15 degrees Celsius below the Tm, to require at least about 85% nucleotide complementarity of the hybridized sequences. Moderately stringent wash conditions are selected to be about 15-30 degrees Celsius below the Tm, to require at least about 70% nucleotide complementarity of the hybridized sequences. Highly permissive (very low stringency) wash conditions may be as much as 50 degrees Celsius below the Tm, allowing for a high level of mismatch between hybridized sequences. One skilled in the art will recognize that other physical and chemical parameters in the hybridization and wash steps can also be altered to affect the outcome of a detectable hybridization signal from a particular level of homology between the target and probe sequences.

[0216] "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex stabilized through hydrogen bonds between the bases of the nucleotide residues. The hydrogen bonds may occur by Watson-Crick base pairing, Hoogsteen binding, or any other sequence-specific manner. The complex may include two strands forming a double-stranded structure, three or more strands forming a multi-stranded complex, a single self-hybridizing strand, or any combination of these. A hybridization reaction may constitute a step in a more extensive process, such as the initiation of PCR or the cleavage of a polynucleotide by an enzyme. A sequence that can hybridize to a given sequence is referred to as the "complement" of the given sequence.

[0217] As used herein, the term "genomic locus" or "locus" (plural loci) is the specific location of a gene or DNA sequence on a chromosome. A "gene" refers to a section of DNA or RNA that codes for a polypeptide or RNA chain that plays a functional role in an organism, and is thus a molecular unit of heredity in an organism. For the purposes of the present invention, a gene may be considered to include regions that regulate the production of a gene product, whether or not such regulatory sequences are adjacent to the coding and / or transcribed sequence. Thus, genes include, but are not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, origins of replication, matrix attachment sites, and locus control regions.

[0218] As used herein, "expression of a genomic locus" or "gene expression" is the process by which information from a gene is used in the synthesis of a functional gene product. The product of gene expression is often a protein, but for non-protein-coding genes such as rRNA or tRNA genes, the product is functional RNA. The process of gene expression is used by all known life - eukaryotes (including multicellular organisms), prokaryotes (bacteria and archaea) and viruses to generate functional products for survival. As used herein, "expression" of a gene or nucleic acid encompasses not only cellular gene expression, but also the transcription and translation of nucleic acids in cloning systems and other contexts. As used herein, "expression" also refers to the process by which a polynucleotide is transcribed from a DNA template (such as into mRNA or other RNA transcripts) and / or the transcribed mRNA is then translated into a peptide, polypeptide or protein. Transcription products and encoded polypeptides may be collectively referred to as "gene products." If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in eukaryotic cells.

[0219] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acids of any length. The polymer may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. The term also encompasses modified amino acid polymers, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. As used herein, the term "amino acid" includes natural and / or unnatural or synthetic amino acids, including glycine and both D or L optical isomers, as well as amino acid analogs and peptidomimetics.

[0220] As used herein, the term "domain" or "protein domain" refers to a portion of a protein sequence that can exist and function independently of the rest of the protein chain. As described in the embodiments of the present invention, sequence identity is related to sequence homology. Homology comparison can be performed by eye, or more commonly, using a readily available sequence comparison program. These commercially available computer programs can calculate the percent (%) homology between two or more sequences, and can also calculate the sequence identity shared by two or more amino acid or nucleic acid sequences. Sequence homology can be generated by any of a number of computer programs known in the art, such as BLAST or FASTA. A suitable computer program for performing such alignment is the GGC Wisconsin Bestfit package (Devereux et al., University of Wisconsin, USA, 1984, Nucleic Acids Research, Vol. 12, p. 387). Other examples of software capable of carrying out sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999, ibid., Chapter 18), FASTA (Atschul et al., 1990, J. Mol. Biol., pp. 403-410) and the comparison tools of the GENEWORKS suite. Both BLAST and FASTA can be used for offline and online searching (see Ausubel et al., 1999, ibid., pp. 7-58-7-60). However, it is preferred to use the GCG Bestfit program.

[0221] Percent homology can be calculated over a contiguous sequence, i.e., one sequence is aligned with the other sequence and each amino acid or nucleotide of one sequence is directly compared to the corresponding amino acid or nucleotide of the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively small number of residues.

[0222] This is a very simple and consistent method, but for example in a pair of otherwise identical sequences, one insertion or deletion may cause the next amino acid residue to be out of alignment, and thus the % homology may be significantly reduced when performing a global alignment. Most sequence comparison methods are therefore designed to produce an optimal alignment that takes into account possible insertions and deletions, without unduly penalizing the overall homology or identity score. This is achieved by attempting to maximize local homology or identity by inserting "gaps" in the sequence alignment.

[0223] However, in these more complex methods, a "gap penalty" is assigned to each gap that occurs in the alignment, so that a sequence alignment with as few gaps as possible for the same number of identical amino acids (which reflects a higher relatedness between the two compared sequences) can achieve a higher score than one with many gaps. An "affinity gap cost" is typically used, which imposes a relatively high cost for the presence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties can of course produce optimized alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, when using such software for sequence comparison, it is preferable to use the default values. For example, when using the GCG Wisconsin Bestfit package, the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.

[0224] Thus, the calculation of maximum % homology first requires the creation of an optimal alignment, taking into account gap penalties. A suitable computer program for performing such an alignment is the CGC Wisconsin Bestfit package (Devereux et al., 1984, Nuc. Acids Research 12:387). Examples of other software capable of performing sequence comparisons include, but are not limited to, the BLAST package (Ausubel et al., 1999, Short Protocols in Molecular Biology, 4th ed., Chapter 18), FASTA (Atschul et al., 1990, J. Mol. Biol. 403-410) and the comparison tools of the GENEWORKS suite. Both BLAST and FASTA can be used for offline and online searches (see Ausubel et al., 1999, Short Protocols in Molecular Biology, pp. 7-58-7-60). However, for some applications it is preferable to use the GCG Bestfit program. A new tool called BLAST2 Sequences is also available for comparing protein and nucleotide sequences (see FEMS Microbiol Lett., 1999, vol. 174, no. 2, pp. 247-50; FEMS Microbiol Lett., 1999, vol. 177, no. 1, pp. 187-8; and the National Center for Biotechnology information website at the National Institutes for Health website).

[0225] Although the final % homology may be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pairwise comparison. Instead, a scaled similarity score matrix is ​​typically used that assigns a score to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix. This is the default matrix for the BLAST suite of programs. GCG Wisconsin programs generally use the published default values ​​or a custom symbol comparison table (if provided) (see user manual for details). For some applications, it is preferred to use the published default values ​​of the GCG package, or in the case of other software, a default matrix such as BLOSUM62.

[0226] Alternatively, the percentage of homology may be calculated using the multiple alignment feature of DNASIS™ (Hitachi Software), which is based on an algorithm similar to CLUSTAL (Higgins DG and Sharp PM, 1988, Gene, 73(1):237-244). Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. Typically the software will do this as part of the sequence comparison and generate a numerical result.

[0227] The sequences may also have deletions, insertions or substitutions of amino acid residues which produce silent changes and result in functionally equivalent substances. This is useful for grouping amino acids by functional group, since deliberate amino acid substitutions may be made based on similarity in amino acid properties (such as polarity, charge, solubility, hydrophobicity, hydrophilicity and / or amphipathicity of the residues). Amino acids may be grouped based on the properties of their side chains only. However, it is more convenient to also include mutation data. The set of amino acids thus obtained may be conserved for structural reasons. These sets may be described in the form of Venn diagrams (Livingstone CD and Barton GJ, 1993, "Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation", Comput. Appl. Biosci. 9:745-756) (Taylor WR, 1986, "The classification of amino acid conservation", J. Theor. Biol. 119:205-218). Conservative substitutions may be made, for example, according to the following table illustrating commonly accepted Venn diagram groups of amino acids:

[0228] Embodiments of the invention include sequences (both polynucleotides or polypeptides) that may include homologous substitutions that may occur, i.e., conservative substitutions in the case of amino acids such as basic to basic, acidic to acidic, polar to polar, etc. (Both substitution and replacement are used herein to mean the replacement of an existing amino acid residue or nucleotide with an alternative residue or nucleotide). Non-homologous substitutions may also occur, i.e., those involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyridylalanine, thienylalanine, naphthylalanine, phenylglycine, etc., from one class of residue to another, or instead.

[0229] Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence, including alkyl groups such as methyl, ethyl or propyl groups, in addition to amino acid spacers such as glycine or β-alanine residues. Further variations in form, including the presence of one or more amino acid residues in peptoid form, will be appreciated by those skilled in the art. For the avoidance of doubt, "peptoid form" is used to refer to variant amino acid residues in which the α-carbon substituent is on the nitrogen atom of the residue, rather than on the α-carbon. Processes for preparing peptides in peptoid form are known in the art, for example Simon RJ et al., Proceedings of the National Academy of Sciences of the United States of America (PNAS), 1992, vol. 89, no. 20, pp. 9367-9371, and Horwell DC, Trends Biotechnol., 1995, vol. 13, no. 4, pp. 132-134.

[0230] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics, and recombinant DNA, which are within the skill of one of ordinary skill in the art. See, for example, Green and Sambrook (Molecular Cloning: A Laboratory Manual., 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2014); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (eds. F.M. Ausubel et al., 2017); Short Protocols in Molecular Biology (Ausubel et al., 1999); METHODS IN ENZYMOLOGY (eds. F.M. Ausubel et al., 1999); See, for example, PCR 2: A PRACTICAL APPROACH (MJ MacPherson, BD Hames, and GR Taylor, eds., 1995); ANTIBODIES, A LABORATORY MANUAL, 2nd ed. (Harlow and Lane, eds., 2014); and CULTURE OF ANIMAL CELLS: A MANUAL OF BASIC TECHNIQUE, 7th ed. (RI Freshney, ed., 2016).

[0231] (Example) The following examples are given for the purpose of illustrating various embodiments of the present invention, and are not intended to limit the present invention in any way. The examples, together with the methods described herein, are representative of preferred embodiments of the present invention, and are illustrative, not limiting, of the scope of the present invention. Those skilled in the art will recognize modifications thereof and other uses that fall within the spirit of the present invention as defined by the scope of the claims.

[0232] Example 1. Nucleic acid-derived nuclease The sequences of 20 nucleic acid-guided nucleases, designated MAD1 to MAD20 (SEQ ID NOs: 1 to 20), were aligned and compared with other nucleic acid-guided nucleases. Partial sequences of specific amino acids of the nucleases and the phylogenetic tree are depicted in Figures 1A and 1B, respectively. Key residues that may be involved in the recognition of the PAM site are shown in Figure 1A. These include amino acids at positions 167, 539, 548, 599, 603, 604, 605, 606 and 607.

[0233] Sequence alignments were generated using PSI-BLAST to search for MAD nuclease homologs in the NCBI nonredundant database. Multiple sequence alignments were further refined using the MUSCLE alignment algorithm with default settings implemented in Geneious 10. The percent identity of each homolog of the SpCas9 and AsCpf1 reference sequences was calculated based on pairwise alignment matching from these global alignments.

[0234] Genomic source sequences were identified using Uniprot linkage information or NCBI's TBLASTN search using default parameters, searching all possible frames for translation matches.

[0235] The percent identities of MAD1-8 and 10-12 to various other nucleases are summarized in Table 1. These percent identities represent the shared amino acid sequence identity between the indicated proteins.

[0236] [Table 1-1]

[0237] [Table 1-2]

[0238] [Table 1-3]

[0239] [Table 1-4]

[0240] [Table 1-5]

[0241] Example 2: Expression of MAD nuclease The wild-type nucleic acid sequences of MAD1-MAD20 include SEQ ID NOs: 21-40, respectively. These MAD nucleases were codon-optimized for expression in Escherichia coli (E. coli), and the codon-optimized sequences are listed as SEQ ID NOs: 41-60 (summary in Table 2).

[0242] Codon-optimized MAD1-MAD20 were cloned into expression constructs containing a constitutive or inducible promoter (e.g., the proB promoter SEQ ID NO:83 or the pBAD promoter SEQ ID NO:81 or SEQ ID NO:82) and an optional 6x-His tag (SEQ ID NO:376) (e.g., FIG. 2). The resulting MAD1-MAD20 expression constructs are provided as SEQ ID NOs:61-80, respectively. The expression constructs shown in FIG. 2 were generated by either restriction / ligation-based cloning or homology-based cloning.

[0243] Example 3. Test guide nucleic acid sequences compatible with MAD nuclease A nucleic acid-guided nuclease and a compatible guide nucleic acid are required to have a functional targetable nuclease complex. Several approaches were taken to determine compatible guide nucleic acid sequences, particularly the scaffold sequence portion of the guide nucleic acid. First, the endogenous locus of each MAD nuclease was scanned to check for potential scaffold sequences. In some cases, such as MAD2, no endogenous scaffold sequence was found. Therefore, the compatibility of MAD2 with scaffold sequences near the endogenous locus of other MAD nucleases was tested. The MAD nucleases and the corresponding endogenous scaffold sequences tested are shown in Table 2.

[0244] [Table 2]

[0245] To evaluate the function of MAD nucleases and corresponding guide nucleic acids, editing cassettes were created as shown in FIG. 3. Each editing cassette comprises a promoter operably linked to an editing sequence and the encoded guide nucleic acid. The editing cassettes further comprise primer sites (P1 and P2) at the flanking ends. The guide nucleic acids contained various scaffold sequences to be tested and a guide sequence to guide the MAD nuclease to the target sequence for editing. The editing sequences contained PAM mutations and / or codon mutations associated with the target sequence. The mutations were flanked by homology regions (homology arms or HA) that allow recombination into the cleaved target sequence.

[0246] Figure 4 shows an experiment designed to test different MAD nuclease and guide nucleic acid combinations. An expression cassette encoding a MAD nuclease was added to the host cell along with various editing cassettes as described above. In this example, the guide nucleic acid was engineered to target the galK gene of the host cell, and the editing sequence was designed to mutate the targeted galK gene to block the gene, thereby allowing for screening of cells that were successfully edited. This design was used to identify functional or compatible MAD nuclease and guide nucleic acid combinations. Editing efficiency was determined by qPCR to measure the edited plasmid of the recovered cells in a high-throughput manner. Validation of the specificity of the MAD11 and Cas9 primers is shown in Figures 14A and 14B. These results show that the selected primer pairs are orthogonal, allowing for quantitative measurement of the input plasmid DNA.

[0247] Figures 5A-5B are depictions of experiments with a similar experimental design. In this case, the editing cassette (Figure 5B) further contains a selection marker, in this case kanamycin resistance (kan), and the MAD nuclease expression vector (Figure 5A) further contains a selection marker, in this case chloramphenicol resistance (Cm) and the lambda RED recombination system to aid in homologous recombination (HR) of the edited sequence into the target sequence. The combination of a compatible MAD nuclease and guide nucleic acid will cause a double-strand break in the target sequence if the PAM sequence is present. Because the edited sequence (such as in Figure 3) contains a PAM mutation that is not recognized by the MAD nuclease, edited cells containing the PAM mutation survive cleavage by the MAD nuclease, while wild-type non-edited cells die (Figure 5C). The edited sequence further contains a mutation in the galK gene that allows for screening of edited cells, while the MAD nuclease expression vector and the editing cassette contain a drug selection marker that allows for selection of edited cells.

[0248] Using these methods, guide nucleic acids compatible with MAD1 to MAD20 were tested. 20 scaffold sequences were tested. The guide nucleic acid used in the experiment included one of 20 scaffold sequences, called scaffold-1, scaffold-2, etc., and a guide sequence targeting the galK gene. The sequences of scaffold-1 to scaffold-20 are listed as SEQ ID NOs: 84 to 103, respectively. As will be apparent to one of skill in the art upon reading this disclosure, it should be understood that the guide sequence of the guide nucleic acid is variable and can be engineered or designed to target any desired target sequence. Since MAD2 has no endogenous scaffold sequence to test, a scaffold sequence from a highly homologous nuclease (scaffold-2, SEQ ID NO: 85) was tested and found to be non-functional. That is, MAD2 and scaffold-2 are not compatible. Thus, despite the low sequence homology between MAD2 and other MAD nucleases, MAD2 was tested with 19 other scaffold sequences.

[0249] This workflow was also used to identify or test PAM sequences that are compatible with specific MAD nucleases. Another method for identifying PAM sites is described in the Examples below.

[0250] In general, transformation was performed as follows for the described assays. An E. coli strain expressing the codon-optimized MAD nuclease was grown overnight. A saturated culture was diluted 1 / 100, grown to an OD600 of 0.6, and induced by adding arabinose at a filing concentration of 0.4% and shifting the culture to 42 degrees Celsius in a shaking water bath (if a temperature-sensitive plasmid is used). After induction, cells were chilled on ice for 15 minutes and washed three times with ¼ of the original culture medium containing 10% glycerol (e.g., 50 mL for a 200 mL culture). Cells were resuspended in 1 / 100 of the initial volume (e.g., 2 mL for a 200 mL culture) and stored at -90 degrees Celsius until use. To perform the compatibility and editing efficiency screens described here, 50 ng of the editing cassette was transformed into a cell aliquot by electroporation. After electroporation, cells were allowed to recover in LB for 3 hours and 100 μL of cells were plated onto MacConkey plates containing 1% galactose.

[0251] Editing efficiency was determined by dividing the number of white colonies (edited cells) by the total number of white and red colonies (edited and non-edited cells). Example 4. PAM selection assay To generate a double-stranded break in a target sequence, the guide nucleic acid must hybridize to the target sequence and the MAD nuclease must recognize a PAM sequence adjacent to the target sequence. If the guide nucleic acid hybridizes to the target sequence but the MAD nuclease does not recognize the PAM site, no cleavage will occur.

[0252] PAMs are specific to MAD nucleases, and not all MAD nucleases recognize the same PAM. To assess the requirement of the PAM site for MAD nucleases, the assays shown in Figures 6A-6C were performed.

[0253] As described elsewhere, FIG. 6A shows the MAD nuclease expression vector that also contains a chloramphenicol resistance gene and the lambda RED recombination system. Figure 6B shows a self-targeting editing cassette. The guide nucleic acid is designed to target a target sequence contained in the same nucleic acid molecule. The target sequence is flanked by random nucleotides, designated N4, which means four random nucleotides on both ends of the target sequence. It should be understood that any number of random nucleotides can be used (e.g., 3, 5, 6, 7, 8, etc.). The random nucleotides serve as a library of potential PAMs.

[0254] FIG. 6C shows the experimental design. Essentially, an editing cassette containing a MAD nuclease expression vector and a random PAM site was transformed into a host cell. If a functional targetable nuclease complex was formed and the MAD nuclease recognized the PAM site, the editing cassette vector was cleaved, causing cell death. If a functional targetable complex was not formed or if the MAD nuclease did not recognize the PAM, the target sequence was not cleaved and the cell survived. The starting and final cell populations were sequenced using a detection mechanism (such as next generation sequencing (NGS)) to identify the PAM site recognized by a particular MAD nuclease. These recognized PAM sites were then used to determine the consensus or non-consensus PAM of a particular MAD nuclease.

[0255] The consensus PAM for MAD1-MAD8 and MAD10-MAD12 was determined to be TTTN. The consensus PAM for MAD9 was determined to be NNG. The consensus PAM for MAD13-MAD15 was determined to be TTN. The consensus PAM for MAD16-MAD18 was determined to be TA. The consensus PAM for MAD19-MAD20 was determined to be TTCN.

[0256] Example 5: Testing of Heterologous Guide Nucleic Acids Editing efficiency was tested for MAD1, MAD2 and MAD7 and is shown in FIG. 7. Experimental details and editing efficiency are summarized in Table 3. Editing efficiency was determined by dividing the number of edited cells by the total number of cells recovered. To allow screening of edited cells, various editing cassettes targeting the galK gene were used. The guide nucleic acid encoded in the editing cassette contained a guide sequence targeting the galK gene and one of various scaffold sequences to test the compatibility of the indicated MAD nuclease with the indicated scaffold sequence, as summarized in Table 3.

[0257] Editing efficiencies of compatible MAD nucleases and guide nucleic acids (containing the indicated scaffold sequences) were observed to have editing efficiencies of 75-100%. MAD2 had editing efficiencies of 75-100% and MAD7 had editing efficiencies of 97-100%.

[0258] Combining MAD2 with scaffold-1, scaffold-2, scaffold-4 or scaffold-13 in these experiments results in 0% editing efficiency. These data imply that MAD2 did not form a functional complex with these tested guide nucleic acids and that MAD2 is not compatible with these scaffold sequences. Combining MAD7 with scaffold-1, scaffold-2, scaffold-4 or scaffold-13 in these experiments results in 0% editing efficiency. These data imply that MAD7 did not form a functional complex with these tested guide nucleic acids and that MAD7 is not compatible with these scaffold sequences. Thus, guide nucleic acids useful in the systems and methods of the present disclosure can be identified using experimental data and would require reasonable experimentation by those of skill in the art when using the methods taught in this disclosure.

[0259] In the case of MAD1, all combinations of guide nucleic acids tested had 0% editing efficiency, meaning that MAD1 did not form a functional complex with any of the guide nucleic acids tested. These data also mean that MAD1 is not compatible with the scaffold sequences tested.

[0260] Together, these data highlight the unpredictability of finding a compatible MAD nuclease and scaffold sequence pair to form a functional targetable nuclease complex. Some tested MAD nucleases did not function with any of the tested scaffold sequences. Some tested MAD nucleases only worked with some tested scaffold sequences and not with others.

[0261] [Table 3-1]

[0262] [Table 3-2]

[0263] Example 6. Evaluation of MAD2 and MAD7 Using a similar experimental design as above, we tested the ability of MAD2 and MAD7 to function with heterologous guide nucleic acids. The compatibility of MAD2 with other scaffold sequences was tested, and the experimental results are shown in Figure 8. The MAD nucleases, guide nucleic acid scaffold sequences, and editing sequences used in this experiment are summarized in Table 4.

[0264] The compatibility of MAD7 with other scaffold sequences was tested and the experimental results are shown in Table 9. The MAD nucleases, guide nucleic acid scaffold sequences and editing sequences used in this experiment are summarized in Table 5.

[0265] [Table 4]

[0266] [Table 5]

[0267] In a separate experiment, editing efficiency (Figure 10A) was determined by calculating the ratio of edited colonies (white colonies, edited galK gene) to total colonies. Transformation efficiency (Figure 10B) was determined by calculating the total number of recovered cells compared to the starting number of cells.

[0268] In this example (FIGS. 10A-10B), cells expressing galK were transformed with expression constructs expressing either MAD2 or MAD7 and the corresponding editing cassettes containing a guide nucleic acid targeting the galK gene. The guide nucleic acid consisted of a guide sequence targeting the galK gene and a scaffold-12 sequence (SEQ ID NO: 95).

[0269] In the examples shown, MAD2 and MAD7 had lower transformation efficiency compared to Cas9 for S. pyogenes, but the editing efficiency of MAD2 and MAD7 was slightly higher than that of Cas9 for S. pyogenes.

[0270] Colonies were harvested from the editing experiments and a representative number were subjected to NGS to confirm the presence of editing. Figure 11 shows the sequencing results from these selected colonies harvested from the above assay. The target sequence was in the galK coding sequence (CDS). The TTTN PAM is shown as the reverse complement (wild type NAAA, mutant NGAA). The targeted mutation in the editing sequence is labeled as the targeted codon. The changes compared to the wild type sequence are highlighted. In these experiments, the scaffold-12 sequence (SEQ ID NO: 95) was used. The guide sequence of the guide nucleic acid was targeted to the galK gene.

[0271] Six of the seven sequences represented in the MAD2 experiment contain the designed PAM mutation and the designed mutation in the target codon of galK, and one sequence colony maintains the wild-type PAM and wild-type target codon but also contains an unintended mutation upstream of the target site.

[0272] Two of the four represented sequences from the MAD7 experiment contained the designed PAM mutation and a mutated target codon: one colony contained the wild-type sequence and the other a deletion of eight nucleotides upstream of the target sequence.

[0273] FIG. 12 shows the results of two experiments testing the selection function to aid in the recovery of edited cells. In this example, MAD2 nuclease was used with a guide nucleic acid containing a scaffold-11 sequence and a guide sequence targeting galK. The editing cassette contained an editing sequence designed to incorporate an L80** mutation in galK, thereby allowing for screening of edited cells. In this example 1, MAD2 nuclease was used with a guide nucleic acid containing a scaffold-12 sequence and a guide sequence targeting galK. The editing cassette contained an editing sequence designed to incorporate an L10KpnI mutation in galK. In both experiments, a negative control plasmid using a guide nucleic acid incompatible with MAD2 was included in the transformation. After transformation, the ratio of compatible editing cassettes (containing scaffold-11 or scaffold-12 guide nucleic acids) to incompatible editing cassettes (negative control) was measured. Experiments were performed in the presence or absence of selection. The results show that more cells containing the matching editing cassette were recovered compared to the non-matching editing cassette, a result that is expanded using selection.

[0274] Example 7. Characterization of guide nucleic acids The sequences of scaffolds 1-8 and 10-12 (SEQ ID NOs: 84-91 and 93-95) were aligned and shown in FIG. 13. Nucleotides that match the consensus sequence are faded, while nucleotides that differ from the consensus sequence are clearly visible. The predicted pseudoknot region is shown. Without being bound by theory, the 5' region of the pseudoknot may affect the binding and / or kinetics of the nucleic acid-guided nuclease. As shown in FIG. 13, in general, there appears to be less diversity among scaffold sequences within the pseudoknot region (e.g., SEQ ID NOs: 172-181) compared to sequences outside the pseudoknot region.

[0275] Example 8. Editing efficiency of MAD nuclease The editing efficiency of various MAD nuclease and guide nucleic acid combinations was tested using a plate-based editing efficiency assay and a molecular editing efficiency assay.

[0276] Figure 15 shows quantification of data obtained using a molecular editing efficiency assay using MAD2 nuclease with a guide nucleic acid containing a guide sequence targeting scaffold-12 and galK. The indicated mutations were incorporated into galK using the corresponding editing cassettes containing the mutations. Figure 16 shows a comparison of the editing efficiencies determined by the plate-based assay and the molecular editing efficiency assay using white and red colonies as described above. As shown in Figure 16, the editing efficiencies determined in the two separate assays are in agreement.

[0277] Example 9. Trackable Edits Gene editing can be tracked using barcodes. As described herein, barcodes can be incorporated into or near the editing site. If an operation is repeated multiple times with different editing in each round, it may be beneficial to insert barcodes into common regions in each round of operation. In this way, a single site can be sequenced, and all sequences of barcodes can be obtained from each round without the need to sequence each edited site individually. Figures 17A and 17C, 18 and 19 show examples of such trackable operation workflows.

[0278] As shown in Figure 17A, cells expressing MAD nuclease are transformed with a plasmid containing an editing cassette and a recording cassette. The editing cassette contains the PAM mutation and the gene edit. The recorder cassette is equipped with a barcode, in this case a 15 nt barcode unique to the sequence being tested. Both the editing cassette and the recording cassette each contain a guide nucleic acid to a distinct target sequence. In such a library of plasmids, the recorder cassette for each round can contain the same guide nucleic acid. Therefore, regardless of which editing cassette and corresponding gene edit is used, the barcode from the first round is inserted in the same place as all variants. However, the correlation between the barcodes and the editing cassette is predetermined so that the edits can be identified by sequencing the barcode. Figure 17B shows an example of a recording cassette designed to incorporate a 15 nt barcode and delete the PAM site. The deleted PAM is used to enrich for edited cells because cells containing the wild-type PAM sequence die, but mutant PAM cells escape cell death.

[0279] A similar approach is shown in FIG. 18. In this case, the recorder cassette from each round is designed to target adjacent sequences from the previous round, and each time a new PAM site is deleted by the recorder cassette. The result is a barcode sequence containing barcodes from each round that can be sequenced to confirm each round of manipulations made and determine the combination of mutations contained in the cell and the order in which the mutations were made. Each successive recorder cassette can be designed to be homologous at one end of the region containing the mutated PAM from the previous round. This can improve the efficiency of obtaining fully edited cells at the end of the experiment. In another embodiment, the recorder cassette is designed to target a unique landing site incorporated by the previous recorder cassette. This allows subsequent recorder cassettes and barcodes to target only cells that have successfully completed the previous series of manipulations, improving the efficiency of recovery of cells containing all the desired mutations.

[0280] Figure 19 shows another approach that allows for the reuse of selectable markers or to rescue cells of plasmids that otherwise form a previous chain of operations. In this case, transformed plasmids containing guide nucleic acids designed to target a selectable marker or other specific sequence within the plasmid form a previous chain of operations.

[0281] Example 10. Plasmid-based PAM (pPAM) library design The pPAM target library was designed by taking individual spacer sequences flanked by degenerate nucleotides at the 5' and 3' ends of the target sequence. The N4-SPACERN=20-N4 and N5-SPACERN=20-N3 arrangement formats were used. These sequences were ordered as single oligonucleotides with degeneracy at the designated positions (N3, N4, and N5, etc.). The oligonucleotides were amplified and cloned into gRNA vectors containing spacers matching the target library to create self-targeting gRNA vectors that are depleted in competitive growth conditions (Figure 20). In one experiment, a total of eight different spacer sequences were cloned into vectors containing gRNAs designed to match each target.

[0282] Example 11. Method Targeted library cloning All target libraries used to analyze PAM and spacer motif specificity were cloned into the desired cloning sites by amplification of single-stranded overlapping oligo pools. Linearized backbones for cloning were generated by PCR amplification with overlaps compatible with the insert amplicons and dpnI digested to exclude parental vector contamination. Linearized backbones and insert pools were cloned via Gibson assembly (using either Gibson Assembly Master Mix or NEB Builder HiFi DNA Assembly Kit according to the manufacturer's protocol). Half of each Gibson assembly was desalted for 30 min using a 0.025 μm dialysis membrane floating on deionized water in a Petri dish. This was used to transform E. cloni 10G supreme competent cells and allowed to recover in LB for 1 h. 1% (10 μL) of the recovered transformation was used for dilution-based plating to estimate CFU and library coverage per cloning reaction. If the CFU count was less than 10x the library size, cloning was repeated to ensure complete coverage of the desired sequence space. The remaining harvest was transferred to a 25 mL overnight culture containing 100 µg / mL carbenecillin to maintain selection pressure for replicating the cloned library.

[0283] After overnight recovery, 2x1mL aliquots were taken from each library cloning reaction and stored as glycerol stocks. The remaining 23mL culture was pelleted and used to extract plasmid DNA using a Qiagen Plasmid Plus Midi kit. This DNA was used in subsequent transformations to generate the data presented.

[0284] Preparation of competent cells for gRNA depletion studies Prepare competent cells for gRNA depletion, editing plasmid into E. coli MG1655. The editing plasmid contained the temperature-inducible RNA nuclease of interest (RGEN), arabinose-inducible λRED operon and chloramphenicol resistance marker. After overnight growth, saturated RGEN-containing cell strains were introduced at 1 / 100 dilution into 250 mL of LB + 25 μg / mL chloramphenicol in 500 mL baffled shake flasks. The inoculated culture was grown to 0.5-0.8 OD and transferred to a 42 °C shaking water bath to induce RGEN expression. Following induction cells at 42 °C were placed on ice for 10 min. Cells were then washed 3 times with 100 mL of ddH2O or 10% glycerol. After a final washing step, cells were resuspended in 2.5 mL (or 1 / 100 of the total culture volume) of 10% glycerol and stored at -80°C in 200 μL aliquots.

[0285] gRNA depletion method Each gRNA depletion experiment was performed using a single 200 µL aliquot of RGEN-containing competent cells. This aliquot of cells was dispensed into a chilled 2 cm gap cuvette and electroporation was performed using the Nepa Gene system. Electroporation used a mixed 2400 V transfer pulse and twenty 150 V pulses. Each transformation was performed with 50–500 ng of the desired library as described in the experimental folder. After 2 h recovery, 1% of the transformants were spot plated to determine transformation efficiency (i.e. total CFU) and the remaining transformation volume was used to inoculate a 100 mL growth culture. Cultures were sampled at various time points by removing 1 mL aliquots and DNA extraction was performed using Qiagen's QiaPrep Miniprep kit for downstream sequencing.

[0286] General NGS Preparation and Analysis Plasmid minipreps were amplified with experimentally indexed primers. Amplicons were pooled to normalize expected read counts and gel purified before loading onto the MiSeq / NextSeq instrument. The indexed fastq read files were then mapped against variants expected to have 100% identity from the experimental design and counts are tallied to perform comparative analysis found in the data. All counts were frequency normalized by eqn: Vf=(V count) / (total count), where Vf is the frequency of a variant in a particular index, V counts are the counts seen in that variant, and total counts are the total counts observed across experimental indexes.

[0287] Data analysis and depletion calculations Depletion scores (or absolute fitness scores) were calculated as log2 depletion scores using the following formula: W = log2(Fx,f / Fx,i), where Fx,f is the frequency of cassette X at the final time point, Fx,i is the initial frequency of cassette X, and W is the absolute fitness of each variant. Frequency was determined by dividing the read counts for each variant by the total experimental counts, including those lost in filtering. Each selection was performed in two replicates, and a count-weighted average of the two measurements was used to estimate the average fitness score for each mutation as follows: W = (Σ N i=1 counts i *W i ) / (Σ N i=1 counts i ). Note that the calculated score may be referred to as a depletion score if the calculated value is negative, but may also be referred to as an enrichment score if the calculated value is positive.

[0288] These scores were used to rank-order and evaluate the fitness contribution of each mutation under the various selective pressures investigated. For every selection, the average absolute fitness score for synonymous mutants was provided as a composite measure of mean growth rate. Absolute enrichment scores were considered significant if the enrichment of the mutant was at least μ±2*σ of the wild-type value (i.e., p=0.05 assuming normal distribution). Means and significance thresholds were reported for each selection. At least two replicates were performed for each selection, and a cut-off threshold of 10 was applied across replicates for inclusion in each analysis.

[0289] In some cases, data were normalized to NRRN PAM control library data or other non-target control library data. FIG. 21A shows that impedance reflects the number of transformants per well containing SOP competent cells and a given amount of DNA. FIG. 21B shows a comparison of count-weighted average depletion scores with Ec110 (4 replicates), Ec83* (5 replicates) and Ec78* (2 replicates). These amplicons were sequenced and 3'-PAM was used as the sample barcode. FIG. 22A shows that the counts of the input EC110 control plasmid and the EC110 control plasmid after 15 hours of growth are nearly identical. FIG. 22B shows that the counts of the EC110 control plasmid after 15 and 20 hours of liquid growth are nearly identical, indicating stable maintenance of the input plasmid.

[0290] Example 12. pPAM assay for identification of MAD7 PAM and MAD2 PAM PAM preferences for MAD2 and MAD7 were determined using the pPAM plasmid depletion assay and data analysis methods described above. Depletion scores for various PAMs were calculated as described above for both MAD7 (Figure 23A) and MAD2 (Figure 23B) at 20 hours. Depleted or reduced PAMs were recognizable and therefore cleaved by the nuclease and gRNA complex. The preferred PAM sites for both enzymes are shown from left to right, respectively. Both MAD2 and MAD7 preferred the NYYN PAM, although some NYYN PAMs performed better than others (Figures 23A and 23B). Editing versus cleavage efficiency was further characterized for selected MAD7PAM plasmids (Figure 23C).

[0291] Example 13. Synthetic Plasmid-Based Off-Target (SPOT) Plasmid-based Off-Target Assay Design A synthetic plasmid-based off-target (SPOT) target library was designed by making each spacer sequence 20 nucleotides long and adding a subset of PAM sequences on either side. In some experiments, a YTTN PAM was added to the 5' side of each target and a NGG PAM was added to the 3' side. This generated the format YTTN-SPACERN=20-NGG (SEQ ID NO: 377). Based on the IUPAC formal nomenclature, Y=C or T; N=A, C, T or G. Eight combinations of 5'PAM-3'PAM pairs were tested in the initial experiments for each target. Two samples were made, one for each 5'PAM along with each 3'PAM. Specifically, the following 5'PAM-3'PAM combinations were generated and tested: TTTA-AGG (SEQ ID NO: 378); TTTC-CGG (SEQ ID NO: 379); TTTG-GGG (SEQ ID NO: 380); TTTT-TGG (SEQ ID NO: 381); CTTA-AGG (SEQ ID NO: 382); CTTC-CGG (SEQ ID NO: 383); CTTG-GGG (SEQ ID NO: 384); and CTTT-TGG (SEQ ID NO: 385), where a 20 nucleotide spacer was between each PAM combination. In this experiment, only a representative number of combinations were tested, but it should be understood that all possible 5'-YTTN-N=20-NGG-3' (SEQ ID NO: 377) PAM combinations could be tested as well. The set of target spacers with different PAM combinations was then used as a template to design point mutations throughout the spacer sequence. The design of the target spacer mutation library consisted of four different sets of mutations for each PAM spacer sequence and internal standard.

[0292] The initial mutation library was a scanning mismatch library consisting of 1, 2, 3 or 4 bp consecutive mismatches, where each mismatch was the complementary nucleotide of the wild-type sequence. Possible 1, 2, 3 and 4 consecutive bp mutations were generated along the entire length of the spacer sequence, respectively.

[0293] The second mutation library was a scanning deletion library consisting of consecutive deletions of 1, 2, 3, or 4 bp, where each possible 1, 2, 3, and 4 consecutive bp mutations were generated along the entire length of the spacer sequence, respectively.

[0294] The third mutation library was a single insertion library in which a single base insertion was made at each position in the spacer. In some experiments, each 1 bp insertion was made by directly duplicating the nucleotide 5' to the insertion site. Other insertion library designs include directly duplicating the nucleotide 3' to the insertion site, or generating individual variants for each possible nucleotide insertion variant, for example inserting one of A, T, C, or G at each position in the spacer region.

[0295] The fourth mutation library was a random mutagenesis library in which 2-5 bp positions were randomly mutated to create a set of mutant sequences that approximated the most biologically relevant variety of diversity. These 2-5 bp mutations did not have to be contiguous, so often had intervening nonmutated or wild-type nucleotides between the mutated nucleotides. Such noncontiguous random mutations have been found to be common in biological systems.

[0296] Similar to the pPAM library, the SPOT sequences were cloned into a gRNA vector containing a spacer matching the target library to generate self-targeting gRNA vectors. The oligo pool was amplified and cloned into a gRNA vector containing a spacer matching the target library to generate self-targeting gRNA vectors that would be depleted under competitive growth conditions due to cleavage and loss of the plasmid under selective pressure. Eight alternative 5'-3'PAM combinations flanked individually by eight different spacer sequences were cloned into a vector containing gRNAs designed to match the target.

[0297] The SPOT assay allows for in vivo depletion assays regardless of the production of ribonucleoprotein complexes. The assay also allows unique off-target analysis with systematic off-target design due to various mutation library design options. Additional advantages of the SPOT assay include more controlled variation of off-target candidates. The assay can be used to compare different PAM structures. The assay can also be combined or mixed with the pPAM library assay described above.

[0298] Other off-target assays such as Site-Seq, BLISS, Digenome-Seq or Circle-Seq mine cleaved sites from mammalian experiments and report off-target sequences with NHEJ repair efficiency from deep sequencing. Using these other assays, most studies have shown off-target effects of random mismatches >3bp.

[0299] Example 14. Off-target characterization The off-target effects of MAD7 and MAD2 were analyzed using the synthetic plasmid-based off-target (SPOT) assay described above. First, the cleavage activity of eight targets with various adjacent PAM sites was tested using either the reference nuclease, MAD7 or MAD2. Then, the target selected from above was used as a starting point to generate a library of various random mutations within the target. In this example assay, a 171 bp amplicon was generated when the target and the adjacent PAM region were amplified, allowing 87 bp reads with in-line indexing or 46 bp reads with 12 bp indexing.

[0300] Data from an example experiment are shown in Figures 24A-C. Targets contained the indicated number of random mutations (r3=3bp; r4=4bp; r5=5bp). Cas9 was used to generate the depletion plot in Figure 24A, MAD7 was used to generate the depletion plot in Figure 24B, and MAD2 was used to generate the depletion plot in Figure 24C.

[0301] As can be seen when comparing the reference protein depletion plots with the MAD7 and MAD2 depletion plots, the reference protein has far more off-target cleavage events across the r3, r4 and r5 libraries, respectively. Both MAD7 and MAD2 showed fewer off-target cleavage events for random mutations, and there were virtually no off-target cleavage events with 5 bp random mismatches. These off-target cleavage events, or lack thereof, are unrelated to the PAM or target sequence.

[0302] Example 15. Combination of PAM determination and off-target analysis The ability to characterize PAM specificity and off-target effects in combination experiments was tested by combining the pPAM and SPOT assays described above. This combination is referred to herein as the Inscripta assay. (e.g., FIG. 25). In this Inscripta assay example, a 171 bp amplicon is generated when the target and adjacent PAM regions are amplified, allowing 46 bp reads with 12 bp index reads. The targeting sequence was selected to uniformly sample a wide range of melting temperature values ​​of the spacer sequence.

[0303] The Inscripta assay was used to rapidly characterize the PAM specificity and off-target rates of the 10 enzymes. MAD7 depletion was essentially identical at 20 hours (MAD7) to 24 hours (MAD7.24) of depletion. Plasmid input was similar to Ec110, an E. coli strain containing a control plasmid similar to the engine vector backbone described above but lacking the nuclease-encoding gene. MAD2 depletion remained the same with the constitutive promoter Ec78*(MAD2) versus Ec113, an E. coli strain containing the engine vector backbone described above with the MAD7 nuclease-encoding gene controlled by the constitutive proA promoter instead of the pL inducible promoter system. Strong depletion was observed using MAD7 or MAD2 and the multi-target library, and strong depletion in the multi-target library was also observed with MAD4. Less depletion was observed for MAD5 compared to MAD2, MAD7 and MAD4.

[0304] Based on these data, MAD7, MAD2, MAD4 and MAD5 were selected for further characterization. PAM specificity was analyzed using the pPAM assay data, respectively. Depletion plots of the tested PAMs TTN and CTTN are shown in Figures 26A and 26B, and the PAMs RTTN and YCCN are shown in Figure 26C.

[0305] The MAD7 depletion scores for various PAMs are also shown in Figures 27A-27B, and these data indicate that the GC content of the target sequence can affect the scale of depletion activity, suggesting that cleavage and targeting can be tuned based on the choice of PAM and target sequence.

[0306] The MAD2 depletion scores of various PAMs are also shown in Figures 28A-29B, and these data indicate that the GC content of the target sequence can affect the scale of depletion activity, suggesting that cleavage and targeting can be tuned based on the choice of PAM and target sequence. For example, the PAM TTTA, which has a GC content similar to target 8, shows very strong depletion.

[0307] MAD4 depletion scores for various PAMs are also shown in Figures 29A-29B, and these data indicate that the GC content of the target sequence can affect the scale of depletion activity, suggesting that cleavage and targeting can be tuned based on the choice of PAM and target sequence. MAD4 also showed high depletion scores for target 8, which has the highest GC content of all targets tested.

[0308] The MAD5 depletion scores of various PAMs are also shown in Figures 30A-30B. These data indicate that MAD5 does not provide potent depletion of the target and PAM sequence combinations tested.

[0309] The off-target cleavage effects of MAD7, MAD2 and MAD4 were further characterized. Example data from SPOT assays using mutant libraries of various tested targets are shown in Figures 31A-31C. MAD4 showed even less off-target activity than MAD2 and MAD7 in many of the tested target classes, as shown in the example data shown in Figures 32A-32H. The mutant libraries depicted in each graph are indicated and include random mutations (Figures 32A and 32E), deletion mutations (Figures 32B and 32F), mismatch mutations (Figures 32C and 32G) or insertion mutations (Figures 32D and 32H). Figures 32I-32P show the depletion scores from experiments using MAD7 and the mutant libraries containing mutations at the indicated positions within each tested target sequence. These data are a combination of all YTTN PAMs used in experiments using MAD7. For Figures 32I-32P, non-T is calculated from the 5'-NGGN PAM, wt (wild type) is a control with no mutation in the target, and "position" is the position of the mutation within the target sequence. Figures 32I-32J show data from a 1 bp scanning mutation library (m1). Figures 32K-32L show data from a 2 bp scanning mutation library (m2) with two consecutive mutations starting at the positions indicated. Figures 32M-32N show data from a 3 bp scanning mutation library (m3) with three consecutive mutations starting at the positions indicated. Together, these data indicate that the seed sequence at positions 1-7 is important, as mutations within this region tend to disrupt MAD7 cleavage activity, as indicated by the reduced depletion scores for mutations within these positions. Figures 32O-32P show data from a 2 bp scanning mutation library (m2) with data from one target organized by PAM sequence. Taken together, these data indicate that some PAM sequences are less specific than others, suggesting a relationship between PAM strength and target specificity. The PAM, for example, appears to support cleavage of templates with 2-bp tandem mismatches at a higher rate than the remaining combinations tested when compared to the CTTT PAM. These observations suggest that the strength of the PAM should be incorporated into target selection.

[0310] Example 16. Characterization of compatible guide RNA sequences To characterize which scaffold sequences are compatible with the tested MAD nucleases, various guide RNAs containing different scaffold sequences were tested. Scaffolds from endogenous CRISPR arrays of the MAD nucleases of interest were tested, as well as non-homologous scaffold sequences derived from heterologous or orthogonal MAD nuclease systems. Figure 33 shows examples of schematics of various MAD nuclease and guide RNA scaffold combinations tested, as well as constructs used to test the compatibility of the MAD nucleases (e.g., MAD#) and guide RNA scaffold sequences (e.g., crMAD#) being tested. The constructs included a promoter driving expression of a guide RNA containing a scaffold sequence (crRepeat) and a targeting sequence (e.g., galT45 spacer). The constructs also included a target sequence (e.g., galT45, 24bp) targeted by the targeting sequence of the guide RNA. A 3-4bp PAM region flanked the target sequence. Each construct also contained a unique sequence ID or barcode that was used to identify the scaffold sequence. Identification can be achieved after amplifying the target sequence region using, for example, the barcode / unique ID and primers flanking that region, as shown in Figure 33. In some examples, amplification produces a 176bp amplicon, allowing 50bp reads with 12bp index reads using the V3HIGH throughput 1x75bp kit.

[0311] In an exemplary experiment, 12 MAD enzymes were tested with 10 scaffold sequences, resulting in amplicons that were subsequently sequenced in one NextSeq Run.

[0312] The compatibility of certain MAD enzymes with various scaffold sequences was tested using this assay. The primary and secondary structures of some of the scaffold sequences (crMAD#) tested are shown in Figures 34A and 34B. Figure 34A shows an alignment of crRNA scaffold sequences from the indicated MAD systems. Figure 34B shows a portion from the pseudoknot region from the indicated MAD crRNAs. These alignments in Figures 34A-34B show the structure of these aligned MAD The alignment shows strong sequence and structural conservation of the pseudoknot region of the crRNAs. The alignment further shows that the presence of the 5' end of the repeat region (marked in Figure 34A), although not necessarily the sequence, is not significantly related to the cleavage activity. Sequence variations from the consensus sequence of selected MAD crRNAs are shown. For example, the most depicted nucleotide at 5' is a C in MAD3 crRNA, as opposed to a U in the consensus sequence. As further examples, the second nucleotide of the loop structure is an A in the consensus sequence, instead being 1) a U in MAD10 crRNA, 2) a G in MAD4, MAD7 and MAD11 crRNAs, 3) a C in MAD25 crRNA, and 4) a CU in MAD3 crRNA. As further examples, the third nucleotide of the loop structure of the consensus sequence is a U, instead being a G in MAD5 crRNA. As shown, for some MAD crRNAs, the length of the loop sequence is 4 nucleotides, whereas for others (e.g., MAD3 In the case of crRNA, the length of the loop sequence is 4 nucleotides.

[0313] Examples of results from this assay are shown in Figures 35A-35C for MAD7, MAD2, and MAD4, respectively. Some observations from each data set are shown below. As shown in Figure 35A, MAD7 appears to be compatible with most of the scaffold sequences tested with a 4 bp loop. Also, the UAGU loop sequence appeared to have slightly lower cleavage activity when combined with a weaker PAM sequence. MAD7 activity is spread across a wide range of PAM sequences as shown by the respective depletion scores. Taken together, these results suggest that MAD7 activity can be tuned by manipulation of the scaffold sequence. Additional data from these MAD7 experiments are shown in Figures 36A-36B, which show a comparison of MAD7' compatibility with native and non-homologous scaffold sequences containing different stem-loop sequences. Additional data showing the compatibility of MAD7 with various scaffold sequences with different stem-loop sequences is shown in Figure 37. As this data shows, the sequence at the -1 position upstream of the PAM appears to be important, with the first "C" nucleotide at the -1 position negatively affecting depletion. There appears to be the following priority at the -1 position: G>T>A>C, except in the CTTT PAM situation. In that case, the order of preference appears to be A>G>T>C. In particular, pyrimidine (T / C)-rich spacer sequences in the seed region appear to be slightly disfavored in both MAD7 and MAD2, and purine (A / G)-rich ones are slightly enriched. Having a C upstream of the PAM also appears to be detrimental.

[0314] As shown in Figure 35B, MAD2 appears to be compatible with many of the scaffolds tested that contain a 4 bp loop. Bimodal PAM recognition was also observed. Additional data from these experiments are shown in Figures 36C-37D, which show a comparison of MAD2' compatibility with native and non-homologous scaffold sequences containing different stem-loop sequences.

[0315] As shown in Figure 35C, MAD4 appears to be compatible with many of the scaffolds tested that contain a 4 bp loop. Also, the UAGU loop sequence appeared to have slightly lower cleavage activity when combined with weaker PAM sequences. PAM recognition appeared to be slightly bimodal. Additional data from these experiments are shown in Figures 36E-36F, which show a comparison of MAD4' compatibility with native and non-homologous scaffold sequences containing different stem-loop sequences.

[0316] Example 17. Characterization of MAD7 activity in yeast A number of yeast MAD7 cassette structures were tested using the CAN1 selection assay. In some example experiments, 11 different cassettes with various homology arm orientations were tested for editing efficiency of the target sequence. In general, yeast cells were transformed with one of the cassettes of interest and a vector expressing the MAD7 enzyme codon-optimized for expression in S. cerevisiae. The transformed cells were plated on canavanine for selection. Only successfully edited cells survived the canavanine selection, indicating that the combination of MAD7 and cassette effectively succeeded in the desired editing. DNA was then extracted from the selected cells and the desired editing was confirmed by digestion or sequencing. Details of the cassettes tested are listed in Table 6. In Table 6, the underlined nucleotides indicate potential problematic sequences as the penta-T motif may act as a signal for transcription termination in eukaryotic cells and therefore may cause expression problems. These potentially problematic sequences were therefore altered in the various tested linker sequences by deleting or substituting one or more nucleotides with the nucleotides shown in bold italics. Data from the example experiments are summarized in Table 7. These data indicate that the 36 bp T to C-F style cassette is in the preferred orientation and configuration.

[0317] [Table 6]

[0318] [Table 7-1]

[0319] [Table 7-2]

[0320] Additional cassette configurations were also tested, as shown in Table 8. In this set of experiments, the cassette parameters were filtered to ensure that there was no TTTTT (targeting sequence) in the spacer and no homopolymeric regions longer than 6 bp in the homology arms or spacer (targeting sequence).

[0321] Table 9 summarizes the editing efficiency of selected cassettes in additional experiments, showing a range of 25-100% editing efficiency based on predicted mutations. Table 10 summarizes other experimental details including sequences contained in the indicated cassettes, the targeted WT gene sequence and the mutated sequences inserted after DNS cleavage by the subject MAD enzyme and crRNA complex.

[0322] [Table 8]

[0323] [Table 9]

[0324] [Table 10]

[0325] Example 18. In vitro and in vivo cleavage of mammalian target sequences. MAD7 was used to target and cleave mammalian cell targets. E. coli or human codon-optimized MAD7 expression constructs were generated (e.g., FIG. 38A). Briefly, construct I69 contains an hCMV promoter operably linked to an E. coli codon-optimized MAD7 sequence that also contains a 5' (N-terminal) V5 epitope tag and a nuclear localization signal (NLS), and the construct also contains an EF1alpha promoter-driven expression of a GFP reporter and a blasticidin resistance gene. Construct I19 is similar to I69, except that the NLS and V5 sequences are at the 3' end (C-terminal) of the MAD7 sequence. The I9 construct is similar to the I69 sequence, except that the MAD7 sequence is codon-optimized for expression in human cells rather than E. coli. The I18 construct is similar to the I19 construct, except that the MAD7 sequence was codon-optimized for expression in human cells rather than E. coli. Two guide RNA sequences were used, as shown in Figure 38B.

[0326] Figures 39A-39B show target sites within two target genes, PPIB (Figure 39A) and DNMT3B (Figure 39B). Figures 39C-39D summarize the PAM sequences and target sequences targeted by the indicated guide RNA sequences, as well as the CG content of the target sequences and which DNA strand was targeted.

[0327] Mammalian cells were individually transfected with MAD7 expression vectors and cell lysates were collected. To confirm MAD7 expression, cell lysates were evaluated by Western blot analysis. Cell lysates were also used in an in vitro cleavage assay to evaluate MAD7 protein function, indicating proper expression and folding of the protein expressed in mammalian cells. This assay allows the expression and cleavage ability of MAD7 to be evaluated without the cellular machinery modifying or blocking the cleavage event due to chromatin condensation of the target sequence. After performing the cleavage assay, the lysates were separated by gel electrophoresis and analyzed using ImageJ software and densitometry to determine the % cleavage (% cleavage), calculated by dividing the cleavage product intensity by the total band intensity.

[0328] Figure 40 shows quantification of cleavage rates (cleavage efficiency) from example experiments of the indicated PPIB and DNMT3B target sequences using the I18 construct. Little difference in cleavage was observed in vitro between 42-mer and 56-mer guide RNA sequences, so the average values ​​of the two are plotted in Figure 40. For PPIB, 8 of the 10 guide RNAs tested caused target cleavage, with gRNA-14 and gRNA-25 causing undetectable cleavage using this assay. gRNA-15 targeting PPIB resulted in efficient cleavage, but the size of the cleavage products generated was small (approximately 70 bp difference from the uncleaved one) and difficult to measure, so the percent cleavage was estimated to be >90%. For DNMT3B, 9 of the 10 guide RNAs tested caused target cleavage, with gRNA-14 and gRNA-4 causing undetectable cleavage using this assay. gRNA-1 targeting DNMT3B resulted in efficient cleavage, but the percentage cleavage was estimated to be >90% because the size of the cleavage products generated was small (~70 bp difference from the uncleaved one) and difficult to measure.

[0329] FIG. 41 shows quantification of indel (insertion or deletion) formation in mammalian cells. Briefly, MAD7 nuclease expression vector (I9 or I18, see FIG. 38A) and synthetic guide RNA were co-transfected into HEK293T cells. After an incubation period of about 72 hours, in vivo cleavage was assessed by detecting indel formation. Without wishing to be bound by theory, it is believed that after cleavage occurs, in some cases the cleaved DNA is repaired via a non-homologous end joining (NHEJ) mechanism. This often results in the insertion or deletion of one or more nucleotides from the cleavage site. These insertion and / or deletion events are called indels. Indels were detected using a DNA mismatch detection assay using a T7EI assay. This mismatch assay detects mismatches between the expected unmodified sequence and the modified sequence, including indels after cleavage and NHEJ repair. In some cases, 56-mer guide RNAs resulted in higher indel formation compared to 42-mer guide RNAs. In the case of PPIB, two of the three guide RNAs resulted in detectable cleavage with this method, while three of the three detected the DNMT3B gene target. Two other constructs using the E. coli codon-optimized MAD7 nuclease also showed indel formation with relatively the same efficiency as the human codon-optimized construct (data not shown). Overall, these data indicate successful MAD7 cleavage activity in vivo in mammalian cells.

[0330] Together, these data indicate that MAD7 is efficiently expressed and folded in mammalian cells and functions efficiently in vitro and in vivo at mammalian target sequences. The in vitro data also indicate that the shorter 42-mer gRNA cuts as efficiently as the longer 56-mer gRNA, although this was not always observed when measuring endogenous indel formation in mammalian cells.

[0331] Example 19. Further characterization of MAD nucleases An editing screen was performed to further characterize the PAM preferences of the selected MAD nucleases. The galK gene was used as the target for this screen. Some notable observations from these data include that editing was observed at MAD7 using GTTG and TTTC PAMs, and editing was observed at MAD2 using TTTC PAM. Some cytotoxicity was observed in these experiments. Table 11 summarizes the results of these experiments.

[0332] [Table 11]

[0333] The PAM screen assay was repeated using MAD2, MAD4 and MAD7. According to the experimental design of this assay, white colonies reflect the insertion of a stop codon by homologous recombination of the mutation-containing editing cassette, and red colonies indicate that a stop codon was not inserted. MAD2 showed editing consistent with the previously described PAM specificity data. MAD4 showed high cytotoxicity and fewer observable colonies compared to MAD2 and MAD7 transformed cells. MAD7 showed editing results consistent with previous PAM specificity data and showed a broader range of editing efficiencies than MAD2.

[0334] These data show that the editing efficiency is over 90% despite low cell viability. Table 12 summarizes the results of these experiments. These data show low variability between PAM sites for MAD4 (approximately 2.3-fold) compared to MAD2 (25-fold) or MAD7 (101-fold). This fold change was calculated as follows: Fold difference = Maximum (CFU edited) / Minimum (CFU edited).

[0335] [Table 12]

[0336] Although the present invention is fulfilled by the disclosure of many different forms of embodiments, as described in detail in connection with the preferred embodiment of the present invention, it is understood that the present disclosure should be considered as an exemplification of the principles of the present invention, and is not intended to limit the present invention to the specific embodiments shown and described herein. Numerous modifications may be made by those skilled in the art without departing from the spirit of the present invention. The scope of the present invention is determined by the appended claims and their equivalents. The abstract and title of the invention should not be construed as limiting the scope of the present invention, and their purpose is to enable the appropriate authorities and the general public to quickly determine the general nature of the present invention. (Additional Note) As a preferred embodiment, the technical ideas that can be understood from the above embodiment will be described below. [Item 1] 1. A method for modifying a target region in the genome of a cell, comprising: (a) a cell; A nucleic acid-induced nuclease comprising the amino acid sequence of SEQ ID NO: 7; an engineered guide nucleic acid capable of complexing with said nucleic acid-guided nuclease; and an edited sequence encoding a nucleic acid complementary to the target region having a sequence change relative to the target region; and contacting the (b) enabling the nuclease, guide nucleic acid, and editing sequence to create a genome edit in a target region of the genome of the cell; The method includes: [Item 2] 2. The method of claim 1, wherein the engineered guide nucleic acid and the editing sequence are provided as a single nucleic acid. [Item 3] 3. The method of claim 2, wherein the single nucleic acid further comprises a mutation at a protospacer adjacent motif (PAM) site. [Item 4] 2. The method according to item 1, wherein the nucleic acid-induced nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 47 or 203 to 222. [Item 5] 2. The method according to item 1, wherein the nucleic acid-induced nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 133 or 183 to 202. [Item 6] 2. The method according to item 1, wherein the nucleic acid-induced nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 153 or 243 to 262. [Item 7] 2. The method according to item 1, wherein the nucleic acid-induced nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NOs: 223 to 242. [Item 8] 2. The method according to item 1, wherein the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172 to 182. [Item 9] 2. The method of claim 1, wherein the engineered guide nucleic acid comprises a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU. [Item 10] A nucleic acid-guided nuclease system comprising: (a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO: 7; (b) an engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease; and (c) an edited sequence having a sequence change relative to the sequence of the target region in the genome of the cell; wherein the nucleic acid-guided nuclease system results in genome editing at the target region in the genome of the cell facilitated by the nuclease, the engineered guide nucleic acid and the editing sequence. [Item 11] 11. The system according to item 10, wherein the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 47 or 203 to 222. [Item 12] 11. The system according to item 10, wherein the nucleic acid-induced nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 133 or 183 to 202. [Item 13] 11. The system according to item 10, wherein the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 153 or 243 to 262. [Item 14] 11. The system according to item 10, wherein the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NOs: 223 to 242. [Item 15] The system of claim 10, wherein the nucleic acid-guided nuclease is codon-optimized for the cell to be edited. [Item 16] 11. The system of item 10, wherein the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172 to 182. [Item 17] 11. The system of item 10, wherein the engineered guide nucleic acid comprises a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU. [Item 18] 11. The system of claim 10, wherein the engineered guide nucleic acid and the editing sequence are provided as a single nucleic acid. [Item 19] 19. The system of claim 18, wherein the single nucleic acid further comprises a mutation at a protospacer adjacent motif (PAM) site. [Item 20] 1. A composition comprising: (a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO: 7, and (b) an engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease, the engineered guide nucleic acid comprising a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU; A composition comprising: [Item 21] 21. The composition of claim 20, wherein the engineered guide nucleic acid is a heterologous engineered guide nucleic acid. [Item 22] 21. The composition of claim 20, wherein the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172 to 182. [Item 23] 21. The composition of claim 20, wherein the nuclease is encoded by a nucleic acid sequence that is codon-optimized for use in a cell derived from a particular organism. [Item 24] 23. The composition of claim 22, wherein the nucleic acid sequence is codon-optimized for E. coli. [Item 25] 23. The composition of claim 22, wherein the nucleic acid sequence is codon-optimized for S. cerevisiae. [Item 26] 23. The composition of claim 22, wherein the nucleic acid sequence is codon optimized for mammalian cells. [Item 27] 23. The composition of claim 22, wherein the nucleic acid sequence is codon optimized for human cells. [Item 28] 23. The composition of claim 22, wherein the nucleic acid sequence is codon optimized for a plant cell. [Item 29] A nucleic acid-guided nuclease system comprising: (a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO: 7, and (b) a heterologous engineered guide nucleic acid capable of complexing with said nucleic acid-guided nuclease; A nucleic acid-guided nuclease system comprising: [Item 30] (c) the system of item 29, further comprising an edited sequence having a sequence change relative to the sequence of the target region. [Item 31] 31. The system of claim 30, wherein the system provides editing of a target region facilitated by the nuclease, the heterologous engineered guide nucleic acid, and the editing sequence. [Item 32] 30. The system of item 29, wherein the engineered guide nucleic acid comprises a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU. [Item 33] 30. The system of item 29, wherein the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172 to 182. [Item 34] 30. The system of item 29, wherein the nuclease is encoded by a nucleic acid sequence that is codon-optimized for use in a cell derived from a particular organism. [Item 35] 31. The system of item 30, wherein the nucleic acid sequence is codon-optimized for E. coli. [Item 36] 31. The system of claim 30, wherein the nucleic acid sequence is codon-optimized for S. cerevisiae. [Item 37] 31. The system of claim 30, wherein the nucleic acid sequence is codon optimized for mammalian cells. [Item 38] 31. The system of claim 30, wherein the nucleic acid sequence is codon optimized for human cells. [Item 39] 31. The system of claim 30, wherein the nucleic acid sequence is codon optimized for a plant cell. [Item 40] 1. A method for modifying a target region in the genome of a cell, comprising: (a) a cell; A nucleic acid-induced nuclease comprising the amino acid sequence of SEQ ID NO:2; an engineered guide nucleic acid capable of complexing with said nucleic acid-guided nuclease; and an edited sequence encoding a nucleic acid complementary to the target region having a sequence change relative to the target region; and contacting the (b) enabling the nuclease, guide nucleic acid, and editing sequence to create a genome edit in a target region of the genome of the cell; The method includes: [Item 41] 41. The method of claim 40, wherein the engineered guide nucleic acid and the editing sequence are provided as a single nucleic acid. [Item 42] 42. The method of claim 41, wherein the single nucleic acid further comprises a mutation at a protospacer adjacent motif (PAM) site. [Item 43] 41. The method according to Item 40, wherein the nucleic acid-induced nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 42 or 283 to 302. [Item 44] 41. The method according to Item 40, wherein the nucleic acid-induced nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 128 or 263 to 282. [Item 45] 41. The method according to Item 40, wherein the nucleic acid-induced nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 148 or 323 to 342. [Item 46] 41. The method according to Item 40, wherein the nucleic acid-induced nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NOs: 303 to 322. [Item 47] 41. The method of claim 40, wherein the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172 to 182. [Item 48] 41. The method of claim 40, wherein the engineered guide nucleic acid comprises a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU. [Item 49] A nucleic acid-guided nuclease system comprising: (a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO:2; (b) an engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease; and (c) an edited sequence having a sequence change relative to the sequence of the target region in the genome of the cell; wherein the nucleic acid-guided nuclease system results in genome editing at the target region in the genome of the cell facilitated by the nuclease, the engineered guide nucleic acid and the editing sequence. [Item 50] 50. The system according to item 49, wherein the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 42 or 283 to 302. [Item 51] 50. The system according to item 49, wherein the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 128 or 263 to 282. [Item 52] 50. The system according to item 49, wherein the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 148 or 323 to 342. [Item 53] 50. The system according to item 49, wherein the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NOs: 303 to 322. [Item 54] 50. The system of claim 49, wherein the nucleic acid-guided nuclease is codon optimized for the cell to be edited. [Item 55] 50. The system of item 49, wherein the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172 to 182. [Item 56] 50. The system of item 49, wherein the engineered guide nucleic acid comprises a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU. [Item 57] 50. The system of claim 49, wherein the engineered guide nucleic acid and the editing sequence are provided as a single nucleic acid. [Item 58] 58. The system of claim 57, wherein the single nucleic acid further comprises a mutation at a protospacer adjacent motif (PAM) site. [Item 59] 1. A composition comprising: (a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO:2, and (b) an engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease, the engineered guide nucleic acid comprising a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU; A composition comprising: [Item 60] 60. The composition of claim 59, wherein the engineered guide nucleic acid is a heterologous engineered guide nucleic acid. [Item 61] 60. The composition of item 59, wherein the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172 to 182. [Item 62] 60. The composition of claim 59, wherein the nuclease is encoded by a nucleic acid sequence that is codon-optimized for use in a cell derived from a particular organism. [Item 63] 63. The composition of claim 62, wherein the nucleic acid sequence is codon optimized for E. coli. [Item 64] 63. The composition of claim 62, wherein the nucleic acid sequence is codon-optimized for S. cerevisiae. [Item 65] 63. The composition of claim 62, wherein the nucleic acid sequence is codon optimized for mammalian cells. [Item 66] 63. The composition of claim 62, wherein the nucleic acid sequence is codon optimized for human cells. [Item 67] 63. The composition of claim 62, wherein the nucleic acid sequence is codon optimized for a plant cell. [Item 68] A nucleic acid-guided nuclease system comprising: (a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO:2, and (b) a heterologous engineered guide nucleic acid capable of complexing with said nucleic acid-guided nuclease; A nucleic acid-guided nuclease system comprising: [Item 69] (c) the system of item 68, further comprising an edited sequence having a sequence change relative to the sequence of the target region. [Item 70] 70. The system of claim 69, which provides editing of a target region facilitated by the nuclease, the heterologous engineered guide nucleic acid and the editing sequence. [Item 71] 70. The system of item 68, wherein the engineered guide nucleic acid comprises a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU. [Item 72] Item 69. The system of item 68, wherein the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172 to 182. [Item 73] 70. The system of claim 68, wherein the nuclease is encoded by a nucleic acid sequence that is codon-optimized for use in a cell derived from a particular organism. [Item 74] 74. The system of claim 73, wherein the nucleic acid sequence is codon-optimized for E. coli. [Item 75] 74. The system of claim 73, wherein the nucleic acid sequence is codon-optimized for S. cerevisiae. [Item 76] 74. The system of claim 73, wherein the nucleic acid sequence is codon optimized for mammalian cells. [Item 77] 74. The system of claim 73, wherein the nucleic acid sequence is codon optimized for human cells. [Item 78] 74. The system of claim 73, wherein the nucleic acid sequence is codon optimized for a plant cell. [Item 79] 1. A method for modifying a target region in the genome of a cell, comprising: (a) a cell; A nucleic acid-induced nuclease comprising the amino acid sequence of SEQ ID NO:4; an engineered guide nucleic acid capable of complexing with said nucleic acid-guided nuclease; and an edited sequence encoding a nucleic acid complementary to the target region having a sequence change relative to the target region; and contacting the (b) enabling the nuclease, guide nucleic acid, and editing sequence to create a genome edit in a target region of the genome of the cell; The method includes: [Item 80] 80. The method of claim 79, wherein the engineered guide nucleic acid and the editing sequence are provided as a single nucleic acid. [Item 81] 81. The method of claim 80, wherein the single nucleic acid further comprises a mutation at a protospacer adjacent motif (PAM) site. [Item 82] 80. The method according to item 79, wherein the nucleic acid-induced nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 44 or 722 to 741. [Item 83] 80. The method according to item 79, wherein the nucleic acid-induced nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 130 or 742 to 761. [Item 84] 80. The method according to item 79, wherein the nucleic acid-induced nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 150 or 762 to 781. [Item 85] 80. The method according to item 79, wherein the nucleic acid-induced nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NOs: 782 to 801. [Item 86] 80. The method of item 79, wherein the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172 to 182. [Item 87] 80. The method of claim 79, wherein the engineered guide nucleic acid comprises a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU. [Item 88] A nucleic acid-guided nuclease system comprising: (a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO:4; (b) an engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease; and (c) an edited sequence having a sequence change relative to the sequence of the target region in the genome of the cell; wherein the nucleic acid-guided nuclease system results in genome editing at the target region in the genome of the cell facilitated by the nuclease, the engineered guide nucleic acid and the editing sequence. [Item 89] 89. The system according to Item 88, wherein the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 44 or 722 to 741. [Item 90] 89. The system according to Item 88, wherein the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 130 or 742 to 761. [Item 91] 89. The system according to Item 88, wherein the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NO: 150 or 762 to 781. [Item 92] 89. The system according to Item 88, wherein the nucleic acid-guided nuclease is encoded by a nucleic acid having at least 85% identity to SEQ ID NOs: 782 to 801. [Item 93] 89. The system of claim 88, wherein the nucleic acid-guided nuclease is codon optimized for the cell to be edited. [Item 94] 89. The system of item 88, wherein the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172 to 182. [Item 95] 89. The system of item 88, wherein the engineered guide nucleic acid comprises a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU. [Item 96] 90. The system of claim 88, wherein the engineered guide nucleic acid and the editing sequence are provided as a single nucleic acid. [Item 97] 97. The system of claim 96, wherein the single nucleic acid further comprises a mutation at a protospacer adjacent motif (PAM) site. [Item 98] 1. A composition comprising: (a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO:4, and (b) an engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease, the engineered guide nucleic acid comprising a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU; A composition comprising: [Item 99] 99. The composition of claim 98, wherein the engineered guide nucleic acid is a heterologous engineered guide nucleic acid. [Item 100] 99. The composition of item 98, wherein the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172 to 182. [Item 101] 99. The composition of claim 98, wherein the nuclease is encoded by a nucleic acid sequence that is codon-optimized for use in a cell derived from a particular organism. [Item 102] 102. The composition of claim 101, wherein the nucleic acid sequence is codon optimized for E. coli. [Item 103] 102. The composition of claim 101, wherein the nucleic acid sequence is codon-optimized for S. cerevisiae. [Item 104] 102. The composition of claim 101, wherein the nucleic acid sequence is codon optimized for mammalian cells. [Item 105] 102. The composition of claim 101, wherein the nucleic acid sequence is codon optimized for human cells. [Item 106] 102. The composition of claim 101, wherein the nucleic acid sequence is codon optimized for a plant cell. [Item 107] A nucleic acid-guided nuclease system comprising: (a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO:4, and (b) a heterologous engineered guide nucleic acid capable of complexing with said nucleic acid-guided nuclease; A nucleic acid-guided nuclease system comprising: [Item 108] (c) the system of item 107, further comprising an edited sequence having a sequence change relative to the sequence of the target region. [Item 109] 109. The system of claim 108, which provides editing of a target region facilitated by the nuclease, the heterologous engineered guide nucleic acid, and the editing sequence. [Item 110] 108. The system of claim 107, wherein the engineered guide nucleic acid comprises a loop sequence comprising the sequence UAUU, UUUU, UGUU, UCUU, UCUUU, or UAGU. [Item 111] Item 108. The system of item 107, wherein the engineered guide nucleic acid comprises any one of SEQ ID NOs: 172 to 182. [Item 112] 108. The system of claim 107, wherein the nuclease is encoded by a nucleic acid sequence that is codon-optimized for use in a cell derived from a particular organism. [Item 113] Item 113. The system of item 112, wherein the nucleic acid sequence is codon-optimized for E. coli. [Item 114] Item 113. The system of item 112, wherein the nucleic acid sequence is codon-optimized for S. cerevisiae. [Item 115] 13. The system of claim 112, wherein the nucleic acid sequence is codon optimized for mammalian cells. [Item 116] 13. The system of claim 112, wherein the nucleic acid sequence is codon-optimized for human cells. [Item 117] 13. The system of claim 112, wherein the nucleic acid sequence is codon optimized for a plant cell.

Claims

1. A nucleic acid-guided nuclease system comprising: (a) (i) a nucleic acid-derived nuclease comprising an amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 7, or (ii) a nucleic acid molecule encoding said nucleic acid-derived nuclease; and (b) (i) an engineered guide nucleic acid that comprises a region for complexing with the nucleic acid-guided nuclease and a region for hybridizing with a target sequence, thereby directing the nucleic acid-guided nuclease to the target sequence, or (ii) a nucleic acid molecule encoding the engineered guide nucleic acid. A nucleic acid-guided nuclease system comprising:

2. The nucleic acid-guided nuclease system according to claim 1 , wherein the region for binding to the nucleic acid-guided nuclease is a pseudoknot region.

3. 3. The nucleic acid-guided nuclease system of claim 2, wherein the region for complexing with the nucleic acid-guided nuclease is at least 95% identical to the sequence of SEQ ID NO:93 or SEQ ID NO:

94.

4. The nucleic acid-guided nuclease system according to any one of claims 1 to 3, wherein the target sequence is in a eukaryotic cell.

5. The nucleic acid-guided nuclease system according to any one of claims 1 to 3, wherein the target sequence is in a bacterial cell.

6. The nucleic acid-guided nuclease system according to any one of claims 1 to 3, wherein the target sequence is in a plant cell.

7. The nucleic acid-guided nuclease system according to any one of claims 1 to 3, wherein the target sequence is in a mammalian cell.

8. 4. The nucleic acid-guided nuclease system of any one of claims 1 to 3, wherein the system has an editing efficiency of 97% to 100% as determined by dividing the number of edited cells by the total number of recovered cells.

9. The nucleic acid-guided nuclease system of any one of claims 1 to 3, further comprising an editing sequence having a sequence change relative to the sequence of the target region.

10. 10. The nucleic acid-guided nuclease system of claim 9, wherein the engineered guide nucleic acid and the editing sequence are provided as a single nucleic acid.

11. The nucleic acid-guided nuclease system of claim 10, wherein the editing sequence further comprises a mutation at a protospacer adjacent motif (PAM) site.

12. The nucleic acid-guided nuclease system according to any one of claims 1 to 3, wherein the nucleic acid-guided nuclease has at least 95% amino acid sequence identity to the sequence of SEQ ID NO:

7.

13. The nucleic acid-guided nuclease system according to any one of claims 1 to 3, wherein the nucleic acid-guided nuclease induces cleavage of a single nucleic acid strand in the target sequence.

14. The nucleic acid-guided nuclease system according to any one of claims 1 to 3, wherein the nucleic acid-guided nuclease induces cleavage of two nucleic acid strands in the target sequence.

15. 3. The nucleic acid-guided nuclease system of claim 1 or 2, wherein the engineered guide nucleic acid comprises a sequence that is at least 95% identical to the sequence of SEQ ID NO:

90.

16. 2. The nucleic acid-guided nuclease system of claim 1, wherein the engineered guide nucleic acid comprises a pseudoknot region comprising nucleotide residues 18-26 of SEQ ID NO:

93.

17. 2. The nucleic acid-guided nuclease system of claim 1, wherein the engineered guide nucleic acid comprises a pseudoknot region comprising a sequence selected from the group consisting of nucleotide residues 19-34 of SEQ ID NO:93 and nucleotide residues 19-34 of SEQ ID NO:

94.

18. A nucleic acid-guided nuclease system comprising: (a) a nucleic acid-derived nuclease comprising an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 7, or a nucleic acid molecule encoding said nucleic acid-derived nuclease; and (b) an engineered guide nucleic acid, or a nucleic acid molecule encoding the engineered guide nucleic acid, that comprises a region for complexing with the nucleic acid-guided nuclease and a region for hybridizing with a target sequence, thereby directing the nucleic acid-guided nuclease to the target sequence; Including, A nucleic acid-guided nuclease system, wherein the engineered guide nucleic acid comprises a pseudoknot region comprising a sequence corresponding to nucleotide residues 18-26 of SEQ ID NO:

93.

19. 1. A method for modifying a target region in the genome of a non-human cell, or a human cell in vitro or ex vivo, comprising: said non-human cell or said in vitro or ex vivo human cell comprising said target region, (a) a nucleic acid-guided nuclease comprising an amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 7; and (b) an engineered guide nucleic acid that includes a region for complexing with the nucleic acid-guided nuclease and a region for hybridizing with the target region; and contacting the modifying the target region of the genome of the non-human cell, or the in vitro or ex vivo human cell, with the nuclease and the engineered guide nucleic acid; Including, The method, wherein said in vitro or ex vivo human cell is not a human embryo.

20. The method of claim 19, wherein the non-human cells are selected from bacterial cells and fungal cells.

21. The method of claim 20, wherein the bacterial cell is an Escherichia cell.

22. The method of claim 20, wherein the fungal cell is a cell of the genus Saccharomyces.

23. The method described in claim 19 or 20, wherein the nucleic acid-induced nuclease comprises an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO:

7.

24. The method of any one of claims 19 to 23, wherein the engineered guide nucleic acid comprises a sequence that is at least 95% identical to the sequence of SEQ ID NO:

90.

25. The method of any one of claims 19 to 23, wherein the engineered guide nucleic acid comprises a pseudoknot region comprising nucleotide residues 18 to 26 of SEQ ID NO:

93.

26. The method of any one of claims 19 to 23, wherein the engineered guide nucleic acid comprises a pseudoknot region comprising a sequence selected from the group consisting of nucleotide residues 19 to 34 of SEQ ID NO:93 and nucleotide residues 19 to 34 of SEQ ID NO:94.

Citation Information

Patent Citations

  • Methods for generating barcoded combinatorial libraries

    WO2017223538A1